Skip to content
Regulatory news list Vol. 20 · 2026-11-02

Global Regulatory Monitor
Regulatory News, Week 1 · 2026/11

Period 2026-10-26 ~ 2026-11-02 Published 2026-11-02 Collected 185 · 133 cards Evidence A 20 · B 113 · C 0

19 cards in this issue cover Korean regulator documents. Company and institution names, and quoted source text, are shown in Korean exactly as they appear on the official record.

This week's key points
  • FDA issued a Warning Letter to TSP Solutions and Sanrace over CGMP violations including no identity testing of raw materials.
  • Houston Rx recalled two injectable vial products (Class II) for lack of assurance of sterility.
  • A domestic marketer recalled an acne cream product after an out-of-specification assay in stability testing.
This week at a glance
106GlobalFDA 483 observation 98 items · WHO 4 items · Warning Letter 3 items · Regulatory news 1 item
7KoreaGuidance 7 items
20RecallRecall / sales suspension 11 items · Recall 4 items · Recall (UK) 3 items · Recall (Health Canada) 2 items

Deviation, CAPA, and investigation findings in 38 of 100 documents

Country and category from the findings database

About AI-generated content

Summaries, translations, implications, check items, and in-depth analysis are written by generative AI; figures, quotations, links, and machine-extracted tables are provided as in the source. This is reference material — check the official source before making decisions.

Read in full ↓
133 cards

Global 106 cards

🧬 Biologics
[FDA 483 observation · FDA]AGC Biologics S.p.A. — Root cause of repeat alarms not identified
FDA🧬 Biologics483

FDA cited two observations at AGC Biologics S.p.A., a cell and gene therapy manufacturer (FEI 3020270660), in an inspection on 11/10/2023. Root cause and corrective action for repeat alarms were lacking and the alarm procedure was not followed, with procedural non-compliance cited separately.

Published 2026-10-30 · Inspection date 11/10/2023 · Cell and Gene Therapy Manufacturer · FEI 3020270660

Key facts · Basis: official index plus supporting sources
  • Observation 1: No root cause or corrective action for repeat alarms; alarm procedure not followed
  • Observation 2: Procedural non-compliance
Insight · Editorial insight

Citing repeated alarms with no root cause or corrective action signals that handling each alarm as an isolated event becomes an inspection issue. Since non-compliance with the alarm response procedure was also cited, it is worth checking that alarm handling records are kept as the procedure requires.

Check points
  • Trend analysis and root cause investigation of repeat alarms
  • Records of compliance with the alarm response procedure
Observation detail · 2 observations · From the source
Observation 1

There is a failure to identify a root cause and implement corrective actions to address repeated incidents of alarms, in addition to not following procedures regarding alarms, specifically, a.

According to MLN-RPT-000381: “Summary report for GMP environmental monitoring: (b) (4) (©) (4) effective 07/13/2023, there were a total of 19 non-viable particulate alarms during batch production in the presence ofpersonnel in Gride?™space from ; (b) (4) , and 40 alarms for non-viable particulate in the absence ofpersonnel from (b) (4) . The source ofthese particulates has not been investigated. b. According to MLN-SOP-000188: “Monitoring ofparticles classified area (Bresso)", effective 04/14/2023, in the event of an out of action non-viable particulate result during operation in Grade" “space, any unprotected exposed material in direct contact with the product must be removed, the hood air velocity must be verified, and the hood must be sanitized. It is not clear if the procedure regarding out of action result for non-viable particles was followed since these actions were not verified during the investigation nor documented in the batch record.

Observation 2

Failure to follow procedures, specifically, a.

According to MLN-SOP-000065: “Behavior and Hygiene for Aseptic Areas ofAGC Biologics”, 05/31/2023, operator movement in a Grade” space should be slow and deliberate and GMP manufacturing operators have to sample gloves before replacement. During the sterile filtration and filling of lot (b) (4) batch | (B) (4) , the Grade ™operator working in the BSC was observed executing rapid movements. Additionally, an operator was observed "

[FDA 483 observation · FDA]Duke University — Inadequate CAPA documentation and 10 more
FDA🧬 Biologics483

FDA cited 11 observations at Duke University, a biologic manufacturer (FEI 3002663011), in an inspection on 08/02/2019. They start with inadequate CAPA documentation under CAPA SOP COMM-QA-076 and include environmental monitoring, qualification of clean room cleaning procedures, quality unit batch record review, and incomplete critical equipment PQ.

Published 2026-10-30 · Inspection date 08/02/2019 · Biologic Manufacturer · FEI 3002663011

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate CAPA documentation under CAPA SOP COMM-QA-076
  • Observation 2: Deviation (DEV-0723 019) related to an invalidated mycoplasma test result from a contract testing laboratory
  • Observation 11: PPQ (November 16, 2018 — January 17, 2019) performed before completion of critical equipment PQ
Insight · Editorial insight

Process performance qualification and aseptic process runs proceeding before critical equipment PQ was finished signals that a misordered qualification sequence can weaken the basis of all later validation results. Because the invalidated mycoplasma result from the contract laboratory and weak quality unit batch record review were cited together, quality unit review of external test results is also worth checking.

Check points
  • Order of equipment PQ completion and PPQ start
  • Deviation handling when a contract test result is invalidated
  • Qualification of clean room cleaning procedures
Observation detail · 11 observations · From the source

Inspectors: Team Lead · Sukhanya Jayachandra

Observation 1

Corrective actions and preventive actions (CAPA) implemented are not always being documented per the CAPA SOP COMM-QA-076.

For example, a. Deviation IR-0111 is regarding failures in the sterile packaging of~ (b) (4) © sterilized critical supplies, which resulted in modified packaging configurations as captured in Change Controls GMP-CCR-434. However, no CAPA was initiated. b. Deviation DEV-0602 is regarding personnel monitoring samples being discovered by the contract lab in the sample receipt area (i.e., “garage of disposed materials” per contract lab deviation DEV2018_0042) one week after receipt. As a corrective action, the contract lab tested the samples and found negative growth on any of the plates, including the control plates. No growth promotion testing results, if performed on these plates, was reported. No CAPA was initiated to capture the corrective action taken and no addition corrective and/or preventive action was deemed necessary. c. Deviation DEV-0556 is regarding incorrect lot number of fetal bovine serum (FBS) being recorded on Thymus Organ Medium (TOM) Batch Record due to failure in secondary verification by the operators. The error was not detected during QA review but was discovered 25 days later by the operator who initially reported the incorrect number. As a corrective action,

Observation 2

Report # DEV-0723 019 documented a deviation for GMP lots GMP-™@, Gmp-®4 Gopwhere final product mycoplasma test results provided by contract testing lab were determined by the contract lab to be invalid.

GMP lots Gmp-@ GMpP-@@) GMP-M@ were transplanted into the intended patients on April 12, April 15 and April 19, respectively. Repeat testing on retention samples of all three lots were negative for the presence of Mycoplasma. Root cause was determined to be an error on the part of the contract testing lab.

Observation 3

The environmental monitoring program is deficient in ensuring that the cleanrooms are operating in a state of environmental control.

For example, a. The 2017 EMPQ performed following the modifications to the HVAC system is inadequate as it was limited in the number of samples collected and the type of sampling performed: (6)(@) sampling was limited to per location for both viable and non-viables; however, only non-viable sampling was performed ( for @@) (BAY per location under(H)4)Nconditions. b. The routine environmental monitoring program does not include (6) (4) monitoring for active air viables and non-viables in the ISO7 and ISO8 areas. c. A single viable active air sample ( (b) (4) 5 is collected during the aseptic processing in the BSC aso™ during the manufacturing process, which can take up tol (Bb) (4) . d. Routine surface sampling for viables is not performed for the ISO7 manufacturing area and the associated passthroughs under |(B) (4) conditions. e. There is no surface sampling ( (b) (4) 2) in the biosafety cabinet (ISOM used for the aseptic manufacturing of the product. f. There is no surface sampling, or sampling of the(b) (4) in the incubator after the manufacturing of a lot. The incubator is located in manufacturing room (®)(4)(1SO 7) and used for the in- process incubation ofthe product up

Observation 4

The current cleaning procedures used in the cleanroom have not been qualified.

a. Disinfectant effectiveness studies have not been performed for the sanitizing agents routinely utilized in the manufacturing facility. b. The procedures established and followed for cleaning the facility are inadequate; for example. i. Procedure GMP-SOP-060 is deficient in that it does not describe in detail the process for cleaning the(b) (4) POY) YBSC: specifically, during observation of the simulated manufacturing operations, we noted the following: a) the operators cleaned the whole BSC with one surface ofa disposable sterile (b) (4) pad using an(b) (4) mop. b) the cleaning solution was dry before the {)(O)(4)) set time required in the procedure. c) one wipe was used multiple times for wiping several items before placing them in the BSC. ii. Procedure GMP-SOP-066, includes two different procedures for cleaning the (SYA) incubator even though only one procedure is used at the facility. iii. Procedure GMP-SOP-006 states that(b) (4) cleaning is required for the cleanrooms (floors and surfaces) even though the production room and supportive areas are used(b) (4)for manufacturing product lots. iv. The cleaning ofthe passthroughs is not performed before or after use. It is cleaned

Observation 5

The existing alarm system and its implementation are deficient.

Specifically, a. Temperature probe in freezer(b) (4)used to store released critical reagent, Thymus Organ Media, is not placed in the worst-case location as determined during equipment qualification. b. The firm did not perform IQ/OQ of the alarms and probes installed after 2014, including those installed in freezer ((b) (4). refrigerator incubators (b) (4)and and BacT instrument. The equipment is used for manufacture and release sterility testing of and storage of critical reagents and source material. c. The firm failed to provide records ofpreventive maintenance for any of(b) (4) alarms used for monitoring of differential pressure, temperature, and humidity within the facility, distribution system, as well as the following critical equipment: ®/@) incubators (®)(4) levels and temperature), freezers and refrigerators used for storage of critical reagents, source material, and retention samples, and BacT instrument used for release sterility testing of the product. d. The alarm notification and response are not adequate. Per deviation IR-0114 dated December 5, 2017 and a corresponding (b) (4) log for events #7285 and 7286: On December 3, 2019 temperature within the incubator was o

Observation 6

The Quality Unit oversight of batch record review is deficient.

Specifically, a. A review of the GMPPM batch record, Preparation of Final Product (GMP-SOP-031, FRM" dated April 19, 2019) and the Roomew incubator use log form does not include: 1) verification or periodic recording ofe)) concentration and temperature during this time period, and/or 2) inclusion of the (6) (4) graph printout, which shows continuous monitoring of(4) concentration and temperature over the 17 day time period, 3/26/2019-4/19/2019. The manufacturing process requires (©) 4) concentration to be maintained between(B) (4) and the temperature (6) (4) during the incubation period.

Observation 7

Procedures and process contro] designed to prevent microbiological contamination of drug product are not established with appropriate acceptance criteria.

Specifically, a. GMP-SOP-060, “Operation and Maintenance ofthe! (BY (4) Biosafety Cabinet”, dated July 29, 2019, states certification is performed every |)(b)(4)9 for every BioSafety Cabinet (BSC). Section 8.11.3 of GMP-SOP-060, states the airflow velocity, aerosol leak, airflow smoke pattern, light intensity at work surface, and particle counts are certified using standards traceable to the NIST, but does not include the acceptance criteria. Additionally. the acceptance criteria for airflow uniformity was not specified but was calculated in the most recent Bsc (Dyan certification, dated April 16, 2019. b. The Bsc System Qualification Summary Report (GMP-2019-025-E), dated March 25, 2019, Ongoing Monitoring, did not include acceptance criteria for Airflow Velocity and Airflow Uniformity, which were calculated in the supporting Bsc. (b) (4)Testing Results from October 2018.

Observation 8

The Quality Unit does not have adequate contro] over critical materials.

For example: a. A new container closure was implemented before approval by MC3 Quality Assurance for use in the MC3 facility on July 27, 2019. It was used for the manufacturing ofGMP lots GMP®@@) Gmp.@@) cGMP @@ initiated beginning on April 27, 2019. b. Sterility of critical product-contact equipment sterilized by external vendors (i.e., sterile Starclick specimen final container closure system, tissue slicer, is not being verified through periodic sampling of incoming lots. c. The firm does not have controls in place to ensure that critical product contact supplies, such as— (b) (4)

Observation 9

The inventory control of raw materials is deficient.

Specifically, a. Per deviation DEV-0455 dated August 22, 2016: thymus organ media lot TOM (BY (4) was conditionally released without sterility testing results due to insufficient volume of released TOM available to complete manufacture of lot GMP@@ b. Expired supplies were used in manufacture ofthymus lots GMP PM er deviation DEV-0667 dated February 4, 2019). c. The control system to prevent mix-ups for materials, components, samples, and containers, intended for use in the (b) (4) manufacturing process does not include inventory records that show the current real-time inventory for refrigerator ((6)(4)) and freezers (D) (4) and(6) (4) used for storage of critical reagents, source material, retention and QC samples. d. Materials are not being properly segregated. Freezer (D) (4) used to store(6) 4) retention samples is also used to store retention samples for other products manufactured in the facility, along with research materials. Aside from the /(5)(4)9) mycoplasma retention sample log on the front of the freezer ((B)(4)). there is no log of the contents of the freezer.

Observation 10

A means of assuring data protection has not been established for the following computerized system.

There is failure to maintain a backup file that is assured as secure from alteration, erasure or loss through keeping hard copy or alternate systems. Specifically, the current GMP-EQUIP-021, Operation, Maintenance and Sterility Culture using the BacT/Alert dated September 27, 2018, does not include criteria for back up of data from a (6) based data management software application used for the BacT/ ALERT System, to removable back-up media (DVD, USB) and verification of back up to a networked path.

Observation 11

Performance qualification (PQ) of numerous critical equipment was not completed prior to conducting process performance qualification runs (November 16, 2018 — January 17, 2019) and aseptic processing runs (August 2018).

Specifically, a. PQ ofthe 4) incubators,— (b) (4) and(b) (4) used to incubate the thymus tissue slices, was approved in March 2019. b. PQ ofthe)distribution system, used to maintain ©)@) level inside the incubators, was approved in March 2019. c. PQ of biological safety cabinet, used during the processing of(b) (4). was approved in March 2019.

See all 11 findings in this document
[FDA 483 observation · FDA]Medlmmune UK Limited (AstraZeneca/Supply Biologics) — Critical reagents not qualified before use
FDA🧬 Biologics483

FDA cited four observations at Medlmmune UK Limited (AstraZeneca/Supply Biologics), a vaccine manufacturer (FEI 3004066112), in an inspection on 06/14/2022. Critical reagents were not always qualified before use in manufacturing US-licensed products (SOP-0069233 v13.0 not followed), along with an inadequate endotoxin test method, failure to notify the license holder of deviations, and insufficient validation supporting expiry dating.

Published 2026-10-30 · Inspection date 06/14/2022 · Vaccine Manufacturer · FEI 3004066112

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate qualification of critical reagents before use (SOP-0069233 v13.0)
  • Observation 3: License holder not notified of deviations that could affect distributed product quality
  • Observation 4: Insufficient validation supporting the established expiry dating
Insight · Editorial insight

The finding that critical reagents could enter manufacturing without qualification signals a gap that arises when reagents are not controlled at the raw material level. The observation on not notifying the license holder shows that the channel for reporting quality-impacting deviations between the manufacturer and the license holder is an inspection issue.

Check points
  • Qualification of critical reagents before release
  • Suitability of the endotoxin test method for detection
  • Notification of the license holder about quality-impacting deviations
Observation detail · 4 observations · From the source
Observation 1

Critical reagents are not always qualified prior to release for use in the manufacturing ofU.S.

licensed product. SOP-0069233, entitled “General Procedure for Processing and Qualifying Critical Reagents”, v13.0 is not always followed. Specifically,| ... are critical reagents designed by the) mS tst—“‘—s~s~s~s~™CCCCS*@S However, critical are not qualified priortouseinthe) mw ~SSsti<‘<«é‘;é‘s*~SCSCS tO determine iff the oe the genotypic and phenotypic properties of the ila ‘

Observation 2

The bacterial endotoxin procedure is deficient to ensure adequate detection of endotoxin in the samples.

A. Analytical method used to detect bacterial endotoxin in|~ _, LATV Monovalent Bulk (MVB), and LATV Finished Product are inadequate. Specifically, SOP-0067568, entitled “The Endotoxin Testing ofProduct b f= | ’, V40.0 is deficient in that the mixing - requirement for the) .. sample! and subsequent .._| preparations are not described. Without qualified mixing, your firm lacks assurance that endotoxin can be adequately recovered and detected when present in the samples. B.are being used to store - |and MVB samples. Endotoxin can adhere to | ww sé. gitve false negative test results. Your firm conducted a study in 2016 to show, aw |__| Suitability in recovering endotoxin spike at 5 EU/mL. However, this study was deficient, it did not, for example, demonstrate spike recovery at a lower endotoxin level of which is the action limit for MVB.

Observation 3

Your firm did not notify the license holder ofa deviation that may potentially affect the quality of a distributed drug product.

Observation 4

There is a lack ofvalidation to support on assigned expiry.

Specifically, |__ im =eg® currently appliedto| .. _—_|used within the manufacturing and QC areas. In 2017, your firm used data provide by the vendor to support the vo You did not : conduct your own validation to support the assigned expiry. For example, you did not demons tate|- | while ~ being used by your personnel following your manufacturing procedure within your facilities, can remain sterile at thewm XY. ss TF

See all 4 findings in this document
[FDA 483 observation · FDA]Baxalta Belgium Manufacturing SA — Key equipment not identified in batch records
FDA🧬 Biologics483

FDA cited one observation at Baxalta Belgium Manufacturing SA, a plasma derivative manufacturer (FEI 3002806503), in an inspection on 11/22/2024. Batch production and control records did not include identification of the major equipment used, with filling line cases for GAMMAGARD Liquid and Cuvitru cited.

Published 2026-10-30 · Inspection date 11/22/2024 · Plasma Derivative Manufacturer · FEI 3002806503

Key facts · Basis: official index plus supporting sources
  • Observation 1: Batch production and control records lack identification of major equipment
  • Related products: GAMMAGARD Liquid, Cuvitru
Insight · Editorial insight

Missing identification of the major equipment in batch records makes it hard to trace affected batches when equipment fails, so this reads as a traceability finding. As in the GAMMAGARD Liquid and Cuvitru filling line cases, it is worth checking that filling equipment identification is recorded in batch records.

Check points
  • Entry of major equipment ID numbers in batch records
  • Ability to trace affected batches when equipment fails
Observation detail · 1 observation · From the source

Inspectors: Alan L Truong · Malgorzata G Norton · Shafiq Ahadi

Observation 1

The batch production and control records are deficient in that they do not include the identity ofmajor equipment used.

Specifically, A. Your firm manufactured and released GAMMAGARD Liquid ® and Cuvitru ® in the (b) (4)_ filling line@ . Filling parameters are embedded in ‘ ” and executed by @@) . The ‘ ” which controls(b) (4) parameters such as fill and filling), are not documented in the batch records. For example, ‘ ” used to manufacture GAMMAGARD Liquid ®, lot no.(b) (4) . manufacture date 7 October 2024 is not documented in the batch record. B. Your firm manufactured and released Glassia ®, used to treat lung problems (emphysema). alarms, such as fill (b) (4) or (b) (4) . generated during filling in filling line@) are not always reviewed/addressed/evaluated during batch record review. For example, alarms such as fill(b) (4) and(BY(4Y) captured by the(b) (4) filling line, during the filling process of Glassia manufacturing batch record no. BE23E022, release date, 4 July 2024, was not evaluated and reviewed.

[FDA 483 observation · FDA]Catalent Maryland, Inc. — Aseptic procedures not followed during filling
FDA🧬 Biologics483

FDA cited two observations at Catalent Maryland, Inc., a biological drug product manufacturer (FEI 3015558590), in an inspection on 04/09/2025. During observation of the APR-03-2025 ELEVIDYS (delandistrogene moxeparvovec-rokl) filling operation, procedures to prevent microbiological contamination of drugs purporting to be sterile were not followed, and the condition of the building repair was also cited.

Published 2026-10-30 · Inspection date 04/09/2025 · Biological Drug Product Manufactucer · FEI 3015558590

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures to prevent microbiological contamination not followed (during observation of the ELEVIDYS filling operation)
  • Observation 2: Poor state of repair of the manufacturing building
Insight · Editorial insight

Aseptic procedure lapses found while observing the ELEVIDYS filling operation signal that the filling step is treated as a key weak point for sterility assurance. Since building repair was cited alongside, it is worth checking that facility maintenance of the filling area supports sterility assurance.

Check points
  • Compliance with aseptic procedures during filling
  • Building repair condition in the filling area
Observation detail · 2 observations · From the source

Inspectors: Lizaida Perez

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, on APR-03-2025, while observing filling operations for delandistrogene moxeparvovec- rokl (ELEVIDYS) drug product batch number| .. | your operator did not follow SOP 05.0105 (titled “Aseptic Techniques andPersonnel Behavior in the Aseptic Filling Suite”, Revision 05, Effective Date: OCT-05-2023) while performing) ..___|checks and an intervention requiring repeated opening of and reaching into the RABS surrounding the filling equipment during filling of product vials in the Grade. area. For example, A. The operator was observed to not perform frequent glove (hand) sanitization. B.The operator was observed to repeatedly perform rapid movements and to not move slowly and deliberately. C.The operator was observed placing their hands, including while holding i to manipulate - vials,| aw -land did not keep their hands at ua times, and did not sanitize their hands oun them ‘om when making an adjustment

Observation 2

Buildings used in the manufacturing of a drug product are not maintained in a good state of repair.

Specifically, on APR-03-2025, while observing filling operations for delandistrogene moxeparvovec- rokl (ELEVIDYS) drug product batch number wna | esas observed on the floor of room |- | a personnel | -. | where operators perform)... and si the Grade. filling area. On APR-08-2025, you clarified that you had determined that the) .. on the floor was due tothe floor) wu the floor of the personnel... during) ... | ‘sik of the|- | Onthe same day, you provided a work order (4MNT-63353-2025) opened on APR-07-2025, to remove the|..__|and adjust the floor... to prevent future) .. from occurring.

[FDA 483 observation · FDA]GlaxoSmithKline Biologicals — Discrepancy review and retain sample gaps
FDA🧬 Biologics483

FDA cited three observations at GlaxoSmithKline Biologicals (FEI 3014752610) in an inspection on 03/12/2024. They are inadequate review of unexplained discrepancies regardless of whether the batch was distributed, an inadequate procedure to confirm equipment cleanliness immediately before use, and no visual inspection of retained samples at least annually.

Published 2026-10-30 · Inspection date 03/12/2024 · Manufacturer · FEI 3014752610

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate review of unexplained discrepancies regardless of distribution
  • Observation 2: Inadequate procedure to confirm equipment cleanliness immediately before use
  • Observation 3: Retained samples not visually inspected at least annually
Insight · Editorial insight

The citation requiring review of unexplained discrepancies even for batches already distributed signals that impact assessment of post-distribution batches is easily missed. Routine and periodic checks cited alongside, equipment cleanliness confirmation before use and annual visual inspection of retained samples, are also worth checking.

Check points
  • Impact assessment of discrepancies including distributed batches
  • Records of equipment cleanliness confirmation immediately before use
  • Annual visual inspection of retained samples
Observation detail · 3 observations · From the source

Inspectors: Susan M Jackson · Latorie S Jones

Observation 1

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, Your firm failed to open a deviation for approximately 46 days after observing and failing to adequately document atypical cracks in| glass vialsusedto Shingrix. Yourfirm's supplierrequest for investigation report from dated 3-24-23 revealed a weakness in the bottom of the glass vials that leads to breakage with increased stress fromyour manufacturing process. Your firm utilizedfs of (ea vials produced before 4-24-23 to manufacture approximately/™batches (®)@) vials) of Shingrix released to the US market . For example, Raw Materia Aseptic Period ial ID Batch Inspection {Quantity Date Delivered 2022 30 022 | 2022 l ) 2022 | 2022

Observation 2

Procedures for the cleaning and maintenance of equipment are deficient regarding inspection of the equipment for cleanliness immediately before use.

Specifically, On 07 March 2024 during the walk through ofthe aseptic filling area in Building (6)(4) Lyo Line8 where US licensed Shingrix vaccine is filled, the(b) (4). covering ofthe vial (bY) was observed to have splinter-like cracks. The cracks were observed directly over the location where the vial enters the) (b) (4)

Observation 3

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

Specifically, Your firm does not perform an(6) (4) inspection ofyour reserve/retain samples for Shingrix vaccine. Adverse drug experiences which are both serious and unexpected have not been reported to FDA within 15 calenda days of initial receipt of the information by your firm. Specifically, A. A total of eighty-four (84) 15-Day Alert reports were reported late (after 15 days) for Shingrix Vaccine (BLA125614). Example of the 15-Day alert reports submitted late to the FDA include but are not limited tq the following cases: Case ID Initial GSK Receipt [Initial Date Submitted to [Number of Calendar Date FDA Days Late r (by 4) pay 2023 (yay 2024 (6) (4) 2023 b) (4) 2024 ) b) (4)2023 b) (4) 2023 ; (bp) (4 b) (4) 2023 y2023 | b) (4) 2023 a) 2023 bs SSC*d (bya) (8) 4) 2023 )(4) 2024

See all 3 findings in this document
[FDA 483 observation · FDA]Medimmune U.K. Limited — No deviation for repeated action limit excursions
FDA🧬 Biologics483

FDA's first observation at Medimmune U.K. Limited, a biologic vaccine drug substance manufacturer (FEI 3004066112), in an inspection on 03/15/2024 was insufficient information and impact assessment in deviation QE-048460. In addition, no deviation was issued under SOP-0067565 for consecutive action limit excursions recorded in the qualification report for Jan 25 —Mar 8, 2023.

Published 2026-10-30 · Inspection date 03/15/2024 · Biologic Vaccine Drug Substance Manufacturer · FEI 3004066112

Key facts · Basis: official index plus supporting sources
  • Observation 1: Insufficient information and impact assessment in deviation QE-048460
  • Observation 3: Inadequate investigation of consecutive action limit excursions; no deviation issued under SOP-0067565
Insight · Editorial insight

Consecutive action limit excursions recorded in a qualification report did not lead to a deviation, signaling that qualification data should be held to the same deviation criteria as routine monitoring. Together with the weak impact assessment in deviation QE-048460, the quality of deviation records was repeatedly an issue, so deviation reporting quality is worth checking.

Check points
  • Deviation issuance for action limit excursions during qualification
  • Thoroughness of impact assessment in deviation reports
Observation detail · 1 observation · From the source

Inspectors: Brentley S Collins · Gene D Arcy · Anissa M Cheung

Observation 3

Inadequate investigation was performed on thehe action level excursions on %(b) (4) of theme) I srom the during Jan 25 —Mar 8, 2023 recorded in the qualification report of the from : a.No deviation was initiated for these consecutive action level excursions on %(b) (4) of the (6) (4)) as per SOP-0067565.

b.The rejected (Bb) (4) were not manually inspected to verify that the(b) (4) were in poor quality prior to concluding that the root cause was due to the malfunction of the light and camera. 4.Your firm’s batch record is not designed to capture critical information in support of 4 which are used in the production of flu vaccine monovalent : Specifically, Master Batch Record, MABR-0009649, entitled (by (4) v10.0, was used to document step. monovalent bulk (Bb) (4). strain serotype H1N1, strain A/Norway/3 1694/2022 V1, is not designed to capture all verification steps performed during

[FDA 483 observation · FDA]Charles River Laboratories — Insufficient training of cell therapy personnel
FDA🧬 Biologics483

FDA cited five observations at Charles River Laboratories, a cell therapy manufacturer (FEI 3006500433), in an inspection on 02/07/2025. They are insufficient training of cell therapy manufacturing personnel, incomplete master production record instructions, inadequate aseptic process validation, poor building repair, and inadequate inventory records for components and containers.

Published 2026-10-30 · Inspection date 02/07/2025 · Cell Therapy Manufacturer · FEI 3006500433

Key facts · Basis: official index plus supporting sources
  • Observation 1: Insufficient job training of cell therapy manufacturing personnel
  • Observation 3: Inadequate aseptic process validation
  • Observation 5: Inventory records for components and containers did not allow tracing of related batches
Insight · Editorial insight

Cell therapy processes generally depend heavily on operator skill, so citing insufficient training as the first observation signals that operator competence translates directly into process control. Since inventory records that cannot identify the related batches were also cited, material traceability is worth checking.

Check points
  • Training completion by job role for cell therapy manufacturing personnel
  • Adequacy of aseptic process validation
  • Batch traceability of component and container inventory records
Observation detail · 5 observations · From the source

Inspectors: Scott T Ballard · Christian Lynch

Observation 1

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically, training of employees who work in cell therapy manufacturing is not adequate a.On 16 DEC 2024 video recording shows employee dropping paper batch record pages on the floor of a Gradelroom and subsequently returning the paper records to a table work surface and continuing with assisting to place materials into a Grade b.On 1 and 16 DEC 2024 video recording shows employees working with their hands in a Grade wiped their hands and work surfaces with a sterile wipe immediately c.On 1 DEC 2024 video recording shows an employee working in a Grade 'Pass processing suite place on top of paper batch records prior to placing the units in a cell culture d.As of 7 FEB 2025, your Senior QC Manager of Microbiology had not completed job specific training on revised SOPs such as: i.CGM-SOP-00042, Investigation of Environmental Alert Level Excursions, Action Level Excursions, Contamination Recovery Rate Excursions and Adverse Trends (Revision 03) ii.CGM-SOP-00027, Plate , Enumeration and Microbial Identification (Revision 02) iii.CGM-SOP-00241, Operation of the (Revision 01) e.Training status is not adequately monitored to ensure employees are up to date on current training requiremen

Observation 2

Master production and control records lack complete manufacturing and control instructions.

Specifically, as stated by your Senior Manager of Quality Control Analytical, no established procedures exist regarding specific handling or loading patterns (and subsequent removal) of up to 50 (b) (4) from during manufacturing operations occurring in 2024. have a (b) (4) WEI/ on the of the unit and are used in the manufacturing of i cellular therapy products.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically, batch records for aseptic process simulation do not adequately describe steps to fully simulate manufacturing processes for cell therapy products. APS protocol #QA -00214 rev 6 (b) executed in Januaiy 2024 1 does not include a specific step for placing units (4) as is done for commercial production.

Observation 4

Buildings used in the of a drug product are not maintained in a good state of repair.

Specifically, we observed facility deficiencies related to the manufacturing of cell therapies in cryostorage i rooms and locker/change rooms for personnel, as follows: a.On 3 FEB 2025, we observed visibly dirty and rough floor surfaces in the (b)1,4) fmished product and intermediate product storage room --."

Observation 5

Records fail to include an individual inventory record of each component and drug product container with sufficient information to allow determination of any associated batch or lot of drug product.

Specifically, raw material and finished product inventory is not adequately controlled and/or withheld from use until appropriate in relation to cell therapy manufacturin as follows: a.On 3 FEB 2025, we observed missing (labeled ) inside as compared to electronic inventory of mished product in software. Additionally, the software indicated the (") holding 19 of cryostorage where thee is only b.On 3 FEB 2025, we observed missin labelled among others) inside storage. c.On 3 FEB 2025, we observed C retain stora or the name/identification of those

See all 5 findings in this document
[FDA 483 observation · FDA]CellTrans Islet Isolation facility — Out-of-spec lot release and 10 more
FDA🧬 Biologics483

FDA cited 11 observations at CellTrans Islet Isolation facility, a cell and gene therapy manufacturer (FEI 3019202665), in an inspection on 06/11/2021. They include release of final product lots with incomplete batch records or failing release specifications, unreported temperature excursion deviations, aseptic process and gowning defects, no periodic verification of cleaning, and no monitoring of carbon dioxide gas quality.

Published 2026-10-30 · Inspection date 06/11/2021 · cell and gene Therapy manufacture · FEI 3019202665

Key facts · Basis: official index plus supporting sources
  • Observation 3: Final product lots released with incomplete batch records or failing release specifications
  • Observation 8: No periodic verification after the initial cleaning validation in 2018
  • Observation 12: Quality of carbon dioxide gas for incubators not monitored; no COA obtained
Insight · Editorial insight

Releasing final product with failing specifications or incomplete batch records shows that the quality unit's release decision function did not work. The lack of revalidation since the initial cleaning validation in 2018 and the gap in process gas quality control were also cited, so the maintained state after initial validation is worth checking.

Check points
  • Batch record completeness and specification conformance check before release decision
  • Periodic revalidation of cleaning effectiveness
  • Process gas quality monitoring and COA acquisition
Observation detail · 11 observations · From the source
Observation 1

Your firm’s Quality Unit lacks a procedure/policy that details requirements for the following: An\ is used for receipt of, for example, deliveries ofyour firm’s r here is no procedure or policy in place that addresses the potential for deliveries that may be ) (4) or where possible storage in(b) (4) | may occur.

Lack of oversight of a sterilization firm: * Sterilization of CellTrans equipment is not performed according to the validated process. Specifically, it was found that the ith CellTrans equipment and other hospital equipment based on (b) (4) and available e validation report only describes load items from CellTrans. * Sterilization load can be re-sterilized, however only documented final sterilization information is forwarded to CellTrans, initial failed or incomplete runs are not required to be reported to CellTrans as of this inspection.

Observation 2

The current deviation reporting procedure was found deficient, for example: * During review of the(b) (4) system for monitoring of(6) 4) temperature and humidity, it was found that temperature excursions are not properly documented and reported as deviations.

‘Biers filters were found to have during routin EPA filter certification. However, there is no documentation that a(6) (4)performed whether the percentage ofarea (6) (4) was

Observation 3

Final product lots were released with incomplete batch record or failed lot release specifications.

The batch records for these lots were part ofyour BLA submission. Specifically Lots were released for with incomplete information of purity tests in the batch record. Lot was released for ith failed potency test.

Observation 4

Regarding your firm's current aseptic process observed during inspection we noted the following deficiencies: * Sterile equipment was exposed to Iso(B)(4) before transferring into the (BD) (4) (b) (4) sok for use in your firm’s aseptic process.

* An ver exposed sterile equipment during a process performed within a NS , ° a(b) (4)study was not performed for any ofthe that are used for aseptic processing.(b) (4) study performed for the ISO(1b) (4) tailed to include conditions. + Equipment and other items were observed in the(1B) (4) partiaty blocking the ISO(b) (4) * The ISO(b) (4) contains equipment that are not used for processing that may interfere with room cleaning and impact room quality such as the following: that have not functioned for many years(D4) | no used for processing, an na wall.

Observation 5

Your gowning procedures are deficient.

Specifically, * The SOP, Gowning: Entering and Exiting Procedures for the Islet Isolation Facility, MFG-SOP-201, section 8.1 “Gowning Process: Preparation Step,” requires changing from including the oa: part ofthe preparation. The (6) (4) include and and ere is no assurance that have not been contaminated by the nvironment. The SOP also requires that(b) (4) ve stored in an which is done after ° (b) (4) _gowning is necessary to work in ISOBevirnment to perform aseptic manufacturing steps, as per the , sterile Gowning Technique, MFG-SOP-221. Your firm does not conduct training in, nor have a gowning qualification program for, such sterile gowning of personnel as described by the SOP.

Observation 6

equipment qualification is deticient.

Specifically, the qualification was not performed under the conditions of use and the verification of@ integrity was limited to visual inspection of the

Observation 7

Effectiveness ofthe(b) (4) used for facility and?) caning was not demonstrated.

effectiveness study design did not include acceptance criteria to demonstrate required id not

Observation 8

CellTrans does not require periodic verification of(B) A)cleaning used w(D) (4) No such verification has been performed since 2018 when the initial cleaning validation was completed.

Observation 9

The Quality Unit oversight of(b) (4) is deficient.

Specifically, * Certificates of Analysis from a manufacturer of medi hat are used in the production of the product CMRL 1066 , and who also manufactures (HEPES and CMRL 1066 Transplant Solution). state that these solutions are not sterile erilily Assurance Level (SAL) 0 . All such (6) (4) specifications have been approved by your firm’s Quality Unit and vere released for use in aseptic operations. * Your firm uses the SOP, Material Management Program, QAL—SOP—402, to manage the acceptance of(b) (4) . such “(b)(4) This SOP is linked to specifications that require sterility testing of | Both the material management SOP and specifications are approved by your firm’s Quality Unit. An sterility method is used as part ofacceptance of . The related sterility method validation only addressed edia nd one However, the validation is also used to support the sterility testing of other and media that are used in production or are part of the final product. Establishment ofthe reliability ofthe(EA serptirs report ofanalysis is deficient in that the test results are not appropriately validated at appropriate intervals. Specifically: * Your firm has not established the reliability of suppliers’ Ce

Observation 10

Your firm has not assessed for impurities regarding single(b)(4) parts cs.(b)(4) and sterilize hat are used in manufacturing ofthe product.

* Your firm has not assessed for impurities for your drug product containers: (Specification (Specification Observation | 1 Your firm failed to establish (PY ®ompie program and did not retain samples for drug products for

Observation 12

Carbon dioxide gas used in incubator is not routinely monitored for chemical quality, oil, or particulate levels and no COA is available to describe gas quality.

See all 11 findings in this document
[FDA 483 observation · FDA]Merck Teknika LLC — Weak quality review of equipment qualification
FDA🧬 Biologics483

FDA cited six observations at Merck Teknika LLC, a biological drug product manufacturer (FEI 1039284), in an inspection on 11/27/2024. They start with deficiencies in the quality control unit's review and approval of major equipment qualification and include inadequate aseptic process validation, missing or unfollowed contamination prevention procedures, review of unexplained discrepancies, and equipment design and maintenance problems.

Published 2026-10-27 · Inspection date 11/27/2024 · Biological drug product manufacturer · FEI 1039284

Key facts · Basis: official index plus supporting sources
  • Observation 1: Quality control unit responsibilities and procedures not followed (deficient review and approval of major equipment qualification)
  • Observation 2: Inadequate aseptic process validation
  • Observation 6: Inadequate maintenance intervals for equipment and utensils to prevent contamination
Insight · Editorial insight

Citing the quality control unit's review and approval of equipment qualification first signals that FDA looks at whether the quality unit actually verified the work, not just whether qualification documents exist. Aseptic process validation and contamination prevention procedures were cited next, so the link from equipment qualification gaps to sterility assurance is worth checking.

Check points
  • Scope of quality unit review of major equipment qualification documents
  • Adequacy of aseptic process validation
  • Maintenance intervals to prevent equipment contamination
Observation detail · 6 observations · From the source

Inspectors: Brentley S Pittman · Lizaida Perez

Observation 1

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, A. The review and approval process of the qualification of major equipment is deficient. Requalification of the’ ——(b)(4)—————_dused in| (by(a) |Suite, Room performed in March 2023, failed, which led to the initiation of a significant investigation, QN 201091153, on 03May2023. The BCG Vaccine manufacturing process has two (2) Critical Process Parameters (CPP) associated with the b)(4 and b)(4 ). The| (4) |is utilized to cool the (b)(4 — (b)(4) —_ prior to use during the) (b)(4) |Process. ification was performed on 9Jun2023 using the protocol (b)(4) L b)(4 . The associated investigation was closed on 15Jun2023, and equipment was released for manufacturing, without confirming that the generated data were within the acceptance criteria. Quality review and approval of the executed re-qualification protocol was completed only on O8Nov2024. During the review process, the firm identified that the execution performed on 9Jun2023 failed due to | |data points reported outside the acceptance criteria of the protocol. The delay in Quality review process led to utilize the equipment in its failed requalified state

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically, Airflow visualization studies (Smoke studies) were not performed for the following inherent and corrective interventions performed during the aseptic) # process ofBCG Vaccine. A. On 20Nov2024, during the fill line setup ofBCG Vaccine batch (b)(4) using aseptic (b)(4) core | we observed a Grade) |operator using an empty tray for removing the entire vials from the vial! (b)(4) | as a vial storage | | was accidentally slipped and fell over the vials. This intervention was never evaluated in the air flow visualization studies. B. The} (6)(4) |changeout is a corrective intervention during the) (4) process. This was never evaluated through smoke studies. C. On 20Nov2024, during the) (6)(4) |set-up for BCG Vaccine batch | (b)(4) | the had alignment issues. The Grade) 4) |operator entered inside the protective enclosure around the

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically, On 20Nov2024, during the) (b)(4) |process ofBCG Vaccine batch_ (b)(4) using aseptic, (b)(4) we observed the following: A. Grade | (4) (Operators involved in| 4) assembly set-up and ()(4) joperation lacked deliberate b)(4 B. During adjustment of|(b)(4)|, the Grade ®) operator’s arms and upper torso were observed reaching over the b)(4 C. | (b)(4) |used for troubleshooting the non-viable particulate | (b)(4) |alarms were not discarded after touching the) =—(b)(4) ~=——sS: The’ (b)(4) |was placed near other (b)(4) |which were utilized by Grade' |operators for opening the (b)(4) of b)(4 D. (b)(4 inside the Grade’ joperator’s goggles was observed.

Observation 4

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, a. The firm has initiated about 9 deviation investigations pertaining to exceedance of « (b)(4) | (b)(4) P defects (Critical defect). This is a critical defect with an action limit ofNMT| (b)(4) (NMT

Observation 5

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, The (b)(4) used in| (b)(4) |Suite, Room |© |is utilized to |» |the [ (b)(4) for (b)(4 . The firm’s requalification performed in 9Jun2023 using the protocol b)(4 was designed to study the criteria for | (b)(4) , while in production, the time allowed is a b)(4 . The requalification strategy is not designed for the (b)(4) to ensure that the] 4) are cooledto| = (b)(4) of (b)(4) | The firm manufactures about‘© [BCG vaccine batches | (b)(4) utilizing this equipment.

Observation 6

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, From 03/31 to 04/07/2023, during annual requalification of the b)(4 (| (b)(4) }, the equipment underwent maintenance to replace and (b)(4) 4) sed during production. However, | (b)(4) remained in service throughout this period. Sterilized components from the | (b)(4) |were used in the manufacture and release oftBCG batches for distribution.

See all 6 findings in this document
[FDA 483 observation · FDA]Catalent Maryland, Inc — No pump calibration in PPQ, EM gaps
FDA🧬 Biologics483

FDA issued a Form 483 to Catalent Maryland, Inc, a gene therapy manufacturer, after an inspection ending 04/28/2025. Three observations (3, 4 and 6) were legible: no maintenance or calibration program for the peristaltic pumps used to read a critical process parameter, no viable surface sampling of filling system parts handled in an ambidextrous manner, and no log of the physical PPQ batch records.

Published 2026-10-27 · Inspection date 04/28/2025 · Gene Therapy Manufacturer · FEI 3015434301

Key facts · Basis: official index plus supporting sources
  • Observations legible: 3 (equipment qualification), 4 (environmental monitoring) and 6 (records retention)
  • Citation: Equipment not qualified; deficient environmental monitoring; records procedures not followed
  • Detail: No routine maintenance, calibration or recertification program for peristaltic pumps used in PPQ batches
Insight · Editorial insight

Reading a critical process parameter only from a peristaltic pump display, with no calibration program for that pump, was cited as an equipment qualification gap. The case shows that calibration of process measurement equipment and logs of physical batch records are checked even at the PPQ stage.

Check points
  • Calibration and independent verification of equipment that measures critical process parameters
  • Whether parts handled in an ambidextrous manner are covered by viable surface monitoring
  • Log of archived physical batch records
Observation detail · 3 observations · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 3

Manufacturing equipment is not qualified for its intended use.

Specifically, the sterile). ofthe owe drug product bulk requires monitoring ofthe[= fs a critical process parameter. The} .., is assessed and documented based on the display shown on the peristaltic pump. However, there is no routine maintenance, calibration or recertification program established for the peristaltic pumps (Equipment ID used during==... ~S ~—S—Ss=«SY tag produit proces performance qualification batches (#sas . There is no independent confirmation ofthe accuracy ofthis |~ | - |.

Observation 4

Routine environmental monitoring program is deficient.

Specifically, the 4. = on the filling system | are used in an ambidextrous manner during the filling of theow SSS« rg product. However, viable surface sampling of ox isnotperformed.| = gays(asi(atsé‘(isé‘is;ésésS*‘s*S monitored accordingto the Document No. 03.1005 Revision No. 09 Effective date 25 Jul 2024 titled Environmental Monitoring Program-B WI.

Observation 6

Written procedures for records retention, archival, and retrieval of controlled documents and records are not followed.

Specifically, Document No. 02.0066 Revision No. 02 Effective date 08 May 2023 titled Records Retention, Archival and Retrieval requires that Document Control Archivist maintain a log of including the “i database. However, on 22 April 2025, the Document Control . _| staff was unable to provide a log of the win for the physical executed batch records ofthe) sam» ~=~—S——S—~*~™S—«Srg produicett process performaannce qualification batches (#s ws and |

See all 3 findings in this document
[FDA 483 observation · FDA]Genzyme Corporation — Packaging and labeling materials not checked
FDA🧬 Biologics483

FDA issued a Form 483 with three observations to Genzyme Corporation, a biological drug product labeling and packaging facility. Cited items include not following the procedure that assures correct labeling materials are used and not examining packaging and labeling materials for suitability before packaging.

Published 2026-10-27 · Inspection date 02/14/2025 · Biological Drug Product Labeling and Packaging Facility · FEI 3009389940

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedure to assure use of correct labeling materials not followed
  • Observation 2: Packaging and labeling materials not examined for suitability and accuracy before packaging
  • Observation 3: No written record of investigation of an unexplained discrepancy
Insight · Editorial insight

Citing the labeling material procedure and the missing pre-packaging line check at the same facility signals that safeguards against labeling errors were weakened twice over. Any site running packaging operations should check that pre-operation material checks and quantity discrepancy investigations are actually recorded.

Check points
  • Records of suitability checks of labeling and packaging materials before packaging starts
  • Written investigation records when labeling material quantity discrepancies occur
Observation detail · 3 observations · From the source

Inspectors: Lizaida Perez · Priscilla M Pastrana

Observation 1

Procedures designed to assure that correct labeling are used for drug products are not followed.

Specifically, according to Section 6.7, “Label Printing” and Section 6.8, “Carton Printing” in SOP QU- OPE-0204067, “BIVV001, Altuviiio, Finished Goods, Labeled Vials, Various Nominal Potency,” version 6.0, effective on 29Oct2024, the “Biological Activity - Assay Activity” or “Lot Potency” value in [U/vial specified in Form QU-FOR-0141268, version 1.0, “Altuvitio Finished Product, 250IU- 4000IU/Vial Nominal Potency, US Specifications, COA” is the potency value to be printed on labels and cartons for Altuviiio Finished Product. However, the potency value for Altuviiio Finished Product 2000IU Lot No. EY0330 was incorrectly transcribed from the Certificate of Analysis, and this incorrect value was printed on the finished product labels and cartons. The potency for Lot No. EY0330 was labeled using the value for “Biological Activity — Specific Activity” (2132 IU/mg) instead of the value for “Biological Activity — Activity” (1811 IU/Vial). Lot No. EY0330 (®)@) vials total) was released by the firm on 09Dec2024, of which (5)(4) vials were shipped to a distribution center in Reno, NV. The error in potency value was not detected by the firm until 11Feb2025 when the batch record for this lot

Observation 2

Examination of packaging and labeling materials for suitability and correctness before packaging operations is not performed.

Observation 3

Written records are not always made of investigations into unexplained discrepancies.

Specifically, protocol 64-0096 [Titled “Protocol for the Real-time Process Validation (PV) for the Transport of BIVV001 Finished Goods via (b) (4) from Sanofi NBO (Northborough, MA) to Sanofi Distribution Center (Reno, NV)] has not been actively executed since 23Aug2024. Specifically, after 23Aug2024, there have been no activities related to the execution of the protocol. No protocols deviations have been opened to investigate the issues that impacted completion of the study. frscila M Pastrana

See all 3 findings in this document
[FDA 483 observation · FDA]Baxalta Belgium Manufacturing S.A. — Recurring rejects and late BPDRs
FDA🧬 Biologics483

FDA issued a Form 483 to Baxalta Belgium Manufacturing S.A., a licensed biological manufacturer, after an inspection ending 05/31/2019. Three observations (2, 3 and 5) were legible: an inadequate review of visual inspection rejects that recurred after a raw material change for Gammagard Liquid and HyQvia, late BPDR submission for broken vial complaints, and no quality investigation of reported viral transmission and fungal infection events.

Published 2026-10-27 · Inspection date 05/31/2019 · Licensed Biological Manufacturer · FEI 3002806503

Key facts · Basis: official index plus supporting sources
  • Observations legible: 2 (failure review), 3 (late BPDRs) and 5 (adverse event quality investigations)
  • Citation: Insufficient change control assessment of a critical material; BPDRs not submitted; no quality investigation
  • Detail: Broken vial complaints from April and May 2017 were not submitted as BPDRs until 02/13/2018
Insight · Editorial insight

The central point is that rejects recurred after a change of source for a critical material, yet change control did not assess it adequately. For plasma-derived products, where adverse events can be linked to infection transmission, inspectors also checked whether complaints and adverse events led to timely quality investigations and BPDRs.

Check points
  • Scope of product quality assessment when changing the source of a critical material
  • BPDR deadline tracking for complaints and adverse events and their link to quality investigations
Observation detail · 3 observations · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 2

There is a failure to thoroughly review a batch or any of its components to meet any of its specifications Whether or not the batch has been already distributed.

Change Control PR1257198. opened on 6-Dec-2017 and closed on 21-Sep-2018, did not include a sufficient assessment on a critical material, used for manufacturing of Gammagard Liquid (GGL) and Hy Qvia. (item code (QGP is used in the PABA steps. Specifically. Change Control PR1252801 was opened on 17-Nov-2017 (closed on 23-Jan-2018) to remove the — (b) (4) | code from the Bulk Drug Substance (BDS) Bill of Materials (BOM) and for use of an alternative IUBYRAYH source of(b) (4) (BY 4 After implementation of this corrective action. final container lots were produced withSQM levels of rejects due toISA Change Control Record PR1257198. closed on 21September 2018. documented a decision to use the en (°) hC) as a backup ofthe for the manufacture of Gammagard Liquid and HyQvia. Since early 2019, an increased level ofvisibleSS) was observed again during the (JM) visual inspection for Gammagard Liquid and HyQvia lots manufactured using (YA)trom theAY. The Were identified as A possible root cause was determined to be related to the implementation of the configuration. As a preventive action. the was replaced by the (64) — (b) (4) for manufacture of Gammagard Liquid and HyQvia on April 30, 2019.

Observation 3

Four non-medical broken vial US complaints for Gammagard Liquid were discovered in April.

May 2017 and Were not submitted as BPDRs until February 13, 2018. Specifically. a) PRI194575. dated O3 April2017. reported 3 leaking damaged vials of Gammagard Liquid (10%. 10g. US). b) PR1198237. dated 20April2017. reported customer received one Gammagard Liquid (10%. 10g. US) broken vial. ¢) PR1205477. dated 24May2017, reported one Gammagard Liquid (10%. 30g. US) leaking/broken vial. EMPL AVFRISRHRNATIIRFo— Ss

Observation 5

Quality Investigations were not conducted per SOP-2024-Adverse Event Quality Investigations.

dated March 23. 2018 for the following reported viral transmission and fungal infection events. The causality assessment in each case was assessed as possible by the company ‘manufacturer, and the lot numbers were known. Specifically. a) Suspect Adverse Reaction Report. Case) (b) (4) dated IGN Gammagard Liquid Immunoglobulin, Lot GG. reported fungal infection. The company comment assessed the event of Fungal infection as possibly related to Gammagard Liquid. b) Suspect Adverse Reaction Report. Case(GG dated IGG Gammagard Liquid Immunoglobulin, Lot— (b) (4) reported that patient contracted Hepatitis B trom Gammagard Liquid (was negative 3 years ago). The company causality assessment assessed the event Hepatitis B as possibly related to Gammagard Liquid. c) Suspect Adverse Reaction Report. Case— (b) (4) dated — (b) (4) Gammagard Liquid Immunoglobulin. reported Hepatitis C in a patient. Several Lots but not limitedob)4 DOIG) were used trom 60012016 to 25May2017, The company comment assessed the event Hepatitis C as possibly related to Gammagard Liquid. _

See all 3 findings in this document
[FDA 483 observation · FDA]Barr Laboratories Inc. — No procedure for periodic batch record evaluation
FDA🧬 Biologics483

FDA issued a Form 483 with three observations to Barr Laboratories Inc., a vaccine manufacturer. Cited items are the lack of a procedure for periodic evaluation of representative batch records and test methods and procedure documents not prepared by an appropriate organizational unit.

Published 2026-10-27 · Inspection date 05/09/2025 · Vaccine Manufacturer · FEI 3000718267

Key facts · Basis: official index plus supporting sources
  • Observation 1: No written procedure for periodic evaluation to review records of representative approved and rejected batches
  • Observation 2: Test methods and changes not prepared by an appropriate organizational unit
  • Observation 3: Written procedures not prepared, reviewed and approved by an appropriate organizational unit
Insight · Editorial insight

The absence of a periodic batch record evaluation procedure signals that there was no mechanism to revisit product quality trends on a regular basis. Since the preparing and approving units for test method and procedure documents were also cited, it is worth checking that responsible organizations for documents are designated as required.

Check points
  • Whether a periodic quality evaluation procedure covering approved and rejected batches exists
  • Designation of units that prepare, review and approve test methods and SOPs
Observation detail · 3 observations · From the source

Inspectors: Scott T Ballard

Observation 1

Written procedures are not established for evaluations conducted at least}...

__to review records associated with a representative number of batches, whether approved or rejected. Specifically, your firm does not adequately conduct -.. product reviews ofrs) | to account for evaluating trends of quantitative data for vo batch release. For example, the following data is not trended: (b)(4) Written procedure - instructs that the firm "will continue to monitor the validation status through: ... production and/or product data to monitor trends, demonstrate that the process is in state on[sic] control and can consistently produce product within desired quality attributes."

Observation 2

The establishment oftest procedures including any changes thereto, are not drafted by the appropriate organizational unit.

Specifically, test methods are not adequately established. For example: a. Test Method ‘ii in the finished product i: | vo does not specify the technique by which so should be conducted in| __,,_~=—=————sS|: for quantifying ia . Currently .

Observation 3

Written procedures are not drafted, reviewed and approved by the appropriate organizational units.

Specifically, written procedures for into manufacturing areas for - are not adequate in that there is no requirement for| or | sa by manufacturing employees. Written procedures wx speak to personnel entry to the facility and .. to processing core but lack requirements for

See all 3 findings in this document
[FDA 483 observation · FDA]Ferring Microbiome Inc. — No lot-level distribution tracing system
FDA🧬 Biologics483

FDA issued a Form 483 with one observation to Ferring Microbiome Inc., a live biotherapeutics manufacturer. The finding is that no system was established to quickly identify where each lot was distributed, as needed for a recall.

Published 2026-10-27 · Inspection date 06/26/2025 · Live Biotherapeutics Manufacturer · FEI 3012047188

Key facts · Basis: official index plus supporting sources
  • Observation 1: No system to quickly identify the distribution of each lot in case of a recall
Insight · Editorial insight

A single observation focused on lot-level distribution tracing signals that recall execution capability itself can be an independent inspection issue. It is worth checking whether shipping records can be retrieved immediately by lot and whether this is verified through a mock recall.

Check points
  • Ability to retrieve shipping and distribution records by lot
  • Mock recall performed and time taken recorded
Observation detail · 1 observation · From the source

Inspectors: Laurel A Beer · Scott T Ballard

Observation 1

A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary, has not been established.

Specifically, your global procedure, 00000596, Non-Conformance and Recall Management, version 4.0, 31Jan2023, defines the requirements for you firm to assess critical situations and conduct product recalls, as necessary. 00000596 requires your firm to establish an effective system for the recall of non-conforming product to include preparing written procedures and evaluating that system at least either by assessing a real recall or performing a recall. On 26Jun2025, your firm's Quality Site Head stated that you did not have a procedure in place to conduct recall activities, nor have you performed a recall since you began commercial manufacturing of Rebyota. From 02May2022 through your firm has distributed of the finished drug product, Rebyota, into . X

[FDA 483 observation · FDA]Bello Bio LLC — No quality control unit and 15 more
FDA🧬 Biologics483

FDA issued a Form 483 with 16 observations to Bello Bio LLC, a biological product manufacturer. Cited items include the absence of a quality control unit, aseptic process validation not covered, inadequate environmental monitoring, and inadequate documentation of HCT/P donor eligibility.

Published 2026-10-27 · Inspection date 12/16/2025 · Biological Product Manufacturer · FEI 3028583081

Key facts · Basis: official index plus supporting sources
  • Observation 1: No quality control unit
  • Observations 2 and 5: Aseptic process validation not included; inadequate environmental monitoring system for aseptic processing areas
  • Observations 12, 15 and 16: Inadequate documentation and procedures for HCT/P donor eligibility determination
Insight · Editorial insight

With the missing quality control unit as the first observation, followed by 16 items spanning stability, complaints, cleaning and pre-release quarantine, the quality system foundation itself was assessed as not in place. Sites handling both sterile products and HCT/Ps should check aseptic process validation and donor eligibility records.

Check points
  • Independence of the quality control unit and its release approval authority
  • Aseptic process validation and environmental monitoring system
  • Records of HCT/P donor eligibility determinations
Observation detail · 16 observations · From the source

Inspectors: Garrad R Poole · Emily S Mcgann · Laurissa S Flowers

Observation 1

There is no quality control unit.

Specifically, your firm does not have a quality unit with the responsibility and authority to oversee the labeling, storage, and distribution of your umbilical cord tissue product, (b) (4) From September 2023 to December 2025, your firm manufactured and distributed human umbilical cord-derived products including but not limited to approximately lots ((®) @) units) of product marketed as Wharton’s Jelly ( (b) (4) ), lots ((b) (4) units) of product marketed as exosomes ®) 4) E ( (b) (4) ), and® lot (~ units) ofproduct marketed as growth factor ( (1b) (4) ).

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic process.

Specifically, a)Your firm did not perform an aseptic process validation for biological products derived from human umbilical cord tissue. b)Your firm has not validated the use the (B) (4) (equipment ID (b) (4)) that is used to sterilize finished product (b) (4) , and processing tools that come into contact with umbilical cord tissue.

Observation 3

Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, your firm has not designed production controls that ensure the human umbilical cord tissue products, (b) (4) , have the identity, strength, quality and purity they purport to possess. The lack ofprocess controls include, but are not limited to, the following: a)You have not validated the manufacturing process for the products listed above. b)You do not have SOPs stating how processing for each product is performed. c)You have not validated the time in which you ()) human umbilical cord tissue in (b) (4) : You®@ human umbilical cord tissue for anywhere from (Bb) (4) with no indication that the process does not affect the product quality or remain asa residual in final finished product. From September 2023 to December 2025, your firm manufactured ~and distributed human umbilical cord-derived products including but not limited to approximately lots (©) @) units) of product marketed as Wharton’s Jelly ( (b) (4) ), ® lots () (4) units) of product marketed as exosomes (b) (4) ), and® lot (units) ofproduct marketed as growth factor ( (b) (4) ).

Observation 4

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your firm did not investigate sterility failures in biological products manufactured from human umbilical cord tissue. : : 7 (b) (4) _ : From September 2023 - December 2025, your firm failed to investigate __ sterility test failures out of ©) manufactured batches of human umbilical cord tissue. Sterility samples are collected (b) (4) from the finished lot, with an average of vials submitted to a (DB) (4) laboratory for sterility testing per batch. ©) 4) of the 11 failed lots were released for distribution. Date of Product olume |Lot# ‘Donor ID iBioburden {Number |Sterility Processing ype esting lof vials jresults | 48) | m)¢4) | )(4) ee ()(4) i _ | || 44) (b) (4), (o) (6), (b) (7C)

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Observation 6

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, your firm has not conducted a stability study to determine the expiration dating of rm (b) (4) from time of processing used for human umbilical cord tissue to include (b) (4) (b) (4) | From September 2023 to December 2025, your firm manufactured and distributed human umbilical cord-derived products including but not limited to approximately lots (©) @) units) of product marketed as Wharton’s Jelly ( (BD) (4) ), lots (B) (4) units) of product marketed as exosomes e) ES ( (b) (4) ), and® lot (~ units) ofproduct marketed as growth factor( (b) (4) ).

Observation 7

Procedures describing the handling of all written and oral complaints regarding a drug product are not established.

Specifically, your firm does not have written procedures for the receipt of complaints associated with

Observation 8

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that components conform to appropriate standards of identity, strength, quality and purity.

Specifically, a) You have not validated or established written procedures for the process of manufacturing sterile antibiotic solutions used in the processing of human umbilical cord product. You reconstitute (b) (4) to create what you call an (b) (4) which is made up of (b) (4) designed to be added to a (b) (4) (b) (4). The ™includes (b) (4) to create an’ (6) (4) for incoming human umbilical cord tissue. You have not validated this process. b) You failed to establish a sampling plan that assesses the sterility assurance of your product. c) You failed to validate in house sterility sampling used to determine the sterility assurance of your products. The final sample used to determine the batch release is obtained© the product is (b) (4) From September 2023 to December 2025, your firm manufactured and distributed human umbilical cord-derived products including but not limited to approximately om lots (©) 4) units) of product

Observation 9

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically, your firm has no written procedures for the cleaning and maintenance of equipment used in the processing, packing and holding of (b) (4) Equipment used in the processing, packaging and holding of drug product human umbilical cord tissue product includes: ¢ (b) (4) e Freezers + (b) (4) e Centrifuge e Biologic Safety Cabinet (BSC) e Pipetman e Incubator From September 2023 to December 2025, your firm manufactured jand distributed human umbilical cord-derived products including but not limited to approximately lots (©) @) units) of product marketed as Wharton’s Jelly ( (Db) (4) ), lots (B) (4) units) of product marketed as exosomes ) 4 . ( (b) (4) ), and® lot (— units) ofproduct marketed as growth factor ( (1) (4) ).

Observation 10

Batch production and control records do not include complete information relating to the production and control of each batch.

Specifically, you did not document each significant step in the manufacture, processing, packing, or holding of each batch of product ofhuman umbilical cord tissue. The batch processing record does not include the following: e who conducted the processing step e labeling of finished product e who performed placing product into quarantine, release from quarantine, and placing into available inventory. e The firm’s records do not document final disposition for failed/rejected or otherwise unacceptable vials. From September 2023 to December 2025, your firm manufactured and distributed human umbilical 5 : . a Khitam - (b) (4) : cord-derived products including but not limited to approximately lots ((6) 4) units) of product marketed as Wharton’s Jelly ( (b) (4) ), lots (() (4) units) of product marketed as exosomes ) 4) . ( (b) (4) ), and® lot (units) ofproduct marketed as growth factor ( (B) (4) ).

Observation 11

Written procedures are lacking which describe in sufficient detail the receipt, identification, storage, handling, sampling, testing, approval and rejection of components and drug product containers.

Specifically, your firm has not established written procedures specifying incoming acceptance criteria for receipt, identification, storage, handling, sampling, testing, approval and rejection of human umbilical cord tissue and processing components and finial product containers. | ~ m Lots (BINA) From September 2023 to December 2025, your firm has manufactured approximately |___ lots (

Observation 12

The eligibility of an HCT/P donor was not documented by a responsible person, based on results of donor screening and donor testing.

Specifically, your firm does not document the donor eligibility determination for HCT/P donors whose tissues are used to manufacture (b) (4) . From September 2023 to December 2025, your firm manufacturedwand distributed human umbilical cord-derived products including but not limited to approximately jots )@) units) of product marketed as Wharton’s Jelly ( (b) (4) ), lots (P) (4) units) of product marketed as exosomes ( (b) (4) ), and® lot ( units) ofproduct marketed as growth factor ( (b) (4) ).

Observation 13

Procedures designed to assure that correct labels and labeling are used for drug products are not written.

Specifically, you have no written procedures ensuring the proper labels and labeling is applied to human umbilical cord tissue products to include (b) (4) : e You do not conduct an examination of labels and labeling at any point during the processing of (6) 4) _ e You do not examine each batch of labels prior to labeling (b) (4) (b) (4) __ vials for injection. There is no control over labeling that is issued. From September 2023 to December 2025, your firm manufactured and distributed

Observation 14

Drug products are not quarantined before being released by the quality control unit.

Specifically, on 11/19/2025, we observed umbilical cord tissue product, (1b) (4) , Lot’ (Bb) (4) , being stored in Bello Bio's ® freezer. Lot (b) (4), has not been released for distribution but was not marked as quarantined. Your firm does not have written procedures on how to handle product held in quarantine.

Observation 15

After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.

Specifically, your firm distributes (b) (4) directly to Regen Suppliers LLC. Your firm provides a Certificate of Analysis (COA) for communicable disease testing to Regen Suppliers LLC. This COA is signed by your Medical Director, however, the certificate lacks: e A statement of whether the donor is eligible or ineligible e A statement of donor eligibility based of donor screening results e A statement that the communicable disease testing was performed by a laboratory certified to

Observation 16

Procedures were not designed to ensure compliance with the donor eligibility requirements.

Specifically, your firm lacks written procedures for donor eligibility determination. From September 2023 to December 2025, your firm manufactured and distributed human umbilical cord-derived products including but not limited to approximately om lots ((6) A) units) of product marketed as Wharton’s Jelly ( (b) (4) ), lots (b) (4) units) of product marketed as exosomes ( (b) (4) ), and ® Jot ( . units) ofproduct marketed as growth factor( (b) (4) i

See all 16 findings in this document
[FDA 483 observation · FDA]Kedrion BioPharma, Inc. — PPQ process non-compliance and data integrity
FDA🧬 Biologics483

FDA cited four observations at Kedrion BioPharma, Inc. (Biologic Manufacturer). They include not following process control procedures during RhoGAM PPQ batches, inadequate documentation of deviation investigations, no procedures to control microbial contamination, and inadequate data integrity controls for computerized data on PPQ lots.

Published 2026-10-26 · Inspection date 12/06/2019 · Biologic Manufacturer · FEI 3003683714

Key facts · Basis: official index plus supporting sources
  • Observations: 4
  • Observation 1: Written process control procedures not followed during RhoGAM PPQ
  • Observations 2 and 3: Inadequate documentation of deviation investigations; no procedures to control microbial contamination
  • Observation 4: Inadequate data integrity controls for computers used for PPQ lots
Insight · Editorial insight

Procedural non-compliance and data integrity problems cited in the PPQ batches themselves signal that the reliability of process validation results may be undermined. It is worth checking that PPQ execution records and computer audit trails support the validation conclusions.

Check points
  • Procedure compliance and deviation handling during PPQ batches
  • Access rights and audit trails of computer systems related to PPQ
  • Microbial contamination control procedures for biologics
Observation detail · 4 observations · From the source
Observation 1

Written production and process control procedures were not followed in the execution ofthe various production and process control functions during the PPQ runs for RhoGAM S(H)4YW Incidences include, but are not limited to, the following: a.

Deviation 117124 due to operator not following SOP (version 12) “Production ofRhoGAM by incorrectly proceeding with the unnecessary and adding directly into the instead to the resulted in a ofan initiated PPQ Lot(b) (4) ana rejection | (b) (4) due to not being suitable for further processing. b. Deviation 121827, the operator did not follow SOPA), ession 10) securting 1D octorn te and entered non-approved(by (4) results from the QC laboratory resulting in need to perform the adjustments based on the erroneous results which is not part ofthe soP 1(B) 4) (version 10) for PPQ Lot c. Deviation 121766, the operator did not follow SOP (version 10) “Production ofRhoGAM od and added the incorrect quantity o 0 | (6)(4) for PPQ Lot d. Deviation 123472, QA verified the dosage calculation for fill, but did not verify that the(b) (A)valne was transcribed appropriately per SOP GQC-00-025 “Review of Test Data and Release ofTest Kesults.” Therefore, the(by(4)based on the incorrectly transcribed(6) A)value for PPQ Lot64

Observation 2

Deviation investigations are not well documented.

Specifically, a deviation ofan operator not following procedure and incorrectly preparing and using) (1b) (4) instead of(SY) for dilution oflO) (4) — (b) (4) atthe (b) (4) step, which may affect the validity ofthe §(jy(4yy was found during the

Observation 3

Procedures designed to control microbiological contamination are not established.

Specifically, WFI point of use is QC sampled after a(6) (4) fush according to SOP MQC-00-056. However, it was verbally confirmed by RhoGAM Manufacturing Supervisor that operators are not required to flush the WFI prior to use during production; and that there is no written procedure.

Observation 4

Appropriate controls for data integrity were not exercised over computers used during PPQ lots.

Specifically, data integrity remediation project as per Document #//(B) (4) is ongoing as ofthis inspection (December 2-6, 2019); however, PPQ lots were prepared between November 2018 to January 2019. The following systems and equipment used during RhoGAMSEINE production are a part ofthis ongoing project

See all 4 findings in this document
[FDA 483 observation · FDA]Plasma Industries Belgium SCRL — CIP cleaning validation and deviation control gaps
FDA🧬 Biologics483

FDA cited CIP cleaning validation, delayed deviation initiation, an unclosed change control, and preventive maintenance at Plasma Industries Belgium SCRL (Biologics Manufacturer). This includes Change Control 92345 being still open as of March 15, 2018.

Published 2026-10-26 · Inspection date 03/16/2018 · Biologics Manufacturer · FEI 3003208230

Key facts · Basis: official index plus supporting sources
  • Key findings: Inadequate justification of container CIP cleaning validation; delayed or inadequate initiation of deviations (Events)
  • Change control: Change Control 92345 still open as of March 15, 2018
  • Particles: Procedure did not require opening a deviation when particles were detected
  • Other: Inadequate preventive maintenance in 2016 and 2017; discoloration observed (3-12-18)
Insight · Editorial insight

Deviations not being opened for CIP abnormalities and changes being implemented while change control remained open signal that the criteria for initiating quality events were themselves treated as an issue. It is worth checking that events that should immediately become deviations, such as particle detection or abnormal cleaning, are not deferred by the procedure.

Check points
  • Scope of CIP cleaning validation and rationale for exclusions
  • Criteria for initiating a deviation for abnormal events
  • Closure of change control before a change is implemented
Observation detail · 7 observations · From the source
Observation 2

The following deviations (Events) related to (b) (4) were not initiated in a timely manner or are otherwise inadequate: A.

Deviation Investigation 79659 initiated 18 August 2016was opened due to unknown substance (later identified as plasma) found in the (b) (4) ana(b) (4) centrifuges (b) (4) during a shutdown. The investigation is inadequate in the following: i. Lots of the drug substance manufactured prior to the shutdown was not evaluated as part of product impact. ii. The preventative maintenance of the centrifuges, including the centrifuge (bp) (4) was not evaluated. ili. The last batch manufactured before the shutdown and the discovery ofplasma in the (b) (4) (b) (4) of the centrifuge was not tested to show there was no impact downstream of the centrifugation step; the investigation was closed concluding no impact on product. —. REVERSE : Susan Jackson, CSO OF THIS i i TH AnLAC 4Kio Mihaly Ligmond, CSO March 16,2018 |

Observation 3

The current procedure for CIP of the fails to require the initiation of a deviation when an atypical event is detected during the ) ifically, CAPA 81235 was initiated as part ofEvent Record 79659 to update SO clean.

This procedure does not require the operator who performs the clean ora clean to initiate a deviation when a substance is observed in the ~ (b) (4) |ofthe centrifuge used during the rocess.

Observation 4

The change to the use ofa new at) for the(D) (4), ¢the (BD) (4) was implemented on February 27, 2018 however the associated change control (Change Control 92345) remained open as of March 15, 2018.

As per Documen 4) 0527 entitled “Change Control” * 9) ( rm 1s form was not completed for this change control. | | amet SEE

Observation 5

As per Document(b) (4) 16 entitled “Particle Contamination” a deviation (Event) is not required to be initiated for the detection ofparticles until particle identification is(b) (4) which is allowed to

Observation 6

There is no written justification for the clarifying imits of(b) (4) as stated in Document 2262 / 14.0 entitle 261 — Appendix |: Production File which is a portion ofthe batch record.

Observation 7

The preventative maintenance program for the hich is used to prepare — (b) (4) for the rocess and the used for CIP was not adequately conducted in year 2016 and 2017.

The preventative maintenance program did not ) at a defined frequency. Specifically, A. The executed preventative maintenance records for the year 2016 and 2017 for thefb) (4) fb) (4) and the re ¢°<: not account for all components an | requency of maintenance on each component. SEE

Observation 8

Discoloration resembling®) @was observed on (b) (4) located in the (®) (4)of the Operations Building Room () ()during a walkthrough ofthe area on 3-12-18.

Open operations related the manufacturing of (b) (4) such as the addition of(6) (4)components into _() (4) used in the(b) (4) and(b) (4) process are performed in this room. SEE

See all 7 findings in this document
[FDA 483 observation · FDA]Abeona Therapeutics Inc — Aseptic process control and disinfectant efficacy
FDA🧬 Biologics483

FDA cited, at Abeona Therapeutics Inc (Cell and Gene Therapy), insufficient aseptic process controls to assure sterility of the prademagene zamikeracel final product, among other items. Quality control of media and reagents, delayed deviation management, and inadequate disinfectant efficacy studies were also included.

Published 2026-10-26 · Inspection date 03/01/2024 · Cell and Gene Therapy · FEI 3008334517

Key facts · Basis: official index plus supporting sources
  • Product: prademagene zamikeracel
  • Aseptic processing: Insufficient controls to assure sterility of the final product; inadequate quality control of media and reagents before use
  • Deviations: Ineffective QA deviation management led to delayed investigations and inadequate risk assessment
  • Disinfection: Inadequate disinfectant efficacy studies
Insight · Editorial insight

Media, reagents and disinfectant efficacy were all cited for a cell and gene therapy aseptic process, signaling that contamination control across all inputs to the aseptic process was assessed. Delayed deviation investigations were recorded as affecting the final decision, so it is worth checking whether investigation deadline management is linked to product disposition decisions.

Check points
  • Quality control of media and reagents before use in aseptic processing
  • Scope of disinfectant efficacy studies
  • Deviation investigation timelines and adequacy of risk assessment
Observation detail · 4 observations · From the source

Inspectors: Ou Olivia Ma

Observation 1

The aseptic manufacturing process lacks sufficient controls to ensure sterility of the prademagene zamikeracel final product, specifically: a.

The used in the preparation of media and other components that are used in the aseptic process tested for integrity after use. Therefore, the sterility of these media and components have not been verified. b. The for the LZRSE-Col7A1 retroviral vector (RVV) has not been validated (including not having an established bioburden limit). c. The final DP sterility sample for lot release collected from the final m., does not capture the risk of the final product manipulations, including d. The 0,34/ culture dish which is step involving the of the final assembled cell sheet (placed in a _ ) between two 1.4.) located in MN) _ in the process) is not included in the aseptic process simulation to assess the impact of this on maintaining aseptic conditions of the drug product.

Observation 2

Media and reagents (e.g., are not adequately controlled for quality prior to being used in the aseptic manufacturing process.

a. Media and reagents are not tested for sterility, endotoxin, and identity. Therefore, the safety of these media and reagents has not been determined prior to being in direct contact with the drug substance (DS) and drug product (DP). b. Studies have not been conducted to support the expiry of the media and reagents to (b)( ensure adequate performance.

Observation 3

The inefficient management of deviations by Quality Assurance resulted in delayed investigations for which risk assessments were inadequate and adversely impacted final decisions and actions.

Specifically: a. Numerous deviations were not addressed in a timely manner ( deviations :o be opened, - REVERSE OF THIS PAGE FORM F 483 (9/011) PREviuus hulTIONO%uLe r E

Observation 5

Disinfectant efficacy studies performed to support the disinfectants used in the facility and during the manufacturing processes are deficient.

Specifically, a. OM) which is used as the primary disinfectant (including for use to disinfect materials in the has not been qualified as this 0.4) disinfectant was not included in the disinfectant efficacy studies which were performed in - . b. Facility isolates were not evaluated in the - (and only) disinfectant efficacy studies performed in - c. The efficacy of disinfectants used in the facility do not undergo a periodic review based on environmental monitoring trending to determine if a re-evaluation study is needed.

See all 4 findings in this document
[FDA 483 observation · FDA]Microvascular Tissue, Inc — Raw material identity testing, complaint records
FDA🧬 Biologics483

FDA cited four observations at Microvascular Tissue, Inc (Biological product manufacturer/distributor). The cited areas were complaint investigation records, written in-process control procedures, identity testing of each raw material component, and review of batches failing specifications.

Published 2026-10-26 · Inspection date 04/08/2025 · Biological product manufacturer/distributor · FEI 3011742679

Key facts · Basis: official index plus supporting sources
  • Observations: 4
  • Observation 1: Complaint investigation records missing findings and follow-up actions
  • Observations 2 and 3: Inadequate written in-process control procedures; identity testing of each raw material component not performed
  • Observation 4: Inadequate thorough review of batches and components failing specifications
Insight · Editorial insight

Citing identity testing of incoming raw materials and complaint investigation records together shows a case where both the starting point and the end point of the quality history were weak. It is worth checking that at least one identity test is performed for each raw material component and that complaint investigation conclusions are closed out in records.

Check points
  • Whether identity testing is performed for each raw material component
  • Records of complaint investigation findings and follow-up actions
  • Review procedure for batches failing specifications
Observation detail · 4 observations · From the source

Inspectors: Garrad R Poole · Richard T Riggie

Observation 1

Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.

Specifically, you did not investigate complaint (ID CM 2022-02) received June 21st, 2022 that reported a patient had "pain" and "minor swelling" in their knee after receiving an injection of your product mVASC-lot ws Furthermore, you did not follow your written procedures entitled "Complaint Handling" Document Number - SOP-8001 which states: "For all complaints, the evaluation shall include an assessment of whether there is potential for harm to a patient or end user ofthe device. Should sucha case arise, appropriate customer notification and failure investigation shall commence without delay". Since commercial distribution beganin| , you have distributed approximately) ... | of mVASC (a product described by your Instructions For Use (IFU) as extracellular matrix derived from hypodermis skin).

Observation 2

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, since your commercial operations began beginning in| wie you have not validated

Observation 3

The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests ifthey exist.

Specifically, you have not specified any identity test to be performed on components used to manufacture mVASC product. You have established acceptance criteria based off the certificate of analysis for the following, but you have not established criteria for a specific test to verify the identity of the components: a. b é, (b)(4)

Observation 4

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, your ‘ait h document number - , does not address evaluating batches that fail to meet specifications. Of the| ... batches produced - have failed for reasons to include wwe ws bioburden. Additionally, you did not investigate into the reason of failure for lot ica that failed for - Since commercial distribution began in aw |! you have distributed approximately of mVASC (a product described by your Instructions For Use (IFU) as extracellular matrix derived from hypodermis skin).

See all 4 findings in this document
[FDA 483 observation · FDA]MSD Ireland (Carlow) — Inadequate environmental monitoring in filling
FDA🧬 Biologics483

FDA cited three observations at MSD Ireland (Carlow) (Biological Drug Manufacturer). During observation of the Gardasil 9 filling process, the environmental monitoring system for aseptic processing areas was found inadequate, and review of unexplained discrepancies and procedures to prevent microbial contamination were also cited.

Published 2026-10-26 · Inspection date 04/01/2025 · Biological Drug Manufacturer · FEI 3008694906

Key facts · Basis: official index plus supporting sources
  • Observations: 3
  • Observation 1: Inadequate system for monitoring environmental conditions in aseptic processing areas (during observation of the Gardasil 9 filling process)
  • Observation 2: Inadequate thorough review of unexplained discrepancies
  • Observation 3: No procedures to prevent microbial contamination of sterile drugs
Insight · Editorial insight

The environmental monitoring system was cited while the filling operation was directly observed, signaling that whether monitoring locations and methods reflect actual operational risk is now being assessed. It is worth checking whether monitoring points on the filling line are set based on interventions and risk assessment.

Check points
  • Risk-based setting of environmental monitoring points in the filling area
  • Scope of investigation of unexplained discrepancies
  • Procedures to prevent microbial contamination of sterile drugs
Observation detail · 3 observations · From the source

Inspectors: Laurel A Beer · Travis S Bradley

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

a) While observing filling operations for Gardasil 9 drug product batch (0.SmL/Dose)) 4. | manufactured for Rest ofWorld (ROW) market within building) = aw sion located near the .. worksite where - of the drug product occur. It was identified that the closest| os | wm | worksite oo . Since the first commercial batch was manufactured on ws total batches of Gardasil 9 have been filled within this. ,,. and released to both US and ROW Markets. b) While observing filling operations for Gardasil 9 drug product batch (0,5mL/Dose am manufactured for ROW market within building wa it was observedthata) ww i not located near the w= _worksitewhere| ss, ~—S—S=s the drug product occur. It was identified that the closest). _|is located ow worksite (from " Since conclusion of the previous inspection, - total batches of biological drug products to includeGardasil 9, Pnuemovax 23, Vaxneuvance, and Capvaxive, have been filled within this, .. and released to both US and ROW Markets.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Deviation investigation QN 201078686 initiated on 14MAR2023, documents a Grade~_ lenvironmental monitoring (EM) action limit excursion ( ..__) identified for... __|within building) - during the production of Capvaxive drug product Process Performance Qualification (PPQ) batch as (0.5mL/Dose) on soa | The probable root cause for the deviation was identified as sample exposure and contamination outside the Grade | environment during transfer and submission for . This conclusion was made without evidence supporting the sample was contaminated during sample transfer. Your investigation concluded that no sample handling errors occurred during transfer of the|. _| sample. However, additional evidence received during the investigation identified that sample contamination may have occurred during an intervention within the and this was not referenced as the probable root cause within the investigation. Capvaxive PPQ batch) wo was utilized to qualify the Capvaxive commercial manufacturing process within) aw

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

See all 3 findings in this document
[FDA 483 observation · FDA]Octapharma AB — Production deviations not recorded or justified
FDA🧬 Biologics483

FDA cited three observations at Octapharma AB (Plasma Derivatives Manufacturer) in an inspection on 09/19/2023. They are deviations from production and process control procedures not recorded or justified, inadequate equipment maintenance intervals, and no batch-specific in-process control procedures.

Published 2026-10-26 · Inspection date 09/19/2023 · Plasma Derivatives Manufacurer · FEI 3005559915

Key facts · Basis: official index plus supporting sources
  • Facility type: Plasma Derivatives Manufacturer, 483
  • Observation 1: Deviations from procedures and their corrective actions not always documented and justified
  • Observation 3: Batch-specific in-process control procedures not established or followed
Insight · Editorial insight

Citing that deviations and corrective actions were not always recorded and justified signals that FDA checks traceability of procedural departures in plasma fractionation processes document by document. Since equipment maintenance intervals and in-process control procedures were cited together, it is worth checking that deviation records link to the process control basis.

Check points
  • Whether procedural departures in production records were registered as deviations and justified
  • Whether equipment maintenance intervals match the actual performance history
  • Whether batch-specific in-process test items are reflected in procedures
Observation detail · 3 observations · From the source

Inspectors: Alan L Truong · Ze Peng · Olga Simakova · Scott T Ballard

Observation 1

Deviations from written production and process control procedures are not recorded and justified.

Specifically, deviations from written procedures and corrective actions for deviations are not always documented and justified. For example: a) Cleaning instructions 4025 and 4065 for the fillingme) for (b) (4) and Octagam and filling room at the department were updated in response to deviation TW #106318 opened on 23 MAY 2019 but no training of operators on the updated instructions was documented. b) Employees setting up and monitoring of temperature alarms in room updated settings after temperature excursions. This room is used for storage of Octagam bulk, bulk, and werfilla. The human error identified in deviation TW #145329 opened 16APR 2021 was not addressed with training. c) Deviation TW #94014 is opened on 1 OCT 2018 for Octaplas(6) (4) machine operations not starting after . Root cause was identified as incorrect assembly of the of the machine and inexperience ofthe . Work instructions were established as part of the CAPA, but no evidence was apparent to demonstrate that firm personnel were trained on these instructions. d) Deviation TW #100586 is opened on 6 FEB 2019 for incorrect amount of PY being added in the (b) (4) for (used for Nuwi operations). The root cause was id

Observation 2

Equipment and(b) (4) are not maintained at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, you do not always adequately maintain equipment in the manufacturing of plasma derivatives. For example: A. On 12 SEP 2023, we observed tank(b) (4) showed visible on the the tank durin fractionation batch . This creates a for : B. On 12 SEP 2023, we observed showed (Bb) (4) on(b) (4) that creates in the basic fractionation area used for manufacturing of pooled plasma intermediates.

Observation 3

Written procedures are not established and followed that describe the in-process controls to be conducted on appropriate samples of in-process materials of each batch.

Specifically, there is no written procedure for directing recovered for(b) (4) — or po when batches of recovered fail testing to standards. Recovered is a processing aid for manufacturing and Octagam.

See all 3 findings in this document
[FDA 483 observation · FDA]Patheon Italia S.p.A. — Drug warehousing procedures not followed
FDA🧬 Biologics483

FDA cited one observation at Patheon Italia S.p.A. (Biological Drug Manufacturer) in an inspection on 09/29/2023: the procedures governing drug warehousing were not followed.

Published 2026-10-26 · Inspection date 09/29/2023 · Biological Drug Manufacturer · FEI 3003065803

Key facts · Basis: official index plus supporting sources
  • Observation 1: Warehousing procedures not followed
Insight · Editorial insight

Non-compliance with warehousing procedures, rather than manufacturing, standing as the sole observation signals that storage operations are treated as an independent inspection item even at biological drug manufacturers. It is worth confirming there is no gap between the operations described in storage procedures and actual practice on site.

Check points
  • Whether warehousing procedures match on-site operations
  • Whether records of storage procedure execution are made and reviewed
Observation detail · 1 observation · From the source

Inspectors: Scott T Ballard · Alan L Truong

Observation 1

Procedures describing the warehousing of drug products are not followed.

Specifically, your written procedure SOP-29727 version « gives instructions to use the(b) (4) " to track storage and movements of materials including those held for dispensing to manufacturing areas and finished product(b) (4) — storage. On 22 SEP 2023, we observed inventory of the dispensing location identified as where inventory did not match the indication in the . For example; differen of were indicated in (b) (4) but only of these items were located in the dispensing area. On 28 SEP 2023, we observed retrieved from(b)(4) location while th showed of product in storage. This batch of finished product was manufactured as batch(b) (4)in 2021.

[FDA 483 observation · FDA]SAFC Pharma Carlsbad — Pathogenic material equipment not segregated
FDA🧬 Biologics483

FDA stated, in an inspection of SAFC Pharma Carlsbad (Biologics Manufacturer) on 06/22/2017, that equipment and consumables handling potentially pathogenic material were not separated from those used for manufacturing product, raising cross-contamination concerns. Aseptic contamination prevention procedures, procedure approval, container closures, calibration, and verification of supplier certificate reliability were also listed as observations.

Published 2026-10-26 · Inspection date 06/22/2017 · Biologics Manufacturer · FEI 978403

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate separation of equipment and consumables handling pathogenic material from manufacturing equipment (cross-contamination)
  • Observation 4: Container closure systems inadequately protected from external factors during storage and use
  • Observation 6: Inadequate periodic verification of the reliability of raw material supplier test certificates
Insight · Editorial insight

Separation of equipment handling pathogenic material was listed as the first observation, signaling that cross-contamination control at biologics sites is checked down to the level of equipment and consumables. Supplier certificates were also not periodically verified, so the basis for receiving raw materials on certificates is worth checking.

Check points
  • Segregated control of equipment and consumables contacting pathogenic material
  • History of periodic verification of supplier test certificate reliability
  • Documentation and execution of the calibration program
Observation detail · 5 observations · From the source

Inspectors: Arie C. Menachem

Observation 2

Procedures designed to prevent microbiological contamination of pi products purporting to be sterile are not established, written, or followed.

Specifically, A. Active non-viable and viable raxticulate sampling is not performed during aseptic processing { (b) (4) (0) (4) in BSc (Grade (4) in Room (6) (4) B. Cleaning of Biological Safety Cabinets (BSCs) as outlined in (b) (4) “Operation, Cleaning, and Maintenance ofthe Biological Safety Cabinets” is inadequate in that: i. The cleaning method for BSCs is not validated to confirm the absence of carryover in the event of a spill or other exposure of product. ii. The cleaning solutions and method specified in your procedure ( (b) (4) were not used during our observation of the cleaning of Biological Safety Cabinet BSC) 4)on 20 JUN 2017. Operators used (b) (4) (which was not specified in the written cleaning procedure) to clean the BSC on this date. iii. | Your procedures for cleaning are ambiguous and do not allow for consistent execution. For example, (b) (4) “Operation, Cleaning, and Maintenance ofthe Biological Safety Cabinets” states "Use of (b) (4) is mandatory in cleaning the BSC" and "Ifusing (b) (4) (b) (4) oo"

Observation 3

Written procedures are not approved by the appropriate organizational units.

Specifically, A. In SOP, (b) (4) , Version 5.0, (b) (4) specific procedures for (b) (4) are not established. B. SOP, (6) (4) Version 7.0, Preventative Maintenance (PM) Program, does not provide instructions for the assessment of equipment that is overdue for PM or calibration. Guat: CDR Donald Ertel, Lead Investigator

Observation 4

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination ofthe (©) @product.

Specifically, you label (b) (4) containing (b) (4) with (b) (4) during (b) (4) steps. Your procedure instructs operators to (b) (4) (b) (4) prior to placing (b) (4) into the BSC. This (0) is then (b) (4) You have not established the compatibility between (b) (4) and (b) (4)

Observation 5

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specifically, probes used to monitor your Liquid Nitrogen Dewars for temperature and LN2 excursions are not regularly calibrated. You use these Dewars to (b) (4)

Observation 6

Establishment ofthe reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.

Specifically, you do not periodically validate your suppliers’ certificates of analysis for components or consumables used during (b) (4) b/22/' et

See all 5 findings in this document
[FDA 483 observation · FDA]Protein Sciences Corporation — Inadequate control of critical starting material
FDA🧬 Biologics483

FDA cited six observations at Protein Sciences Corporation (Licensed Biological Drug Substance Manufacturer) in an inspection on 03/17/2026. They include inadequate inventory control of critical starting materials for Flublok Monovalent Drug Substance, unvalidated computer systems for quality data, contamination prevention design, and inadequate quality unit oversight of CAPA.

Published 2026-10-26 · Inspection date 03/17/2026 · Licensed Biological Drug Substance Manufacturer · FEI 3011286996

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate inventory control of critical starting materials for manufacturing Flublok Monovalent Drug Substance
  • Observation 2: Computer systems for collecting and analyzing quality data not validated
  • Observation 6: Quality Unit failed to provide oversight and ensure effective CAPA implementation
Insight · Editorial insight

Findings running from starting material inventory control to computer systems, contamination prevention design and quality unit oversight signal that the whole quality system of this recombinant vaccine drug substance site was seen as an issue. Unvalidated systems handling quality data in particular are worth checking from a data reliability standpoint.

Check points
  • Whether critical starting material transaction records match physical inventory
  • Validation status of computer systems that process quality data
  • Whether the quality unit reviews CAPA effectiveness evaluations
Observation detail · 6 observations · From the source

Inspectors: Christian Lynch · Richard L Bartlett · Matthew J Gretkierewicz

Observation 1

Inadequate controls for inventory of critical starting materials in (6b)(4) used in the manufacture of Flublok Monovalent Drug Substance, which is used to manufacture Flublok recombinant influenza vaccine.

Specifically, During the FDA inspection conducted on March 10, 2026, your firm's system for storage and identification of master cell banks (MCBs), working cell banks (WCBs), master virus banks (MVBs), and working virus banks (WVBs) used in the manufacture of Flublok drug substance was found to be inadequate. Cell and virus banks are considered critical starting material for Flublok Monovalent Drug Substance and are stored in (b) (4) - Your firm’s validated materials inventory tracking system (b) (4) lists master and working cell and virus bank locations as a generic identifier (b) (4) (b) (4) which is not unique toa (b)(4) records do not differentiate between _(b) (4) (b) (4) During inspectional (b) (4) reconciliation of your cell and virus bank inventory on March 11, 2026, discrepancies were observed between your (6) (4) inventory and physical inventory. Examples of discrepancies the (b) (4) system failed to accurately account for the physical inventory are listed in the following table

Observation 2

Computerized systems used for the collection and analysis of quality data have not been validated.

Observation 3

Flow of materials and equipment is not designed to prevent contamination.

Specifically, Room ®® isa Grade (b) (4) with (6) (4) for movement of (b) (4) - (b) (4) the warehouse receiving area - (b) (4) to the (b) (4) warehouse (b) (4) storage area - (b) (4) (Room /@) - (b) (4) the manufacturing (b) (4) (Grade '§ ) for (B) (4) of (b) (4) Your firm’s environmental monitoring data for Room ®® shows consistent mold recoveries (% of all (b) (4) mold recoveries) with rates of 16.19% in 2023, 22.09% in 2024, and 28.10% in 2025. Although the frequency of sporicidal cleaning was increased, no corrective actions have been implemented to address the fundamental deficiency in material flow and segregation.

Observation 4

Written procedures designed to prevent microbiological contamination of drug substance are not established or are not followed.

Observation 5

Equipment and Facilities are not designed to prevent the potential for contamination.

Specifically, On 03/09/2026, _— (b) (4) utilized for holding Flublok drug substance was observed with apparent corrosion, chipping paint, and condensation. (b) (4) was holding drug substance Lot (b) (4) of —_(b) (4) Lot (b)(4) of B/Austria, and Lot (b)(4) of B/Austria at the time ofthe

Observation 6

The Quality Unit has failed to provide adequate oversight and ensure the implementation of effective corrective and preventive actions.

Specifically, Your firm’s own Product Quality Reviews (PQRs) for 2024 and 2025 identified that the root cause category of “Methods” accounted for approximately 41% and 40%, respectively, of critical/major/significant deviations in each review period. Despite this recurring trend being formally documented in two (b) (4) reviews, the Quality Unit has not initiated a Corrective and Preventive Action (CAPA) to systemically address this issue. During the 2025 review period, your firm initiated Significant deviations QE-137857 (Root Cause - Methods) which resulted in rejection of Flublok Drug Substance batch (b)(4) and QE-159034 (Root Cause — Methods) which resulted in rejection of Flublok Drug Substance batch _(b) (4) During the 2024 review period, your firm initiated Major deviation PRLD24E0046 (Root Cause — Manpower/Attention Error with Methods identified as a contributing factor requiring corrective action) which resulted in rejection of Flublok Drug Substance batch (b) (4)

See all 6 findings in this document
[FDA 483 observation · FDA]Samsung Biologics Co., Ltd. — Cross-contamination procedures at changeover
FDA🧬 Biologics483

FDA cited four observations at Samsung Biologics Co., Ltd. (Drug Substance Manufacturer) in an inspection on 05/27/2025. They include not following cross-contamination prevention procedures during product changeover (PCO), quality control unit responsibilities and procedures not followed, inadequate QC laboratory controls, and not following reporting procedures for changes to approved applications.

Published 2026-10-26 · Inspection date 05/27/2025 · Drug Substance Manufacturer · FEI 3010479596

Key facts · Basis: official index plus supporting sources
  • Observation 1: Drug substance cross-contamination prevention procedures not followed during product change over (PCO)
  • Observation 3: Inadequate procedures and controls in the QC Laboratory supporting drug substance release testing
  • Observation 4: Procedures for reporting and implementing changes to approved applications not followed
Insight · Editorial insight

PCO cross-contamination procedures and change reporting procedures cited together at a drug substance site signal that product changeover operations and change control are direct inspection targets. It is worth checking cleaning and verification records at changeover and the criteria for classifying license changes for reporting.

Check points
  • Step-by-step execution records of the PCO procedure
  • Criteria for classifying approved-application changes for reporting
  • Compliance with QC laboratory release testing control procedures
Observation detail · 4 observations · From the source
Observation 1

Procedures implemented to prevent cross-contamination of drug substances during product change over (PCO) operations were not followed.

a) Specifically, between 010CT2018 to 2IMAY2025, you routinely failed to change change over between manufacturing ofdifferent drug substances wit in(b)(4) (as identified within deviations DEV-017954 and DEV-017965). This practice does not follow your current and histori = 0161, (ver. 2.0 - 14.0), Maintenance Procedure o ” which requires that the e changed ot. You have manufactured, (B)4)§) an the following drug substances (of which (B)(4)/ are within known expiry/retest dates) for manufacture of drug products (for U.S. and ROW markets) without having changed the(4/0 i Drug Substance Proprietary Name Plant Number Batches Product Code of Drug Product Released and Shipped

Observation 2

The responsibilities and procedures applicable to the quality control unit were not followed.

Observation 3

Procedures and controls utilized within the Quality Control (QC) Laboratory in support of drug substance release and(b) (4)testing are deficient.

The following was observed. a) Your firm failed to adhere to established protocols for drug substance (DS) by not performing sample pulls and associatedai within defined protocol timeframes (SOP-QC-00067). The following issues were noted: e (6) (4) samp pulls were conducted outside the allowable time wi ified

Observation 4

Failure to follow established procedures for reporting and implementing changes to an approved application.

a. Your firm implementeda revised version ofthe assay method - Determination of or the r i drug substance (DS) batches for manu acturing prior to receiving FDA approval for the change completion of the required waiting period following submission of a CBE-30 supplement. The revised assay method was u release testing of S batches (Batch numbers: and for stabili ing of S batches (Batch numbers: . The atches including (6)%4) DS batches were released between 09JAN2024 and , after implementation of the new method on 270CT2023, even though the corresponding CBE-30 supplement(HYP) was not submitted until 20MAR2024 and not approved until 1OSEP2024, b. The approved protocol for qualifying new((b) (4) reference standards was not completely implemented, i.e., change was identified when com aring the information provided in Section 3.2.8.5 ofan Annual Report with(b) (4) to that in the original BLA(b)(4) c. The data to support (5)A) reference standard were not completely reported. eee

See all 4 findings in this document
[FDA 483 observation · FDA]ADMA Biologics, Inc — Unexplained discrepancies not investigated
FDA🧬 Biologics483

FDA stated, in an inspection of ADMA Biologics, Inc (Licensed Biological Drug Manufacturer) on 12/11/2024, that unexplained discrepancies were not thoroughly reviewed whether or not the batch had been distributed. The environmental monitoring system for aseptic processing areas and procedures to prevent microbial contamination of sterile drugs were also found inadequate.

Published 2026-10-26 · Inspection date 12/11/2024 · Licensed Biological Drug Manufacturer · FEI 1000525461

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate review of unexplained discrepancies regardless of whether the batch was distributed
  • Observation 2: Inadequate system for monitoring environmental conditions in aseptic processing areas
  • Observation 3: Procedures to prevent microbial contamination of drugs purporting to be sterile not established or followed
Insight · Editorial insight

Weak review of unexplained discrepancies alongside the aseptic environmental monitoring finding signals that FDA looks at how environmental abnormalities lead to batch investigations. It is worth checking whether there are criteria for widening the investigation scope to batches already distributed.

Check points
  • Criteria for investigation scope including distributed batches
  • Rationale for monitoring locations and frequency in aseptic processing areas
  • Link between environmental monitoring excursions and batch investigations
Observation detail · 3 observations · From the source

Inspectors: Thai D Truong · Burnell M Henry · Jennifer L Reed

Observation 1

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, a. You initiated deviation DEV23041 on March 28, 2023, when (b) (4) of stoppers with vials was observed during the filling process of Bivigam lot 233798. To address_the (b)(4). you decided to discontinue the fill and initiate repairs. The bulk line was(b) (4). and the bulk was (b)(4) the fill (b) (4) . You stated that the unfilled bulk was returned to refrigerated storage and “was successfully reprocessed as Bivigam Fill Lot 234608 on 03/29/2023.” There was no further investigation into potential impact of (D) (4) on the bulk. In addition, there is no approved procedure for{D) (4) of Bivigam bulk, and the currently approved license includes no provision for reprocessing or reworking of Bivigam. Bivigam fill lot 234608 was released to the US market on 09/05/23. Additional examples of(b)(4) after stopped Bivigam (6) 4) filling operations are presented in the table below. Each Bivigam lot was released to the US market. Deviation ID Date Original Batch ID |Description ew Batch ID / Release date

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, a. Particle levels were not adequately monitored or well-controlled in the Grade iasof) (6)I(4)H NNN NNNNN ln(5)IC@)NNNNNNNN in which stevte drug components ae exposed during filling operations. For example: I. Particulates from filling components used during the aseptic filling operation were found in your post filled drug product vials. Since August 2021, you have initiated more than ten deviations for particulates that action limit, and about (b) (4) | events for particulates (b) (4). alert limits for particulates found inside iil filled drug product vials. II. A probe used to measure total non-viable particulates in the Grade}! (Iso) (b) (4)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, You currently monitor temperature, humidity, air pressure differential, and non-viable particulates during filling operation in your Grade a (ISOf}) environment. You failed to establish a procedure on how to handle and respond to an excursion when acceptable limits are exceeded during filling operations.

See all 3 findings in this document
[FDA 483 observation · FDA]GSK Vaccines GmbH — Shingrix critical utilities not qualified
FDA🧬 Biologics483

FDA cited, at GSK Vaccines GmbH (Vaccine Bulk Product) in an inspection on 11/12/2024, inadequate maintenance of biological drug manufacturing facilities and equipment, along with inadequate qualification and monitoring of critical utilities for Shingrix manufacturing. Quality oversight and integrity of electronic data and inadequate deviation management were also cited.

Published 2026-10-26 · Inspection date 11/12/2024 · Vaccine Bulk Product · FEI 3001314775

Key facts · Basis: official index plus supporting sources
  • Observation 2: Inadequate qualification and periodic monitoring of critical utilities for Shingrix manufacturing
  • Observation 3: Quality oversight and integrity of electronic data from manufacturing equipment, environmental monitoring and the Process Control System not established
  • Observation 4: Deviation management failed to identify, document and investigate impact on the drug substance
Insight · Editorial insight

Critical utility qualification and Process Control System electronic data integrity cited together signal that data left by automated systems in a vaccine bulk process is also subject to quality oversight. If utility monitoring data is stored in electronic systems, the reviewer and audit trail for that data are worth checking.

Check points
  • Critical utility qualification and periodic monitoring plan
  • Review of audit trails of process control system electronic data
  • Records of impact assessment of deviations on the drug substance
Observation detail · 5 observations · From the source

Inspectors: Massoud Motamed

Observation 2

Critical utilitiesr (b) (4) utilized as productL(b) (4) in the manufacture of Shingrix are not adequately qualified or routinely monitored to ensure reproducible quality.

Specifically, [(6) (4L quality control testing is not performed on thef (b) (4) receivedr (b) (4) J and a routine monitoring program has not been established for these utilities that are supplied 1hroughout the facility (b) Further, the utilization of these (b) (4) has continued in the absence ofcompleted qualifications of theȔb) (4) (b)(4)

Observation 3

Quality oversigflt and integrity of electronic data captured to support the manufacturing equipment, environmental monitoring, and manufacturing systems ( e.g., Process Control System) has not been established.

For example: a. For ther (b) (4) J assessments: i. Electronic documentation of the C (b) (4) ofthef (b) (4) , performed on May 8, 2024 is missing. ii. Self-tests for internal diagnostics of equipment were aborted or failed on October 29, 2024, and June 17, 2024, respectively, without explanation or documentation. iii.1 (b)(4) l which is used for the r (b) (4) J instruments, lacks a requirement for quality oversight of the associated testing and metadata. b.For thel (bf(4) _J procedure 9000087546 titled SDOC - Environmental Monitoring, version 04 permits measurements to be interrupted [aborted] and repeated immediately for occurrences such as ISi

Observation 4

Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and docs not adequately identify, document, or investigate the impact to drug substances.

For example: a. Procedure 9000075940-02, MZP: Alarm Managementand Audit Trail defines critical" alarms (defined as _(b)(4) as (b) (4) critical, (b) (4) Since October 09, 2024, there have been© critical ™alarms that are (b) (4) critical. Despite these (b) (4) critical alarms, (b) (4) has not reviewed, evaluated, or otherwise acknowledged these alarms since October 09, 2024 (as of November 09, 2024). Without (b) (4) of these alarms, the production department continues to issue batch records for the manufacture ofShingrix drug substance per SOP 9000080766 version 4 titled eBR Execution and Review and has initiated manufacture of() 4) batches of Shingrix drug substance without the evaluation of these (b) (4) of alarms. b. High bioburden levels were discovered during a lifetime study of (b) (4) (b) (4) has a (b) (4) which was identified as a source of bioburden contamination to the Shingrix drug substance. Manufacture of Shingrix drug substance continues at risk with (b) (4) (b) (4) Correction of the equipment design is not scheduled until March 2025.

Observation 5

There is inadequate quality oversight to assure that the Shringrix and Measles drug substances have the identity, strength, quality, and purity they purport or are represented to possess.

For example: a. High bioburden levels were discovered during a lifetime study off (b) (4) [()(4) J Quality assurance invalidated this data during the lifetime study, aJbeit the data was considered valid data by quality control. b. There is no quality oversight of unplanned maintenance events to assess the qualification/validation status and product impact. Specifically, procedure GUJ-9000055892-24 General Procedure of Preventive and Corrective Maintenance does not require the quality unit's approval for any unplanned maintenance or repairs to the facility. c. Documentation practices are insufficient. For exampleJ (b)(4) L(b) (4) J in classified Room 1 (b)(4) used to manufacture Measles bulk drng substance lacked supporting documentation. d. Signed and dated original documents pertaining to theL (b) (4) of materials used in the manufacture of Measles drug substance were found in the trash.

Observation 6

There is a lack of data to demonstrate the quality of'Ǖhe (b) (4) J prior to use for vaccine production.

(b) (4) the (6) (4) J have not been inspected and documented for (b)(4) ISi

See all 5 findings in this document
[FDA 483 observation · FDA]GlaxoSmithKline Biologicals SA — In-process specifications and WFI investigation
FDA🧬 Biologics483

FDA cited, at GlaxoSmithKline Biologicals SA (Vaccine Manufacturer) in an inspection on 06/24/2019, purity specifications for in-process materials not set on a scientific basis and findings in Water for Injection (WFI) in the aseptic bulk manufacturing area not thoroughly investigated, among other observations.

Published 2026-10-26 · Inspection date 06/24/2019 · Vaccine Manufacturer · FEI 3002875226

Key facts · Basis: official index plus supporting sources
  • Observation 1: Scientific justification for in-process material purity specifications not established
  • Observation 2: Inadequate investigation of findings in Water for Injection (WFI)
  • Observation 5: No Quality Unit approval documents supporting operations outside the routine operating range
Insight · Editorial insight

Weak WFI investigation in the aseptic bulk area and an in-process specification problem cited together signal that water and intermediate quality criteria are assessed on the same line in vaccine manufacturing. Quality unit approval documents were also required for operations outside the routine range, so the approval path for abnormal operations is worth checking.

Check points
  • Scope of investigation and product impact assessment for abnormal WFI findings
  • Rationale for in-process material specifications
  • Prior quality unit approval records for non-routine operations
Observation detail · 6 observations · From the source

Inspectors: Debra M. Emerson · Susan Jackson · Leslie Wagner · Shuang Tang

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that in-process materials conform to appropriate standards of purity.

Specifically, a. ” for the following steps in) the acceptance criteria or specification for the Microbial Purityteston) = . ——_—i isa b. There is insufficient bioburden and endotoxin monitoring throughout the manufacturin processes for the following bulk products:| : ins - , Shringrix, and) ,,., |...|. Forexample, during routine production, Shingrix is tested for bioburden from the si and bioburden and endotoxin samples are taken) .. sterile filtration.

Observation 2

Failure to thoroughly investigate the presence of) _,,, in the Water for Injection (WFI) | os where sterile bukh is manufactured.

The deviation investigations failed to evaluate complaints for[ |, =Sst~*~<C~«~CSC*deecezi edd (ifanny) sincethe| - [ontheWFI| .., jon December 4, 2015, the attributing root cause. a. Deviation 200578478 was initiated on 28 July2017inBuilding, wy SSCs theofthe WFI_| The... |wereidentifiedas| b. Deviation 200654818 initiated on 26 July 2018 in Building in WFI [ml The root cause also attributedtothe04December20155 a’assi‘“‘#(é‘(asti‘(i‘i‘i‘séis

Observation 3

The following corrective actions were found deficient: a.

Thecorrective actions/preventative actions to multiple deviations opened in 2016 which stopped production until November 2016 is deficient in that there was no assessment of the current automated| ...._—_|for equipment to ensure that the cycle was adequate for the ~__oatamination. This equipment includes)mw SEE

Observation 4

Your firm has not performed adequate process validation for!

used in| yy [Which have ranges to include assessing each end ofthe range. For example,

Observation 5

There is a lack of documentation approved by the Quality Unit to support operating outside of your routine operations.

Specifically, a. Deviation 200543472 was opened on 12 FEB 2017 when|- |wasfoundinthe| ,, | after on . The deviation determined that changes needed to be made to SEE

Observation 6

The following equipment maintenance issues were on observed on June 7, 2019 in the) a | ww manufacturing building: a.

son material and a build-up of| ge was observed belowa leaking vom: b. AL —~«zwas observed forthe! jinroom|andi they SCioom. c. was Observed above the in various| ... _|to include the diel d. Apieceofa| ., _|was observed above the as in room) aw G. | wm was observed dripping from a _ for the) .. for i inthe! = wv. += ~—~«room. The ,,, from this|- _was also observed on the (bya) t SEE

See all 5 findings in this document
[FDA 483 observation · FDA]Serum Institute of India Private Ltd. — Inadequate drug substance OOS investigation
FDA🧬 Biologics483

FDA stated, in an inspection of Serum Institute of India Private Ltd. (Vaccine Manufacturer) on 01/30/2026, that OOS investigation of SARS-CoV-2rS drug substance batches was not thorough, production and process control records were not made at the time of the work, and cleaning and maintenance intervals for equipment and utensils were inadequate.

Published 2026-10-26 · Inspection date 01/30/2026 · Vaccine Manufacturer · FEI 3020223359

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate Out of Specification investigation for Drug Substance
  • Observation 2: Production and process control records not documented at the time of performance
  • Observation 3: Inadequate cleaning and maintenance of equipment and utensils at appropriate intervals
Insight · Editorial insight

Weak OOS investigation together with records not made contemporaneously signals that the reliability of the production records underlying investigation conclusions is itself in doubt. It is worth checking whether, when reviewing production records in an OOS investigation, the timing of the entries is also confirmed.

Check points
  • Scope of root cause review in drug substance OOS investigations
  • Whether production records are made contemporaneously with the work
  • Cleaning and maintenance intervals for equipment and utensils
Observation detail · 3 observations · From the source
Observation 1

Out of Specification Investigation for the Drug Substance is not thoroughly investigated.

(A) Specifically, you initiated an Out-of-Specification (OOS) investigation for SARS-CoV-2rS Drug Batch No. on February 20, 2025, after obtaining a and investigations identified no laboratory or manufacturing errors, respectively, and a on March 18, 2025, confirmed the OOS at ((BY(4y) The investigation timeline and results are summarized below: Investigation Step Result/Finding ‘Specification/Expected The OOS result was invalidated by attributing it to degradation of theUNS) despite inconsistent M(b)(4)l testing where only(PGA data aligned with historical trends. The investigation concluded the reference standard had declined in performance and invalidated the OOS, even though(G4 yyy

Observation 2

Written production and process control procedures are not documented at the time of performance.

Specifically, (A) Pertaining to active air testing used to evaluate the environmental conditions of Grade 8 areas supporting drug product manufacture, the following deficiencies were identified in the concurrence between electronic records (i.¢., instrument history) and official documentation. From February 8, 2025, to October 10, 2025, approximately® active air samples cannot be accounted for based on instrument history. Additionally, there is a lack of correspondence between sample nomenclatures and sampling sites, preventing confirmation that intended samples were procured. Multiple instances were identified where samples retained identical identifiers: Total Samples Taken Samples with Identical Identifier January 8, 2026 | ||

Observation 3

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination of Drug (Bb)(4) Lots.

Specifically, the product contact surfaces of IQ (E)4Iwyys and systems used in SARS-CoV-2rS Drug (64H manufacturing are not adequately maintained. A) On January 29, 2026, the system displayed These conditions were subsequently identified as system. The equipment had been documented as cleaned on January 28, 2026. (B) Additionally, the resin in system yA) vet the was classified as clean and recorded as being on its use of a lifetime allowance.

See all 3 findings in this document
[FDA 483 observation · FDA]GSK Vaccines GmbH — Dedicated equipment cleaning not validated
FDA🧬 Biologics483

FDA stated, in an inspection of GSK Vaccines GmbH (Licensed Biological Drug Manufacturer) on 02/27/2026, that the cleaning procedure for dedicated equipment used to manufacture Aluminum Hydroxide adjuvant was not validated and that unexplained discrepancies were not thoroughly reviewed whether or not the batch was distributed.

Published 2026-10-26 · Inspection date 02/27/2026 · Licensed Biological Drug Manufacturer · FEI 3001314775

Key facts · Basis: official index plus supporting sources
  • Observation 1: Cleaning procedure for dedicated equipment used to make Aluminum Hydroxide adjuvant not validated (contamination and carry-over prevention)
  • Observation 2: Inadequate review of unexplained discrepancies regardless of distribution
Insight · Editorial insight

Requiring cleaning validation to prevent contamination and carry-over even for dedicated equipment signals that dedicated use is not a basis for skipping cleaning verification. The state of cleaning verification for equipment that makes components, such as adjuvants, is also worth checking.

Check points
  • Whether dedicated equipment cleaning validation has been performed
  • Carry-over acceptance criteria for equipment that makes components
  • Scope of investigation of unexplained discrepancies
Observation detail · 2 observations · From the source
Observation 1

Your firm has not validated the cleaning procedures for dedicated equipment used in the manufacture of Aluminum Hydroxide adjuvant to prevent contamination or carry-over.

This adjuvant is a component of your licensed U.S. products including (b) (4) Infanrix, Boostrix, Kinrix, and Pediarix. Specifically, your cleaning validation and monitoring program for the aluminum hydroxide adjuvant production suite( (b)(4) = and (6) (4)) is inadequate. You have introduced unvalidated (b) (4) cleaning steps into routine production, failed to maintain a state of control for your validated (b) (4) cleaning process, and failed to adequately investigate recurring cleaning failures. a) You introduced an unvalidated (6b) (4) workaround into your routine cleaning and manufacturing process. Since May 2023, you have used an unvalidated (b) (4) cleaning procedure with (b) (4) (b) (4) for all batches ofAluminum Hydroxide adjuvant. This procedure was implemented to mitigate a known design flaw where aluminum hydroxide (b) (4) (implemented January 2026) and (b) (4) (implemented May 2023) and is (b) (4) This (6) (4) cleaning step was not validated to demonstrate its effectiveness. Furthermore, this change to your cleaning process was not managed through your firm's change control system.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has already been distributed.

Specifically, the firm failed to conduct formal investigations, in accordance with SOP-082366, “Deviation Handling,” for failed (6) (4) test results associated with the Aluminum Hydroxide Adjuvant filling equipment. SOP 9000087625, “Requirements for (b) (4)

[FDA 483 observation · FDA]Nova Laboratories Ltd — Inadequate equipment maintenance intervals
FDA🧬 Biologics483

FDA cited one observation at Nova Laboratories Ltd (Biologics - Pharmaceuticals, Medical Devices) in an inspection on 08/23/2024: equipment and utensils were not maintained at appropriate intervals to prevent contamination that could alter the safety or quality of the drug.

Published 2026-10-26 · Inspection date 08/23/2024 · Biologics - Pharmaceuticals, Medical Devices · FEI 3000323524

Key facts · Basis: official index plus supporting sources
  • Observation 1: Equipment and utensils not maintained at appropriate intervals to prevent contamination
Insight · Editorial insight

Maintenance intervals standing as the sole observation signals that delayed maintenance is treated as a matter that can lead through contamination to product safety and purity problems. It is worth checking that maintenance intervals are set based on contamination risk.

Check points
  • Rationale for setting equipment and utensil maintenance intervals
  • Whether a delayed maintenance event is handled as a deviation
Observation detail · 1 observation · From the source
Observation 1

Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, Regarding the cleaning of manufacturing equipment or glassware used in the production of a sterile (b) (4) and a (b) (4) used for a (b) (4) the production of (b) (4) drug product ((b) (4) )in (b) (4) _, includes, but is not limited to, (b) (4) , the SOP titled, Preparation of Equipment, Including Pressure Vessels, Mixing Vessels, Glassware, Tools And Seals For Use In Manufacturing, SOP1367, Ver. 15, states that for post cleaning, ‘ (b) (4) ” The cleaning of each piece of equipment or glassware is documented on (b) (4) In addition, no study could be provided that substantiates the (b) (4) — until drying.

[FDA 483 observation · FDA]GSK Vaccines GmbH — Aseptic contamination control and mix-up areas
FDA🧬 Biologics483

FDA cited four observations at GSK Vaccines GmbH (Licensed Biological Drug Manufacturer) in an inspection on 03/06/2024. They are procedures to prevent microbial contamination of sterile drugs not established or followed, inadequate review of unexplained discrepancies, inadequate areas to prevent mix-ups, and inadequate documents used for distribution.

Published 2026-10-26 · Inspection date 03/06/2024 · Licensed Biological Drug Manufacturer · FEI 3001314775

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures to prevent microbial contamination of drugs purporting to be sterile not established or followed
  • Observation 3: Inadequate separate or defined areas to prevent mix-ups
  • Observation 4: Inadequate documents used for drug distribution
Insight · Editorial insight

Mix-up prevention areas and distribution documents cited alongside aseptic contamination control signal that post-manufacturing storage and distribution controls fall within the same inspection scope. It is worth checking that area separation and distribution documents reliably ensure product identification.

Check points
  • Separation and labeling state of mix-up prevention areas
  • Accuracy of product identification information in distribution documents
  • Records of execution of aseptic contamination prevention procedures
Observation detail · 4 observations · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.

Specifically, a.On 2/26/2024 during operation of MenA Vaccine batch using (b) (4) unit, and after exchanging located approximately vials, the grade, operators did not reject the(b) (4) product vials located directly below the intervention. As per your SOP instruction# 9000085445-02, before carrying out a change, the line must be (b) (4) so that there are no vials in the . However, the operators did not ensure that the (b) (4) line was to the intervention. In addition, there is not documentation available in the executed batch records to ensure that the operators (b) (4) the (b) (4) lines or reject the product vials the interventions. The firm has used the unit to RabAvert (batch , Expiry(b) (4) ) and MenA Vaccines (batch and Expiry(b) (4) ) for US market. b.On 3/6/2024, during set up operations of(b) (4) unit for MenA batch , | observed the shoulder ofGrade operator touch the Gradey, side of th . No sanitization was performed on the Grade1) side ofthe before closing the .

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, investigation related to of Aluminum Hydroxide is not adequate. Aluminum Hydroxide is an adjuvant used for Infanrix, , Pediarix, and Boostrix Vaccine products for US market. On 06Apr2023, and were observed on the(b)(4) of , which is used for th of Aluminum Hydroxide bulk material (Deviation # 200991257). The root cause was identified as of(b) (4) due to(b) (4) contact with Aluminum Hydroxide suspension. Based on the investigation, you have identified that a contact time of more than can lead to(b)(4) parts. However, the investigation was not extended to other | surfaces to re-evaluate the established dirty hold times of 72 hours for fixed equipment, such as but not limited to , and for(b) (4) parts, such as not limited to utilized for Aluminum Hydroxid production.

Observation 3

Separate or defined areas to prevent mix-ups are deficient.

Specifically, your firm failed to discard and/or transfer materials to a physical quarantine location to prevent the materials being used beyond dates.(b) (4) materials were observed to be stored in your on 2/27/2024. There was no clear demarcation between materials and or materials in your(b)(4), More than material batches (material lots) had been identified that are currently stored at the

Observation 4

Documents and (6) (4) used for distribution of the(6) (4) drug products are deficient.

Specifically, your firm failed to ensure correct (b) (4) were applied to (b) (4) drug product containers before release. The final (b) (4) on your containers that hold (b) (4) drug products contain incorrect expiration date. The expiration date on thel®) (4) was not based on the associated stability studies. Furthermore, your documentations that accompanied with the (b) (4) drug product shipment, including the packing lists, contain incorrect information. The documents do not bear an expiration date determined by the associated stability studies and do not match with the expiration date on the container (b) (4) that hold ©)@) drug products.

See all 4 findings in this document
[FDA 483 observation · FDA]Protherics UK Limited — Mold in storage room not assessed
FDA🧬 Biologics483

FDA cited one observation at Protherics UK Limited (Biological Drug Substance Manufacturer) in an inspection on 08/13/2024: various molds were found in a room storing manufacturing materials and stability samples, yet they were not adequately investigated or assessed for impact.

Published 2026-10-26 · Inspection date 08/13/2024 · Biological Drug Substance Manufacturer · FEI 3001417487

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate investigation and impact assessment of various molds found in the room storing manufacturing materials and stability samples
Insight · Editorial insight

That the mold was found in the room holding manufacturing materials and stability samples signals that an abnormal storage environment can affect both material quality and the reliability of stability data. It is worth checking whether stability samples are included in the impact assessment when microbial abnormalities occur in storage areas.

Check points
  • Investigation and impact assessment procedure when mold is found in storage areas
  • Environmental monitoring of stability sample storage
Observation detail · 1 observation · From the source
Observation 1

Your firm has not fully investigated or assessed the impact of finding various molds in a (DB) (4) room in which manufacturing materials (used for manufacturing of (b) (4) and (®) (4) ) and stability samples are held.

From March 2023 to April 2024, five quality investigations were initiated to address molds in (b) (4) = (4) (b) (4) room (b) (4) of a (b) (4) and include: ® #70445; #73010; © #73044; DEV-00267; and DEV-00331. These investigations were generated in accordance with procedure (b) (4) -SOP-"-000015, Control of Quality Events and Corrective and Preventive Actions, Ver 21, 23 & 23, which allow for such actions as additional monitoring activities (e.g., (b) (4) ) and requires the use of a root cause investigation (which would allow for the expansion of the scope of investigation). Although your firm initiated various corrective actions (CAPAs), the following was revealed during this inspection: a) Your firm did not initiate investigative environmental monitoring and sampling in manufacturing areas of building to detect for mold contamination beyond routine EM monitoring to address, for example, routes or pathways of supply items which were put at risk by being exposed to molds in (6) (4) room (©) (4). Note that supply items undergo a cleaning/disinfection regimen before going into controlled areas but given the potential for cross contamination and movement of mold spores, routine EM migh

[FDA 483 observation · FDA]Sanofi Pasteur — Incomplete batch record instructions, 5 items
FDA🧬 Biologics483

FDA cited 5 observations at the Sanofi Pasteur vaccine manufacturing site (FEI 3002972083) in an inspection on 09/29/2023. The first observation is that time limits and instructions for Concentrated Tetanus Protein (CTP) bulk preparation in the Haemophilus b Conjugate Vaccine process were not defined in the master production and control record.

Published 2026-10-26 · Inspection date 09/29/2023 · Vaccine Manufacturer · FEI 3002972083

Key facts · Basis: official index plus supporting sources
  • Observation 1: Incomplete master production and control record instructions (time limits and instructions for CTP bulk preparation not defined)
  • Observation 2: Visual inspection of a retain sample linked to a broken-vial complaint found cellulose particles
Insight · Editorial insight

The case shows that when time limits and work instructions for intermediate preparation are not fixed in the master record, the basis for explaining batch-to-batch differences is weakened. Particles found in a retain sample during a complaint investigation signal a need to check whether complaint handling leads to detection of product quality signals.

Check points
  • Reflection of time limits for each intermediate preparation step in the master production record
  • Use of retain sample inspection results from complaints in investigations
  • Adequacy of drug product storage conditions
Observation detail · 5 observations · From the source
Observation 1

The master production and control records are deficient in that they do not include complete instructions, Specifically, there are no defined (1) (4)time frames and/or instructions for the (Bb) (4) preparation ofthe Concentrated Tetanus Protein (CTP) bulk in the Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) manufacturing process.

A. The CTP bulk requires the (6)I(4)ofthe bulk after the (NN(B)Z)NNN step in Bldg.(4) (Room PU), The ' (DB) (4) © system is rinsed with a (b) (4) solution and collected into ((6)(4) individual 4) (b) (4) that are NN ©)4) intoa (1) (4) container, (6)(4)i the CTP ((b)(4)) process. The CTP bulk is [MB)I@)NM by the technician| (wy@y_ the \(By(AyI container in a (6) (4) ()(@mifor an unknown specified amount oftime under the biosafety cabinet. A bioburden sample is taken at this step at this step, (By(4y the CTP bulk (1) (4) process. B. The production batch record does not include instructions for the (b) (4) steps for the CTP bulk, (b) (4). C. There is no validated mixing time-frame established for the CTP bulk concentration (6) (4) step to ensure (b) (4).

Observation 2

were observed to contain cellulose particles during visual inspection of retain samples related to @ complaint of vial breakage (complaint no.

200255622). This lot had been released and distributed within the US market and was reported to the agency as a Biological Product Deviation Report (BPDR) on 09/15/2022. While reviewing the firm’s CAPA investigation report MLED22A2877 pertaining to deviation MLED22E3775, it was observed that no effectiveness check was conducted to verify the effectiveness ofthe corrective action (updating instruction MLE-1-006038—clarifying the practice of the cutting of bags within filling line 14) implemented in response to the deviation. B. While reviewing | (b) (4) batch number I(b)(4)" | (b) (4) ) for line ?® utilized at the time for sterile (©) (4) ofAct-Hib (US Market), it was observed that the ill(®)(4)iul batch was invalidated due to a reconciliation difference between the quantity ofcrimped vials (11,997) and the quantity ofinspected vials (11,996) prior to being sent for |§(6)(4). Further review into the investigation of the discrepancy (Deviation MLED21£6490) revealed that the discrepancy was likely the result of a lost vial after the crimping step during transfer to visual inspection (b) (4). Due to the vial being lost, it could not be incubated and read for turbidity resulting in a po

Observation 3

Drug products are not stored under appropriate conditions so that their identity, strength, quality, and purity are not affected.

Specifically, While observing warehousing operations within temperature controlled (2-8C) finished product storage room ®@) within the packaging warchouse, it was observed that one shrink wrapped pallet consisting of | (b) (4) boxes ( (b) (4) ) ofWFI diluent batch (6)(4)) were not stored under appropriate

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity.

Specifically, reference standards are not included in analytical sequences to verify© (b) (4) |control for the following critical test assays. A. SOP: MLE 1-005714, titled, yyy (by 4yyyyyyyy- A blank is analyzed at the beginning of the ved for nes vs pote method analysis Gia sample analysis. The (6)(4)absorbance sample result is used for the Purified Vi Polysaccharide bulk (Typhoi Vaccine) \(b)(4)icontent final release assay. B. SOP: Qu-WIN-0040813, titled, “V16_J(B)N4)N_Use of(IIE) (4 inRooms 8 and DA blank is analyzed nl (6) (4)NNN ethod analysis individual samples are analyzed. An average of the readings are or the measurement. The| is measured at the steps during the ofthe Vi Polysaccharide ((Typhim Vi Vaccine) manufacturing process to for further processing. These steps are identified as critical processing parameters (CPP) in the manufacturing process.

Observation 5

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.

Specifically, While observing sterile (6)(4) operations for Imovax Rabies batch X1C16 (US Market) on (6)(4) line P@within OISTRICT

See all 5 findings in this document
[FDA 483 observation · FDA]Seqirus Vaccines Limited — Unexplained discrepancy and trend actions lacking
FDA🧬 Biologics483

FDA cited 2 observations at the Seqirus Vaccines Limited vaccine manufacturing site (FEI 3002806949) in an inspection on 05/26/2023. They were no investigation of an unexplained discrepancy found during review of calibration certificates for Fluad bulk formulated testing, and no corrective action for a testing trend in Monovalent Bulk Drug Substance.

Published 2026-10-26 · Inspection date 05/26/2023 · Vaccine Manufacturer · FEI 3002806949

Key facts · Basis: official index plus supporting sources
  • Observation 1: No investigation of an unexplained discrepancy (related to calibration certificate review)
  • Observation 2: No corrective action for a testing trend in Monovalent Bulk Drug Substance
Insight · Editorial insight

The finding that a discrepancy from calibration certificate review was not investigated signals that FDA looks at the link between instrument calibration results and the validity of test results. The lack of corrective action despite a trend in drug substance testing shows a need to check that trend analysis ends in action and not only in records.

Check points
  • Evaluation of affected test results when calibration certificates show anomalies
  • Link between drug substance test trend analysis and corrective action
Observation detail · 2 observations · From the source
Observation 1

Failure to conduct investigations into unexplained discrepancies.

Specifically, during the review of the calibration certificate for the ), used for the— (b) (4) testing ofthe (b)(4)) for the bulk formulated of Fluad. We observed that the September 2021 Calibration Certificate “As Found” data had not met the acceptance criteria for thePa measurement — (b) (4) © acceptance criteria). Your firm failed to follow procedure as documented in DOC-000134669 v8.0 Execution of Maintenance, in that quality unit was not notified and no investigation was initiated to determine impact on product since September 2020. Between April 23, 2021 - September 15, 2021, your firm manufactured and shipped|" formulated bulk FLUAD Quadrivalent batches to the US.

Observation 2

Lack of corrective action for trends observed during the —(b) (4) | Test of the Monovalent Bulk Drug Substance sample—(b) (4) .

Specifically, There is an ongoing trend of investigations for — (b) (4) observed in the —(b) (4) sample for * (b) (4) of the Fluad Monovalent Bulk Drug Substance for Influenza Vaccine. The investigation into 18 monovalent bulk drug substance batches is investigated under Master Deviation QE000436. Per Doc 000166303 V39 Determination of Sample(by (4). the—(b) (4) Test

[FDA 483 observation · FDA]ID Biomedical Corporation of Quebec — Weak investigations and complaint records, 5
FDA🧬 Biologics483

FDA cited 5 observations at the ID Biomedical Corporation of Quebec biological drug manufacturing site (FEI 3004835647) in an inspection on 05/20/2022. They included inadequate investigations, incomplete complaint records, inadequate procedures to prevent microbial contamination of drugs purporting to be sterile, uncompleted preventive maintenance, and non-representative sampling.

Published 2026-10-26 · Inspection date 05/20/2022 · Licensed Biological Drug Manufacturer · FEI 3004835647

Key facts · Basis: official index plus supporting sources
  • Observation 2: Complaint records incomplete or deficient
  • Observation 5: Sampling not representative of actual use
Insight · Editorial insight

Citing investigations and complaint records together signals that the whole flow of recording quality events and determining their cause was under inspection. Because uncompleted preventive maintenance and non-representative sampling were also raised, the basis for equipment condition and sampling design should be checked as well.

Check points
  • Completeness of required complaint record items
  • Preventive maintenance performance against plan
  • Rationale for representativeness of sampling points and methods
Observation detail · 5 observations · From the source
Observation 1

The following investigation was inadequate.

Specifically, on April 25, 2022, event 200926036 was opened when the in-process endotoxin test data performed on 4/22/2022 could not be located on the The system administrator was contacted to retrieve a copy of the in order to save the data onto he (BY(4) There was no investigation into why id not retain the endotoxin test data or a determination as to where the data file went. The event was closed after a work order determined no error occurred withthe! (b) (4) _

Observation 2

The following complaint records were found incomplete and/or deficient: a.

Between 10/17/2017 and 12/21/2021, your company has received syringe defect complaints associated with multiple lots of FluLaval in which three separate investigations were opened. The complaints included needle connectivity issues to the luer lock, leaking from luer lock, crack at luer lock, and spinning of luer lock on the syringe. The first investigation concluded “incorrect manipulation ofthe syringe during preparation for injection”; second investigation concluded most probable root cause of “mishandling by the healthcare professional”; and the third was a most probable cause “the defect (LLA crack) was originated in the LLA suppliers process”. No “internal root cause at GSK level”. A crack in the LLA (luer lock adaptor) on the syringe was confirmed by the supplier for multiple lots ofsyringes, one of which was provided to your company. FDA was not notified with regards to the defective devices that were released to the market. b. Complaint files do not always include reply to complainant. For example, the complaint files for complaints 1500115512, 1500093176, and 1500115907 do not contain a reply to complainant.

Observation 3

Procedures designed to prevent microbial contamination ofdrug products purporting to be sterile are inadequate.

Specifically, a. There are styles worn by aseptic operators. The following deficiencies were noted for the orn by the operators working in the aseptic (D) (4) i. There are on the iththe o£ 7 approximately een specifically evaluated by sterility assurance for the impact to the aseptic environment. SEE NIPLOYE! A

Observation 4

Preventative maintenance activities were incomplete.

Specifically, the (b) (4) in the (1) (4) on the are not part of a routine preventative maintenance program to include visual inspection. These wedding (DY)

Observation 5

The sampling ofthe is not representative of use.

Specificall manufacturing d th CLO mentcd On a log. ATT ile QC takes the sample, SEE BLOV NATUR

See all 5 findings in this document
[FDA 483 observation · FDA]Burgwedel Biotech GmbH — No justification for sampling and test deviations
FDA🧬 Biologics483

FDA cited 1 observation at the Burgwedel Biotech GmbH biologics vaccine manufacturing site (FEI 3013514411) in an inspection on 08/29/2023. Deviations from the documented sampling plan, test procedures, and laboratory methods were not justified.

Published 2026-10-26 · Inspection date 08/29/2023 · Biologics Vaccine Manufacturer · FEI 3013514411

Key facts · Basis: official index plus supporting sources
  • Observation 1: No justification for deviations from sampling plan, test procedures, and laboratory methods
Insight · Editorial insight

In this case the target of the citation was less the departure from an approved sampling plan or test method than the absence of a recorded rationale for it. It signals a need to check whether laboratory deviations are assessed for justification within the deviation management system.

Check points
  • Justification records for deviations from test methods and sampling plans
  • Link between laboratory deviations and deviation handling
Observation detail · 1 observation · From the source
Observation 1

Deviations from written sampling plans, test procedures and laboratory mechanisms are not justified.

Specifically, There is a failure to thoroughly review any unexplained discrepancy from the firm's contract testing lab used for stability studies of ERVEBO drug product vaccine and related materials. For example, the contract testing lab in is used to perform stability studies for ERVEBO vaccine (recombinant vesicular stomatitis virus-Zaire Ebola live attenuated virus). From 2019-2023, there were 7 out of 18 stability deviations from this contract testing lab for different reasons including missed stability time point; use of expired media for cell potency assay; sample mismanagement; incorrect temperature sample storage during testing; and other reasons. The firm has not fully investigated these deviations to ensure that the contract testing lab is managing the stability samples and performing the stability testing correctly.

[FDA 483 observation · FDA]ENDO USA, Inc. — Operator behavior not following aseptic SOP
FDA🧬 Biologics483

FDA cited 1 observation at the ENDO USA, Inc. biological drug manufacturing site (FEI 1818977) in an inspection on 06/05/2025. Procedures to prevent microbial contamination of drugs purporting to be sterile were not followed, and operator behavior did not match the instructions in the aseptic processing procedure (VV-SOP-00953).

Published 2026-10-26 · Inspection date 06/05/2025 · Biological Drug Manufacturer · FEI 1818977

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures to prevent microbial contamination of drugs purporting to be sterile not followed
  • Related procedure: Aseptic Processing procedure (VV-SOP-00953)
Insight · Editorial insight

The mismatch between the aseptic movements set in procedure VV-SOP-00953 and actual operator behavior signals that aseptic control is judged by on-the-floor conduct and not by having documents. It is worth checking, through observation, that the aseptic movements set in the procedure are followed consistently in real work.

Check points
  • Match between movements set in the aseptic processing SOP and actual work
  • Records of observation and correction of aseptic operator behavior
Observation detail · 1 observation · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, the following actions/behaviors do not conform to the instructions in your Aseptic Processing procedure (VV-SOP-00953). e During the review of video recording of filling operation of Aplisol (Stabilized Solution) (b) (4) in Suite (Bb) (4) — dated 30" April 2025, we observed an operator repeatedly talking and moving his/her hands in a fast : : : b) (4 : and non-deliberate motion in a Grade ®§ manufacturing area. The employee observed was identified as a Trainer. e During the review of video recording of filling operation of (b) (4) (b) (4) in Suite (b) (4) , dated 13"" January 2025, we observed operators talking and moving hands in a fast and non-deliberate motion in a Grade” manufacturing area.

[FDA 483 observation · FDA]Serum Institute of India Pvt. Ltd. — Weak GDP and data integrity practices
FDA🧬 Biologics483

In the 483 from the 04/19/2022 inspection of the Serum Institute of India Pvt. Ltd. biological manufacturing site (FEI 3020223359), FDA cited inadequate GDP and data integrity practices as the first observation. The 5 extracted observations include inadequate deviation and investigation reporting, no HEPA filter replacement schedule, and an inadequate environmental monitoring system in aseptic processing areas.

Published 2026-10-26 · Inspection date 04/19/2022 · Biological Manufacturer · FEI 3020223359

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate GDP and data integrity practices
  • Observation 6: Inadequate deviation and investigation reporting, including inconsistent classification of repeated deviations
  • Observation 7: Maintenance procedure has no schedule for replacing HEPA filters before failure
Insight · Editorial insight

Inconsistent classification of repeated deviations signals that deviation classification criteria drive trend detection and decisions on preventing recurrence. Read together with the missing pre-failure HEPA filter replacement schedule, it points to a need to check for a preventive, not reactive, maintenance system.

Check points
  • Consistency of classification of repeated deviations
  • Reflection of HEPA filter replacement intervals in maintenance procedures
  • Environmental monitoring system for aseptic processing areas
Observation detail · 5 observations · From the source
Observation 1

Good Documentation Practices (GDP) and data integrity practices were deficient.

Specifically, a) Deviation Report No. M26/06/21/03, dated 6/19/2021, - lew reported that the limit ofconductivity for) SS SSSSs«Wass documented a mo instead of,__|_in the following records: 1) Master Formula Record (MFR) for) wwe 0 sie 2) Batch Manufacturing Record(BMR) for; sw Ssés nd or scale for Manufacturing of Lie (BMR no. MBR sg and 3) SOP for Preparation of| me Aree fof] we (SOP No. 101 eet | A typographical error occurred while preparing the SOP, BMR, and MFR where a|] was typed instead ofa b) Deviation Report No. M03/07/21/01lowe sd] reported on 7/3/2021, in the |_| for GMP. __ [cleaning inthe ~ |area, that ‘| > was written on page no.- | of[- | after completion of cleaning on 6/30/2021, for the remaining entry lines. After the operator was accidentally hit by a | | page oii ag of|- |was inadvertently torn from thel w |, resulting in a damage (torn)| a. page. The operator discarded the completed page due to panic and fear of being caught by the supervisor. GMP cleaning was performed on 6/30/2021, but the - —_ cleaning entry on 6/30/2021, which was documented on page ~ |, was not available. c) Deviation Report No. M19/07/21/O1, dated 7/18/2021, wy |was noted during processi

Observation 2

Deficiencies were observed in the detection of ome of the +49 method: a.

No control is included in the initial =e sts=~<CSsSC Step to ensure acceptable quality and quantity of DNA used for the subsequent| .. __ reaction. b. The instructions given for the interpretation of the test results shown in Table | of SOP # 1003-0393-002 are

Observation 6

Reporting of deviations and investigations were deficient as follows; a Inconsistent categorization of recurring deviations: i.

M11/01/22/04 was categorized as major deviation while M30/01/22/01 was categorized as a critical deviation with the same incident of media contamination due to|- clogging. ii, M23/08/21/01 and M15/01/22/01 were both categorized as major with the same incident of unusual peak observed in) ya L b. SOP for the reporting of deviations does not have instruction on the upgrading of the severity of deviation if a similar incident reoccurs. c. A|-_ {throughput study was performed to investigate the root cause ofthe clogged) - _| in deviations M11/01/22/04 and M23/08/21/01. The outcome of the study suggested that the current|- _|configuration is appropriate only for the etn and therefore) .., are recommended (| .. the current number of|- —_|used) forthe! 0 si usedinthe|.. |stepofthe_.. | bioreactor. The same iii study is also applicable to th process because the sam is used forthe)_|usedinthe|...|step; however, the firm did not re-evaluate ifan additional. _|maybeneededinthe| = ~—=S——S—S—Sst mitigate the potential contamination caused by the clogging off | d. Deviation M23/08/21/01 was initiated because an unusual peak was observed duringa | The sii ofthe was substantially different from th

Observation 7

Written procedures for maintenance fail to include schedules for the replacement of HEPA filters prior to failure.

Observation 10

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, a) You do not perform) identification each time action level is reached for each[igs b) Your|. (did not consider manufacturing operations when determining sample locations. c) You do not perform complete investigations when an action level is reached to include root cause and corrective action. d) You do not have a system in place that allows for monitoring recurring wa to identify repeated significant organism,

See all 5 findings in this document
[FDA 483 observation · FDA]IDT Biologika GmbH — Lot released before testing, 5 observations
FDA🧬 Biologics483

FDA cited 5 observations at the IDT Biologika GmbH vaccine manufacturing site (FEI 3005001757) in an inspection on 09/08/2023. They were release of a licensed product lot before conformance testing was complete, an inadequate environmental monitoring system, test methods not verified under actual conditions of use, inadequate GMP training, and inadequate laboratory data backup and audit.

Published 2026-10-26 · Inspection date 09/08/2023 · Vaccine Manufacturer · FEI 3005001757

Key facts · Basis: official index plus supporting sources
  • Observation 1: Licensed product lot released before conformance testing was complete
  • Observation 3: Suitability of test methods not verified under actual conditions of use
  • Observation 5: Backup data protection not assured, GMP laboratory data not audited
Insight · Editorial insight

The observation that a licensed product lot was released before conformance testing finished signals that FDA directly checks whether release approval requirements are enforced by the system. Citing inadequate laboratory data backup and audit alongside it shows that the reliability of the data behind release decisions is assessed on the same axis.

Check points
  • Controls confirming required testing is complete before release approval
  • Confirmation of test method suitability under actual conditions of use
  • Scope of GMP laboratory data backup and audit
Observation detail · 5 observations · OCR reading of the scanned original

Inspectors: Roger F Zabinski · Laurel A Beer

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

Lots of licensed products were released by the manufacturer prior to completion of tests for conformity with standards applicable to such product.

Specifically, The firm implemented a assay of(b) (4). The following (b) (4) batches (b) (4) and were released for distribution to the ial market, but the firm lacked evidence of whether an application supplement was submitted for review and approval pursuant to the drug product application.

Observation 2

(b) (4) processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, the following locations of environmental monitoring within line fa , located in room of building ee. are not adequate to monitor environmental during production: used to monitor the environment during filling operations are, (b) (4) ,

Observation 3

The suitability of all testing methods is not verified under actual conditions of use.

Specifically, The QC microbiology review ofenvironmental monitoring(b) (4) is deficient including room design and equipment. During inspection of the lab, it was observed that the room used for environmental monitoring ) is small (about ) with operators and a supervisor to review as many as A system to prevent mix-ups is lacking. °N@) are(A/T ona (b) (4) throughout the room.

Observation 4

GMP training is not conducted on a continuing basis and with sufficient frequency to assure that employees remain familiar with CGMP requirements applicable to them.

Specifically, The training effectiveness is not systematically monitored, with respect to deviations and CAPA effectiveness. The firm had 25 deviations for training deficiencies in the past 3 years, in (b) (4) classified areas. Corrections and CAPAs to individual traiming deficiencies are not well described in the deviation reports and training on deficiencies are not extended to all relevant operators or production areas. The firm has only recently started to trend and categorize deviations based on root cause and has only recently begun to implement a continuous improvement training but has not taken action to ensure that critical manufacturing steps are carried out effectively.

Observation 5

Backup data is not assured as exact, complete and secure from alteration, erasure or loss through keeping (B)I@)EN LN s9stems Specifically, The firm's Quality Unit including Quality Control Molecular Biology lab manager and IT staff do not perform audits of all GMP lab data inclu...

ding all to ensure adequate controls are in place for all lab systems including the — systems.

See all 5 findings in this document
[FDA 483 observation · FDA]AGC Biologics, Inc. — Raw data not matching reported test results
FDA🧬 Biologics483

FDA cited 2 observations at the AGC Biologics, Inc. drug substance manufacturing site (FEI 3000209996) in an inspection on 04/18/2025. Review of in-process and release test data for drug substance was inadequate, so raw data did not match the final results documents, and inventory records for critical materials were inaccurate.

Published 2026-10-26 · Inspection date 04/18/2025 · Drug Substance Manufacturer · FEI 3000209996

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate review of in-process and release test laboratory data (raw data does not match results documents)
  • Observation 2: Inaccurate inventory records for critical materials
Insight · Editorial insight

The finding that raw data did not match the final results documents suggests that test result review stopped at the summary document and did not reach comparison with raw data. Together with the inaccurate critical material inventory records, it shows that record accuracy overall can be assessed from a data integrity viewpoint.

Check points
  • Review comparing in-process and release test raw data with results documents
  • Match between critical material inventory records and physical stock
Observation detail · 2 observations · From the source

Inspectors: Christian Lynch

Observation 1

Review of laboratory data for drug substance in-process and release testing is not adequate: a)We observed raw data from does not match the analytical packet| lw SStttsti‘<iststsS@S for lot He mw used to document the final results.

This data is generated as part of Final Bulk Drug Substance release testing for residual ik . The analysis packet was reviewed by a QC reviewer on 19 NOV 2024 and did not catch the error. b)On 15 APR 2025, your quality control associate (analyst) who performs the sun testing method for|-_{final bulk drug substance, demonstrated (with typical system access rights) the ability to delete original electronic data from the|_». which saves data files from nel. 6 used for _ test method ( 6 , among others). There is no routine system-level review to ensure the veracity ofelectronic data files submitted. c)On 8 Jun 2016, uw instrument for in-process monitoring of|- |andI~ | bio-reactors in Building- were qualified by testing reference| __,,,, at various concentrations. Along with deviations noted in the protocol, the final report was reviewed and approved in April 2024. One} used in the qualification is the _ which was evaluated by | wa ~~—Ss~té<«éd KO SHOW aeeragee results of The qualification of the instrument has no acceptance criteria for accuracy. These instruments - are still in use today for monitoring bio-reactor cell viability including fo production.

Observation 2

Documentation of critical material inventory is not accurate.

On 14 APR 2025, we observed the inventory system “f > P indicating - | vials ofworking cell bank (WCB| i lot # ) located within liquid nitrogen storage vessel # - _| at Building4 .. | records of the same lot show conflicting inventory of|-vials. Upon observation ofthe storage location, only - |vials were found in cryo-storage. This working cell bank is the starting material for upstream culture that will produce the drug substance - _ under BLA} .. As stated by your Senior Director, Quality Systems and Compliance, no established procedures exist for conducting inventory/cycle counts ofWCB stored in the release and quarantine liquid storage vessels (#-|and#~ | respectively) in Building | Scot T Sallad National Expert XK Dale Sgned Os16.3028 20 39 00

[FDA 483 observation · FDA]Regen Suppliers LLC — No complaint handling, QC unit, or lot tracking
FDA🧬 Biologics483

FDA issued a 483 with 8 observations to Regen Suppliers LLC (Biological Product Distributor) after an inspection on 12/16/2025, covering complaint handling procedures, the quality control unit, and lot distribution tracking.

Published 2026-10-26 · Inspection date 12/16/2025 · Biological Product Distributor · FEI 3017397160

Key facts · Basis: official index plus supporting sources
  • Number of observations: 8
  • Key citation: There is no quality control unit
  • Distribution control: No system established to identify distribution by lot and enable recall
  • Labeling: Expiration date not shown on the label in the required manner
Insight · Editorial insight

Citations spanning the lack of a quality control unit, complaint handling, labeling, and lot tracking signal that basic cGMP requirements apply in full to distribution-stage firms. The citation that HCT/P products were not accompanied by a donor eligibility determination statement shows a need to check accompanying documentation when distributing human-derived products.

Check points
  • Written and oral complaint handling procedures and complaint record file management
  • Recall traceability through lot-level distribution records
  • Whether HCT/P products are accompanied by a donor eligibility determination statement
Observation detail · 8 observations · From the source

Inspectors: Garrad R Poole · Laurissa S Flowers · Emily S Mcgann

Observation 1

Procedures describing the handling of all written and oral complaints regarding a drug product are not established.

Specifically, since beginning operations in January 2021 your firm has not established or approved your written procedures for handling consumer complaints entitled “Regen Suppliers- Customer Complaint Standard Operating Procedures” that are still in draft form. For example, per these draft procedures under section titled (b) (4) for which your firm defines as any complaint involving (b) (4) (b) (4) . must be investigated by Quality Control and Operations within”? (b) (4), e Your firm does not have a designated Quality Control unit as explained in Observation Number 2. e Your firm received the following two complaints in 2025 that represented a serious adverse event and were not investigated: Adverse Event # 1 On November 9th, 2025, your firm received a compliant which stated three patients had been hospitalized with meningitis after product was administered intrathecally. The administered product was determined to be (b) (4) -lot! (6) (4) _ received by your customer on 10/28/2025 and labeled as“ (DB) (4). Per your customers request your firm provided sterility and communicable disease testing from your Cord Blood supplier (b) (4) . This complaint case was then closed without furth

Observation 2

There is no quality control unit.

Specifically, since beginning operations in January 2021 your firm has not established a quality control unit with the responsibility and authority to oversee the labeling, storage, release, distribution, and complaint investigation of your umbilical cord and umbilical cord blood products. Additionally, on 12/10/2025 your firm signed an agreement for manufacturing and direct distribution to customers with the contract manufacturer (b) (4) without qualifying them as a supplier. Your firm markets and distributes human umbilical cord-derived products that include but are not limited to: Wharton's Jelly and Exosome Products: e Private labels: (b) (4) e Customer private labels: (b) (4) Umbilical Cord Blood Products: e Private label: (1) (4) e Customer private labels: (b) (4)

Observation 3

After the completion of the donor-eligibility determination, HCT/Ps were not accompanied with a statement whether the donor has been determined to be eligible or ineligible, based on the results of screening and testing.

Specifically, a) Your firm provides a Certificate of Analysis (COA) to your customers which includes communicable disease testing results for your private label products (b) (4) . and (b) (4) . These COAs are provided to your firm by your contract manufacturer. (D) (4) This COA is signed by the (1) (4) —-Medical Director, however, the certificate lacks: e A statement of whether the donor is eligible or ineligible e A statement of donor eligibility based of donor screening results e A statement that the communicable disease testing was performed bya laboratory certified to perform such testing on human specimens under the Clinical Laboratory Improvement Act of 1988 or has met equivalent requirements determined by the Centers for Medicare and Medicaid Service. e The address of the establishment reviewing the donor records documents to make a donor eligibility determination. b) Your firm issues Certificates of Analysis (COAs) to customers for the private label product (b) (4) . which include communicable disease testing results. While these COAs bear your contract manufacturer's name (_ (1D) (4) __). they originate from your cord blood manufacturer (b) (4) . The COAs provided to custo

Observation 4

Procedures designed to assure that correct labeling and packaging materials are used for drug products are not written.

Specifically, you have not established written procedures to include the review and approval of labels that are applied to finished product containers or labeling that is sent with product upon final packaging.

Observation 5

Drug product expiration dates do not appear on the labeling in the manner prescribed by regulations.

Specifically, your firm distributes private label cord blood under the brand () (4) that is manufactured by (b) (4) . There is no expiration date on either the primary label or the Certificate of Analysis that accompanies the product. Your firm markets and distributes human umbilical cord blood products under multiple brand labels: Umbilical Cord Blood Products: e Private label: (1D) (4) ¢ Customer private labels: (b) (4)

Observation 6

Complaint procedures are deficient in that written complaint records are not maintained in a file designated for drug product complaints.

Specifically, per your draft written procedures entitled "Regen Suppliers-Customer Complaint Standard Operating Procedure" complaints can be received via (b) (4) . There is no official complaint file to document or track such complaints. Your firm markets and distributes human umbilical cord-derived products that include but are not limited to: Wharton's Jelly and Exosome Products: e Private labels: (b) (4) e Customer private labels: (b) (4) Umbilical Cord Blood Products: e Private label: (1D) (4) e Customer private labels: (b) (4) Respectively, your firm has distributed (©) @) units marketed as Whartons Jelly labeled for (b) (4) (b) (4) units marketed as exosomes labeled for (b) (4) units marked as growth factor labeled for (b) (4) and (©) (4) units marked as cord blood marketed and labeled for (b) (4)

Observation 7

A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary, has not been established.

Specifically, since beginning operations in January 2021 your firm has not established written procedure for recall operations. Your firm markets and distributes human umbilical cord-derived products that include but are not limited to: Wharton's Jelly and Exosome Products: e Private labels: (b) (4) e Customer private labels: (b) (4) Umbilical Cord Blood Products: e Private label: (1) (4) e Customer private labels: (b) (4) Respectively, your firm has distributed (©) 4) units marketed as Whartons Jelly labeled for (b) (4) (b) (4) units marketed as exosomes labeled for (b) (4) units marked as growth factor labeled for (b) (4) and (6) (4) units marked as cord blood marketed and labeled for (b) (4)

Observation 8

The distribution system is deficient in that each lot of drug product cannot be readily determined to facilitate its recall if necessary.

Specifically, during a review of your product transfer logs to customers that are tracked using Microsoft Excel spreadsheets, it was noted that records pertaining to lot distribution could not be reconciled.

See all 8 findings in this document
▫️ Other
[FDA 483 observation · FDA]Henogen SRL — Insufficient viral vector control data
FDA483

This is a 483 from the 11/22/2024 inspection by FDA of the Henogen SRL viral vector manufacturing site (FEI 3005932318). The excerpt indicates insufficient control data for viral vector manufacture and mentions control records such as the downstream process batch record (master record 000150367 v6.0); details of the observations need to be confirmed in the official source PDF.

Published 2026-10-30 · Inspection date 11/22/2024 · Viral Vector Manufacturer · FEI 3005932318

Key facts · Basis: official index plus supporting sources
  • Citation (excerpt): Insufficient viral vector control data
  • Related record: Downstream process master record 000150367 v6.0
Insight · Editorial insight

Naming the downstream process batch record as a subject of citation signals that FDA checks whether control data for each step of a multi-step viral vector process is captured in the batch record. The specific items cited should be confirmed in the official source PDF.

Check points
  • Scope of control data recorded in downstream process batch records
  • Reflection of master batch record revisions in the process
Observation detail · 1 observation · From the source

Inspectors: Priscilla M Pastrana

Observation 2

Toassist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides: "Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."

[FDA 483 observation · FDA]Boehringer lngelheim RCV GmbH & Co KG — Inadequate SOP for critical transport steps
FDA483

FDA cited 2 observations at the Boehringer lngelheim RCV GmbH & Co KG manufacturing site (FEI 3003433722) in an inspection on 12/05/2023. The SOP for critical transport steps was inadequate, and equipment preventive maintenance was not sufficient to prevent frequent breakdowns.

Published 2026-10-30 · Inspection date 12/05/2023 · Manufacturer · FEI 3003433722

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate SOP for critical transport steps
  • Observation 2: Equipment preventive maintenance does not prevent frequent breakdowns
Insight · Editorial insight

Citing the SOP for critical transport steps as inadequate signals that GMP control is viewed as extending past the manufacturing site to transport. The preventive maintenance citation for frequent equipment breakdowns shows a need to check whether breakdown history feeds back into resetting maintenance intervals.

Check points
  • Scope of SOP coverage for critical transport steps
  • Link between equipment breakdown frequency and preventive maintenance intervals
Observation detail · 2 observations · From the source
Observation 1

SOP for critical steps in shipping is inadequate.

Specifically, BI-RCV SOP 033-AA-VS-01719 “Packing Product " for Shipping” does not describe the duration in which the drug substance final containers need to be loaded in the _In addition, the SOP lacks instructions on the activation ofRCV final container.

Observation 2

Equipment preventive maintenance isnot adequate to prevent frequent malfunction.

Specifically, seal leaks were found.on the final container bottle head tubing ofthree DS batches (Batch # |(b) (4), (4), and (6) (4) after sealing (NNN)I@)NN. FAD! OVEFIS)

[FDA 483 observation · FDA]Fenwal International, Inc. — Inadequate equipment design and upkeep, 7 items
FDA483

FDA cited 7 observations at the Fenwal International, Inc. manufacturing site (FEI 2627511) in an inspection on 09/18/2024. They were inadequate equipment design, inadequate equipment maintenance intervals, poor building repair, inadequate in-process material testing procedures, no differential pressure control equipment, no hot and cold water at washing and toilet facilities, and inadequate record keeping for annual review.

Published 2026-10-30 · Inspection date 09/18/2024 · Manufacturer · FEI 2627511

Key facts · Basis: official index plus supporting sources
  • Observation 1: Manufacturing equipment not designed to suit its use
  • Observation 5: No differential pressure control equipment
  • Observation 7: Inadequate record keeping for annual quality review
Insight · Editorial insight

Equipment design, maintenance, building repair, and pressure control cited all at once reads as a case where hardware-based control was judged weak overall. With the record keeping citation for annual review added, it signals a need to check whether facility condition connects to the product quality evaluation system.

Check points
  • Fit-for-use design of manufacturing equipment
  • Provision of differential pressure control equipment
  • Record keeping for annual quality review
Observation detail · 7 observations · From the source

Inspectors: Scott T Ballard · Cody D Rickman · Lizaida Perez

Observation 1

Equipment used in the manufacture, (b)(4) of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, the 4 is not adequately qualified to produce| (b)(4) wa) for = (b)(4) ~—_[ products such as red cell preservation solution and anti-coagulant. a. On 11 SEP 24, we observed unknown white material b)(4 is (b)(4) pieces of equipment producing b)(4 for (64) product formulation. b.| (b)(4) _lis| (b)(4) landusedtoclean’ —=——(B(4)—SSCid equipment. b)( and (b)(4) L CA) equipment create b)(4 long _———(b)(4) ~———sinotused since 4 JUL 2024 d. Equipment connected tothe) ———(b)(4) ~—_—|suchas b)(4 4) |(Open to environment), an (b)(4) connections not represented on approved drawings. e. Approved Drawing for product} (>)(4) module *|does not show product solution! (b)(4) from; = (b)(4) ~~—_—| This module is used for Alyx, Amicus, and Intersol products. Red cell preservation solution and anti-coagulant solutions formulated with are used to manufacture Alyx, Amicus, Intersol, and Blood Pack Units. *This is a repeat observation from the previous inspection in September

Observation 2

Equipment and) (b)(4) |are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.

cifically, theenvironment of solution (b)(4) is not adequately controlled with c b)(4 . For example: a. On 12 SEP 2024 and 14 SEP 2024, we observed the showed apparent biological growth on_ (b)(4) |and from) (b)4) | —(b)(4) __ |along with b)(4 distributed through the equipment. This|s—”-—sSO(by(4)——“(«ts*‘“‘;*CS™CSCSSCOtrcOlled AS Grade} | environment. b. On 12 SEP 2024 and 14 SEP 2024, we observed the showed apparent biological growth and (b)(4) on supply | b)(4 . This | (b)(4 controlled as Grade“ environment. c. On 12 SEP 2024, we observed approximately (b)(4) removed from (b)(4) showed apparent biological growth. Fill (b)(4) _|is controlled as Grade» environment. d. On 10 SEP 2024, we observed| b)(4 in (b)(4) showed apparent biological growth. b)(4 is not a classified/controlled environment. e. On 13 SEP 2024, we observed a yellow/brown stain on in | (bya) b)(4 with unknown cause. (b)(4) is controlled as a Grade »™|environment. (b)(4) is used in formulating solutions for Amicus, Alyx, and Intersol solutions.) (b)(4) __|is used in the manufacture of Blood Pack Units.

Observation 3

Buildings used in the of a drug product are not maintained in a good state of repair.

Specifically, manufacturing equipment and facilities showed disrepair that creates difficult to clean surfaces and difficulty in maintaining clean equipment. For example: a. On 10 SEP 2024, we observed a (b)(4) sagging from apparent saturation with rain water. ee b. On 9 SEP 2024, we observed (b)(4) were not covered/closed after cleaning in (b)(4) (b)(4) c. On 10 SEP 2024, we observed peeling paint on (b)(4) d. On 10 SEP 2024 and 13 SEP 2024, we observed cracked and peeling floor surfaces with) (b)(4) b)(4 . Additionally, we observed| (b)(4) \with peeling) (b)(4) near the _ __(b)(4) rn e. On 10 SEP 2024, we observed white crystal formations on (b)(4) iin the (b)(4 ) | b)(4 is used in formulation of fluids for Blood Pack Units. (b)(4) is used in formulation of Alyx, Amicus, and Intersol products. *This is a repeat observation from the previous inspection in September 2022*

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials conform to appropriate standards of identity, strength, quality and purity.

Observation 5

Equipment for adequate control over air pressure is not provided when appropriate for the manufacture, (b)(4) of a drug product.

Specifically, your firm does not adequately monitor areas of distinct environmental classification. Environmental air samples are collected] (b)(4) which does not provide adequate data on Grade| rooms where blood pack unit and apheresi products are | (b)(4) _ For example, b)(4) for Alyx, Amicus, and Intersol; as well as ( b)(4) for Blood Pack Units. Additionally, there is no continuous monitoring of differential pressures between rooms. of differing classifications. For example, (Gradei) to (b)(4) (Grade ) where the differential pressure is documented once per day of production.

Observation 6

Washing and toilet facilities lack hot and cold water.

Specifically, your hand washing facilities for employees entering manufacturing and lab areas are deficient as follows: a a. On 10 SEP 2024 and 13 SEP 2024, we observed cold water for hand washing in b)(4 for ( b )( 4) f b. On 10 SEP 2024 and 11 SEP 2024, we observed cold water for hand washingin) —_(b)(4)_—_ for (b)(4) . c. On 10 SEP 2024 and 13 SEP 2024, we observed hand cold air in (b)(4) for.(YA).()(4)int by(4)——iand (YA) /C(b)(4)———~—~—Ss before employees enter production areas. d. We observed no hand washing stations for employees entering the, (b)(4) lab. The firm does not have a procedure instructing employees to wash hands before entering the (b)(4)

Observation 7

Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.

Specifically, Annual product reviews fail to include data regarding ( b )(4) components used in manufacturing of blood pack units and apheresis components (Alyx, Amicus, and Intersol). For example APRs do not include defect rates, testing summaries, or supplier qualification status. Annual product reviews for BPU, Alyx, Amicus, and Intersol products for the calendar year 2023 were significantly delayed until being signed and approved on 12 SEP 2024.

See all 7 findings in this document
[FDA 483 observation · FDA]Autolus Limited (referred to as The Nucleus) — Validation of manufacturing components incomplete
FDA483

FDA cited 2 observations at the Autolus Limited (referred to as The Nucleus) drug substance and drug product manufacturing site (FEI 3015674982) in an inspection on 04/30/2024. Validation of components used in manufacturing the finished AUCATZYL (Obecabtagene autoleucel) product was not complete, and critical utilities were not adequately validated or routinely monitored.

Published 2026-10-30 · Inspection date 04/30/2024 · Drug Substance and Drug product Manufacturer · FEI 3015674982

Key facts · Basis: official index plus supporting sources
  • Observation 1: Validation of components used to manufacture AUCATZYL (Obecabtagene autoleucel) not complete
  • Observation 2: Inadequate validation and routine monitoring of critical utilities
Insight · Editorial insight

The citation of incomplete validation for components used to make AUCATZYL signals that the completeness of validation for each process component is under inspection. Because insufficient validation and routine monitoring of critical utilities was also cited, the evidence for reproducible utility quality should be checked.

Check points
  • Validation completion status of each component used in manufacturing
  • Validation and routine monitoring of critical utilities
Observation detail · 2 observations · From the source
Observation 1

The validation ofthe(b) (4) used during the (6) (4) manufacture ofthe AUCATZYL (Obecabtagene autoleucel) drug product is not complete.

Therefore, the validation does not ensure assurance. Specificall a. have not been completed on(ob) (4) which is used to prepare the (6)(4) lentiviral vector and which is used to prepare b. In the , the validation of he(DA demonstrate growth of(b) (4) iin every validation run.

Observation 2

Critical utilities (b) (4) 0 are not adequately validated or routinely monitored to ensure reproducible quality.

Specifically, the validation testing of(0) (4) 0 ets performed by collecting a from each(b) (4) and routine monitoring is not performed. Ls Disiafectant tcc are inadequate to mitigate cross-contamination. Specifically, the disinfectant study does not include data to support the effectiveness against viral contaminants. EMPL OYFF(S) SIGNATURF

[FDA 483 observation · FDA]Clongen Laboratories, LLC — No independent quality unit, 6 observations
FDA483

FDA cited 6 observations at the Clongen Laboratories, LLC release testing facility (FEI 3006579817) in an inspection on 06/17/2025. They included inadequate quality oversight, such as no independent QA unit and failure to follow the internal audit interval, along with no procedures for key laboratory operations, inadequate equipment qualification, inadequate training, and no quality agreement.

Published 2026-10-30 · Inspection date 06/17/2025 · Release testing facility · FEI 3006579817

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate quality oversight (no independent QA unit, internal audits at the Quality Manual interval not performed)
  • Observation 6: No quality agreement defining the roles and responsibilities of the parties involved
Insight · Editorial insight

Citing both the absence of an independent QA unit and the lack of a quality agreement at a release testing facility signals that the testing laboratory's quality system bears directly on the reliability of the sponsor's release decisions. Firms that outsource testing should check the testing laboratory's QA independence and whether a quality agreement is in place.

Check points
  • Independence of the testing laboratory's QA unit
  • Procedures in place for key laboratory operations
  • Quality agreement with the testing laboratory
Observation detail · 6 observations · From the source

Inspectors: Kevin Matthews · Carl Perez

Observation 1

Quality oversight is inadequate.

Specifically, a. There is a lack of a separate and independent quality assurance unit needed to perform objective review. b. Internal audits are not performed at the defined frequency according to the Quality Manual. c. No independent review of final test reports and associated test data is performed. d. An administrative staff member was identified as acting Quality Assurance Manager, and no evidence was found that this individual performs any quality assurance activities as defined by Quality Manual and confirmed per employee. e. SOP ADMIN006, How to Write a Standard Operating Procedure, does not require review and approval of any technical or QA procedures. No evidence was found of any QA review of any controlled SOPs. f. Per the Clongen Quality Manual, (b) (4) review is required to be conducted by the Laboratory Director and the Quality Assurance Manager to assess current policies, practices and procedures to determine effective changes. Clongen stated that (b) (4) review has not been performed since 2023. However, that is no evidence of any reviews being performed.

Observation 2

Written procedures are not established for critical laboratory tasks.

Specifically, for: a. Sample receiving and (b) (4) when receiving sample shipments from (b) (4)

Observation 3

Equipment is not qualified or monitored for its intended use.

Specifically, a. Technician was observed using out of calibration equipment (pipette and thermomixer) during the extraction step for mycoplasma testing on June 16, 2025. (©) @) of® pipettes on a rack were discovered to be out of calibration. b. Preventive maintenance (PM) and calibrations requirements are not established and routinely performed on critical equipment including the (b) (4) PCR System (ID#(®)(4)), (b) (4) Thermomixers# (6) (4) (b) (4) gel imaging system (ID #(6)@4)), Electropheresis (b) (4) (ID #H(b) (4), and ©) @) (ID # ®)@)), c. Qualification studies were not initially performed on the (b) (4) and (b) (4) freezers prior to use.

Observation 4

Quality control documentation and practices are inadequate.

Specifically, a. Test runs are not documented during performance including (b) (4) of electrophoresis gels, critical test parameter checks, and reagents lot numbers and expirations. b. Quality control of positive controls is recorded on an (b) (4) with no record of (b) (4) (b) (4)

Observation 5

Employee training and qualification is inadequate.

Specifically, administrative staffmember performs essential tasks such as (b) (4) with no evidence of training on updated procedures or non-existing procedures.

Observation 6

A quality agreement defining the roles and responsibilities of each involved party is not established.

Specifically, there is no quality agreement established with (b) (4) regarding mycoplasma release testing.

See all 6 findings in this document
[FDA 483 observation · FDA]Andelyn Biosciences, Inc. — Weak quality oversight and contamination control
FDA483

FDA cited 6 observations at the Andelyn Biosciences, Inc. drug substance manufacturing site (FEI 3026042970) in an inspection on 05/30/2025. They were inadequate quality oversight, including inadequate review of manufacturing records by the quality unit, deficiencies in the environmental monitoring program, qualification of manufacturing areas, utility monitoring, disinfectant efficacy testing, and OOS procedures.

Published 2026-10-30 · Inspection date 05/30/2025 · Drug Substance Manufacturer · FEI 3026042970

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate quality oversight (inadequate review of manufacturing records by the quality unit)
  • Observation 5: Inadequate disinfectant efficacy testing for contamination and cross-contamination
  • Observation 6: Inadequate OOS procedure under Laboratory Investigation Management
Insight · Editorial insight

Citing environmental monitoring, area qualification, utility monitoring, and disinfectant efficacy testing all at once signals that the contamination control strategy was assessed as a system and not element by element. Because inadequate manufacturing record review by the quality unit came first, the effectiveness of quality oversight should also be checked.

Check points
  • Scope of disinfectant efficacy testing for contamination and cross-contamination
  • Classification and qualification assessment of manufacturing areas
  • Adequacy of OOS investigation procedures
Observation detail · 6 observations · From the source
Observation 1

Quality oversight is inadequate to ensure (b)(4) drug substance (DS) has the | 7 (b)(4) it purports or is represented to possess.

For example, a. Your quality unit does not review production records adequately to ensure there are no errors that have occurred. Master Batch Records (MBRs) have!(b)(4)lndergone complete review and sign-off by Quality Assurance followed by re-review after additional issues are identified that require corrections and notations. b. Lots (b)(4) and (b)(4) have been re-dispositioned three times after the initial batch release due to identification of additional deviations subsequent to batch disposition. c. Deviation management is inadequate to demonstrate quality oversight of the manufacturing process and does not adequately identify, document, or investigate the impact to ( b )( 4) DS. For example, i. Deviations from written production procedures are not identified as deviations, and procedures governing deviations are not followed. For example, 1. During performanceofMBR. (b)(4) /for lot (b)(4) Me was noted that the (b)(4) [did not have the appropriate| «) connector to connect to the)(b)(4)| Holly Brevig, CSO, Lead Inspector 05/30/2025 OF THIS PAGE SUSAN BUTLER -S Smyanesm xcsinrum Susan S. Butler, Staff Fellow Jacob LBterman jean Jacob L. Bitterman, Biological Reviewer DISTRICT

Observation 2

Environmental monitoringprogram is deficient to ensure environments are classified and controlled to manufacture (b)(4) DS.

For example, a. Validation of the environmental monitoring (EM) sampling for viables has not been conducted. For example, EM samples for viables are transported to an off-site testing facility; however, no studies have been conducted to assess the impact of this process on microbial recovery. b. There was no non-viable particulate monitoring of the ISO) (b)(4) during the manufacturing activities for the processing of (b)(4) DS PPQ lots. OF THIS PAGE SUSAN BUTLER-s —o Susan S. Butler, Staff Fellow Jacob L. Qty sore ac Jacob L. Bitterman, Biological Reviewer Bitterman -S Didte:2025.08.200042:03 400" DISTRICT

Observation 3

Qualification of areas used to manufacture (b)(4) DS is not adequate.

Specifically, a. Cleanroom recovery tests do not support‘your dela for differential pressure alarms contained in the building management system (BMS) (b)(4) | Specifically, you retain a delay setting for differential pressure alarms of |__(b)(4) _despite the cleanroom installation and operational qualification (IOQ) demonstrating a much more rapid room recovery time (e.g., the IOQ for clean room suite, (4) recovers in less than or equal to (b)(4) |). Thus, the differential pressures failures in areas used to manufacture (b)(4) | drug substance are not investigated. b. The Air Handling Unit (AHU) | covers the Grade (b)(4) and the Grade) (b)(4) |(b)(4) | However, the qualification failed to evaluate all rooms supplied by «| For example, Rooms and | ©) |were not included in the cleanroom qualification. Therefore, there is insufficient data to demonstrate that these rooms are ina state of control. c. Diagrams supporting airflow into cleanrooms are deficient. For example, document H-01-000- 621 in support of airflow of cleanroom suite} 4) does not demonstrate a scientifically founded air balance. Thus, the documentation does not support adequate airflow suitable for supporting the respe

Observation 4

Monitoring of utilities is deficient.

For example, a. Critical product contact (b)(4) [used in the manufacture of (b)(4) |DS is not adequately qualified or| (b)(4) |monitored. Specifically, incoming quality control testing is not performed on the (b)(4) |received from the vendor, and |_(b)(4)_|monitoring program has not 2

Observation 5

Disinfectant efficacy studies are inadequate to mitigate contamination and cross-contamination.

For example, a. The disinfection efficacy study does not demonstrate effectiveness against viral contaminants. b. The disinfection efficacy study does not demonstrate effectiveness against microbial agents for all representative surfaces in areas used to manufacture) (b)(4) DS. For example, the _(b)(4) __ that are used to transport material into and out of cleanrooms and store | (b)(4) lwere excluded from the study.

Observation 6

Procedures regarding out of specification results described in sop, tby(4) Laboratory Investigation Management, are inadequate.

The procedures have insufficient detail regarding when expanded investigational activities will be required, how hypothesis testing or retesting investigations will be designed, or how results of the expanded investigational activities will be used to make decisions.

See all 6 findings in this document
[FDA 483 observation · FDA]Baxter Healthcare Corporation — Test methods not scientifically sound, 5 items
FDA483

FDA cited 5 observations at the Baxter Healthcare Corporation contract laboratory (FEI 1416980) in an inspection on 11/25/2025. They were no scientifically sound test procedures, quality control unit responsibilities and procedures not followed, inadequate control of access to change records in computer systems, inadequate training, and sample information missing from laboratory records.

Published 2026-10-30 · Inspection date 11/25/2025 · Contract Laboratory · FEI 1416980

Key facts · Basis: official index plus supporting sources
  • Observation 3: Inadequate control of authority to change records in computer systems
  • Observation 5: Sample description, quantity, and receipt date missing from laboratory records
Insight · Editorial insight

Citing both scientific soundness of test methods and computer system access control at a contract laboratory signals that the accuracy of test results and data integrity are assessed together. The missing sample description, quantity, and receipt date show a need to check the basic elements of sample history tracing.

Check points
  • Scientific rationale for test methods
  • Control of authority to change records in computer systems
  • Reflection of sample receipt information in laboratory records
Observation detail · 5 observations · From the source
Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, your firm's environmental monitoring (EM) program for cross-contamination detection has significant limitations in scope and coverage. (b) (4) (b) (4) , are manufactured at your facilities. However, there are no analytical methods for detection of (b) (4) from (b) (4) samples taken from (b) (4) areas. The current test method utilized only detects (Bb) (4) and fails to include (b) (4) manufactured in the same facility. From January 1, 2025, to November 20, 2025, alone, your firm tested at least © EM samples, but only for the presence of (b)(4) . Results for these were found to be false positives for the presence of (6) (4) , and were then subjected to confirmatory testing, (b) (4) (6) 4) (Procedure RD-02-01-020, Document No. 1138932, Revision H) with a concentration limit of© © for (b) (4) detection.

Observation 2

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Observation 3

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

Observation 4

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

Specifically, QC analysts responsible for testing of environmental samples (EM) for the absence of (b) (4) are not trained by the quality team, resulting in inadequate oversight of personnel qualifications. For example, per the firm’s training procedure No. RD-03-01-019, Revision W, each analyst is required to complete, including but not limited to, (b) (4) containment training (Training Code: (b) (4) containment training (Training Code: (b) (4) ), and good documentation training. QC analysts performing (b) (4) testing have not completed mandatory training requirements per the firm's training procedure (Document No. RD-03-01-019, Revision W).

Observation 5

Laboratory records do not include a description of the sample received for testing, the quantity of the sample and the date the sample was received for testing.

Specifically, your firm does not maintain adequate sample logs for environmental monitoring (EM) samples that failed the absence of (b) (4) test per (b) (4) for Determining the Absence of (b) (4) in Environmental Samples (Document no. RD-02-01-020, Revision S). For example, between January 1 and November 20, 2025, a total of®@) EM samples failed the (6) (4) test for absence of (b) (4) However, there is no record of the receipt and tracking of these samples, which were subjected to (b) (4) Test Method (Procedure RD-02-01-020, Document No. 1138932, Revision H).

See all 5 findings in this document
[FDA 483 observation · FDA]Galaxy Medical Products LLC — Quality unit lacks authority over record review
FDA483

FDA cited 1 observation at Galaxy Medical Products LLC (Medical Gas Manufacturer): the quality control unit did not have the authority to review production records and investigate errors.

Published 2026-10-27 · Inspection date 04/28/2026 · Medical Gas Manufacturer · FEI 3010888324

Key facts · Basis: official index plus supporting sources
  • Number of observations: 1
  • Citation: Quality control unit lacks authority to review production records and investigate errors
Insight · Editorial insight

It signals that the independent authority of the quality control unit is treated as a basic GMP requirement even in a small operation such as a medical gas manufacturer. It is worth checking that the organization explicitly gives the quality unit authority to review production records and open error investigations.

Check points
  • Written statement of quality control unit authority in organization and job documents
  • Record of production record reviews and error investigations actually carried out
Observation detail · 1 observation · From the source
Observation 1

The quality control unit lacks authority to review production records to assure that no errors have occurred and fully investigate errors that have occurred.

Specifically, Your firm failed to document and investigate the use of an out-of-calibration thermometer during the filling of (b) (4) cylinders. On 04/27/2026, an out-of-calibration thermometer (Serial #(b) (4)) hat had exceeded its calibration due date by approximately four months was observed being used during the filling of Lot (b) (4). The thermometer was used to determine cylinder fill pressure based on temperature during filling operations. No documentation, deviation, investigation, or product impact assessment was initiated to determine the effect of the out-of-calibration thermometer on product quality. Approximately lots have been released since Dec 2025.

[FDA 483 observation · FDA]Microchem Laboratory — QC responsibilities and procedures undocumented
FDA483

FDA cited 2 observations at Microchem Laboratory (Contract Laboratory). The quality control unit's responsibilities and procedures were not documented or followed, and scientifically sound test methods were not established.

Published 2026-10-27 · Inspection date 04/30/2026 · Contract Laboratory · FEI 3037143716

Key facts · Basis: official index plus supporting sources
  • Number of observations: 2
  • Observation 1: Quality control unit responsibilities and procedures not documented or followed
  • Observation 2: Scientifically sound test methods not established
Insight · Editorial insight

Citing the contract laboratory's own quality control role and test method soundness is a warning about relying on outside test results as the basis for release. It is worth checking whether the sponsor confirms the rationale for the suitability of outsourced test methods.

Check points
  • Confirmation of the contract laboratory's quality control unit procedures
  • Scientific rationale for outsourced test methods
Observation detail · 2 observations · From the source

Inspectors: Jeffrey T Prosterman

Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically, The Quality Unit failed to maintain adequate oversight of the Quality Management System (QMS), including the following: a) Qualification Protocols Failure to review and approve execution data, and associated documentation to confirm that acceptance criteria and all required activities were completed before implementation, as documented througha final report or formal authorization, including but not limited to: e LD7047: (b) (4) Method created on Dec/01/2025, to support chemical assay testing of approximately ©samples, with the final report approved on April 29, 2026. e DV1049: (©)(4) Media Validation/ Expiration to support the (6) (4) expiration dates of (©) @ media used for microbial testing of approximately "® samples (lot (b) (4) ) with the final report approved on April 28, 2026. b) Out-of-Specification (OOS) Investigations Failure of scientific rationale and evidence to support identification of root causes, and implementation of actions for OOS investigations, including but not limited to: e 20251100SC002 (completed Nov/26/2025): No root cause identified; no rationale provided for

Observation 2

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, a. The intermediate precision studies documented in the Method Verification Report for (b) (4) by HPLC (Method ID: LD7045, Effective date: 02/09/2026) and the Method Verification Report for (0) (4) by (b) (4) (Method ID: LD7023, Effective date: 12/30/2025) are deficient in that the results presented for Analyst II were performed on two separate dates and combined as a single dataset without adequate justification. Furthermore, a laboratory error was identified in each of the two analyses. These errors were not documented, investigated, or disclosed in the corresponding Method Verification Reports. b. The Intermediate Precision study for Method Validation Report for (b) (4) by HPLC (Appendix I) (Method ID: LD7045, Effective date: 01/30/2026) had results which failed the specification. The test specification was changed, and a second test was performed. The results for the second preparation, passed the initial specification and were documented in the final report. The original failing results and the specification change were not included in the final

[FDA 483 observation · FDA]Paxeuticals LLC — Process control, equipment cleaning, 6 items
FDA483

FDA cited 6 observations at Paxeuticals LLC (Contract Packager). The targets were written procedures for production and process control, equipment design and cleaning and maintenance, quality control unit procedures, yield records, and temperature, humidity, and light storage conditions.

Published 2026-10-27 · Inspection date 04/20/2026 · Contract Packager · FEI 3030238141

Key facts · Basis: official index plus supporting sources
  • Number of observations: 6
  • Process and equipment: Inadequate written process control procedures, inadequate equipment design, inadequate cleaning and maintenance intervals for equipment and utensils
  • Records: Batch record lacks actual yield and percentage of theoretical yield
  • Storage: Inadequate temperature, humidity, and light storage conditions
Insight · Editorial insight

Citing yield records and storage conditions at a contract packager signals that the packaging step is subject to the same level of GMP control as manufacturing. When outsourcing packaging, it is worth checking whether yield reconciliation and storage environment control are part of the sponsor's quality assessment.

Check points
  • Records of actual yield and percentage of theoretical yield in packaging
  • Cleaning and maintenance intervals for packaging equipment
  • Temperature, humidity, and light storage conditions for packaged goods
Observation detail · 6 observations · From the source

Inspectors: Yvins Dezan

Observation 1

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, A. You have not performed product specific Filling Validation Studies for (b) (4) (b) (4) and (b) (4) (b) (4) drug products at your firm. B. You have not completed equipment cleaning validation studies to validate equipment cleaning SOP #10, Cleaning and Sanitization Procedure Packaging Room and Equipment, effective date 02/01/2024 which is used for the cleaning of shared equipment used in the packaging of the drug products (b) (4) (b) (4) and (b) (4) (b) (4) as well as several (Db) (4) products.

Observation 2

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Specifically, your firm failed to complete protocol driven Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) studies for the following packaging machines

Observation 3

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Observation 4

Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent malfunctions, contamination, that would alter the safety, identity, strength, quality or purity of the drug product.

Specifically, On 04/16/2026, I observed presence of unknown “Reddish and Whitish” residue inside the product loaders/elevators and inside the product filling ©@ (®) on the (b) (4) Machine Model (b) (4) . You did not document when the equipment was last used, the products packaged, lot number, and cleaning records performed for the equipment. The (b) (4) Machine Model (b) (4) is utilized for packaging capsules and (b) (4) and (b) (4) drug products at your firm.

Observation 5

The batch production and control records are deficient in that they do not include a statement of the actual yield and percentage of theoretical yield.

Specifically, Your Packaging Batch Records for () (4) and (b) (4) drug products do not include a statement of the actual yield and percentage of theoretical yield for packaging, the identity of individual major equipment used, the identification of the persons performing, and checking each significant step in the operation for each batch of drug product packaged (not all-inclusive).

Observation 6

Drug products are not stored under appropriate conditions oftemperature, humidity, and light so that their identity, strength, quality, and purity are not affected.

OF THIS PAGE | DISTRICT ADDRESS AND PHONE NUMBER ., 3rd Fl 04/14/2026-04/20/2026* Parsippany, NJ 07054 een (973) 331-4900 Fax:(973)331-4969 3030238141 [email protected] SUED Mr. Dhaval A. Shah, President Paxeuticals LLC 333 New Rd, Suite 3 CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED Parsippany, NJ 07054-4212 Contract Packager Specifically, your firm failed to complete a summer warehouse temperature mapping study in the warehouse where you store finished (b) (4) which has a labeled storage condition of merc.

See all 6 findings in this document
[FDA 483 observation · FDA]GenTrac, Inc. — Unidentified material on equipment not assessed
FDA483

FDA issued a 483 with 4 observations to GenTrac, Inc., a drug substance manufacturer. The citations included no characterization or quality impact assessment of material found on equipment product-contact surfaces and an inadequate microbial recovery test in the cleaning validation swab method.

Published 2026-10-27 · Inspection date 07/30/2025 · Drug Substance Manufacturer · FEI 3002919848

Key facts · Basis: official index plus supporting sources
  • Observation 1: No characterization of material identified on equipment product-contact surfaces and no assessment of impact on drug substance quality
  • Observation 2: Inadequate microbial recovery test for the cleaning validation swab method
  • Observations 3 and 4: Inadequate documentation of laboratory training and qualification, procedures for segregation of duties in the quality unit not followed
Insight · Editorial insight

Citing both the unexamined material on equipment surfaces and the weak basis for swab recovery signals that the scientific basis for cleaning control as a whole came under review. A drug substance manufacturer should check that characterization and quality impact assessment are actually recorded when residues are found after cleaning.

Check points
  • Records of characterization and quality impact assessment when foreign matter or residue is found on product-contact surfaces
  • Adequacy of the microbial recovery test in the cleaning validation swab method
  • Compliance with segregation of duties procedures within the quality unit
Observation detail · 4 observations · From the source

Inspectors: Lizaida Perez · Peng Zhou

Observation 1

(b) (4) identified on equipment product contact surfaces is not characterized nor its potential impact to drug substance quality assessed.

Specifically, Procedure SOP-105027 (“SOPQ: Visual Inspection ofProcess Equipmentfor Cleanliness”, Version 2.0, Effective on 02/14/2019, and Version 3.0, Effective on 02/01/2024) lists (b) (4) types of (b) (4) as Type (b) (4) , and instructs for a work order initiation upon identification of surface quality and integrity issues, if a work order does not exist. In addition, the procedure the procedure states that “(B) (4) and to (b) (4) ” However, (b) (4) identified during (b) (4) cleaning audits performed for Prothrombin Area Equipment, and during (b) (4) cleaning audits performed on Bulk Thrombin Area Equipment, was not characterized to determine the type of (b) (4) , hor was a risk/impact assessment for the identified (BD) (4) performed. The (b) (4) for (b) (4) inspected as part to the (6) (4) visual inspection of process equipment on| (1) (4) do not provide information about the type of (b) (4) identified nor about the size of (b) (4) or surface area covered to compare with (b) (4) from the previous years. (DB) (4) inspection in (5) 4) found that (b) (4) exhibited (Db) (4), including (b) (4) and (b) (4). (b) (4) inspection in (©)(4) found that (b) (4) exhibited (D) (4). including

Observation 2

Microbiological recovery studies used to validate the swab testing method used in cleaning validation are inadequate.

Observation 3

Training and qualification related to laboratory operations are not adequately documented or implemented and associated corrective actions are not demonstrated to be effective.

Specifically, A.Your firm lacks formal written instructions and training provided to analysts on proper pipette usage. Specifically, an analyst “oe was observed on 07/23/2025 using improper pipetting technique (bubbles were observed in the pipette tip) during sample preparation for bioburden testing of batch (b) (4) of the PROTHROMBIN intermediate. On that same date, another analyst (°) was observed using improper pipetting technique (bubbles were observed in the pipette tips) during sample preparation for potency testing ofbatch (b) (4) of the PROTHROMBIN intermediate using the “ (b) (4) " pipette with the (b) (4) —. This ©0 O}MO) ad previously been the subject of CAPA-162998 initiated on 04/27/2025 as a result of deviation QE- 173372 initiated due to an Out of Limit result for the potency test caused by inconsistent pipetting volumes. The CAPA required a senior analyst to observe ™”” use of the pipette ( (b) (4) and provide retraining if needed. The CAPA also restricted” from the pipette ( (b) (4) ) for volumes of 1 mL or less with the (b) (4) until this evaluation was completed. There is no documentation demonstrating that has been observed, retrained, and reassessed by the seni

Observation 4

Procedures regarding segregation of duties are inadequately defined or not always followed in the Quality Unit.

Specifically, A. (b) (4) does not adequately define roles and responsibilities for individuals regarding use of accounts for individuals having dual system access privileges for (b) (4) used in potency testing. For example: i.On 5/20/2025, (b) (4) ii.On 5/12/2025, (b) (4)

See all 4 findings in this document
[FDA 483 observation · FDA]Janssen Biopharmaceuticals, Inc. — Delayed start of nonconformance investigation
FDA483

FDA issued a 483 to Janssen Biopharmaceuticals, Inc., a lentiviral vector manufacturer. It cited that the nonconformance report investigation was not started in a timely way after a deviation was found, as required by SOP-32984.

Published 2026-10-27 · Inspection date 11/01/2024 · Lentiviral vector manufacturer · FEI 2211100

Key facts · Basis: official index plus supporting sources
  • Observation 2: Nonconformance report investigation not started in a timely way after deviation discovery, per SOP-32984 (Nonconformance and CAPA Pharm Segment)
  • Observation 1 excerpt: Inadequate control and maintenance of manufacturing line systems
Insight · Editorial insight

The gap between discovering a deviation and starting the investigation being cited signals that FDA looks at the timeliness of the start, not just the conclusion. Because inadequate manufacturing line equipment control was also cited, it is worth checking that equipment events connect to the deviation and investigation system on time.

Check points
  • Time from deviation discovery to start of nonconformance report and investigation
  • Criteria for registering equipment events as deviations and the link to CAPA
Observation detail · 1 observation · From the source

Inspectors: Carl Perez · Kevin Matthews

Observation 2

Investigations (nonconformance reports) are not initiated in a timely manner after detection of a deviation according to (4) ‘SOP-32984, Nonconformance and CAPA Pharm Segment.

Specifically, the SOP requires nonconformance reports to be created within fter detection/identification. Since January 2024, creation of 19 nonconformance reports exceeded the requirement with at least three reports exceeding 21 days or more after detection. / /

[FDA 483 observation · FDA]Instituto Grifols, S.A. — Inadequate customer complaint handling
FDA483

FDA issued a 483 with 5 observations to the Instituto Grifols, S.A. manufacturing site. The citations included inadequate procedures for handling written and oral complaints, inadequate review of unexplained discrepancies, and failure to follow the stability testing program.

Published 2026-10-27 · Inspection date 11/17/2023 · Manufacture · FEI 3002807257

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures for handling written and oral complaints not adequately written or followed (related to SOP IG_MSP-000532_ING version 20.0)
  • Observations 2 and 3: Inadequate review of unexplained discrepancies, no justification for deviations from manufacturing and process control procedures
  • Observation 5: Written stability testing program not followed
Insight · Editorial insight

The customer quality complaint SOP being cited first signals that the flow from complaint receipt to investigation is treated as central to post-release quality surveillance. With the missing deviation justification and stability program noncompliance also cited, it is worth checking the gap between written procedures and actual operations.

Check points
  • Operating records of the quality complaint receipt and investigation procedure
  • Documents giving the justification for deviations from manufacturing and process control procedures
  • Stability testing program performance against plan
Observation detail · 5 observations · From the source

Inspectors: Susan M Jackson · Shafiq Ahadi · Natalya M Ananyeva · Sergey S Akimov

Observation 1

Procedures describing the handling of written and oral complaints related to drug products are deficiently written or followed.

Specifically, SOP IG_MSP-000532_ING version 20.0 describes the process for receipt, management, and investigation of customer product quality complaints. Your firm’s handling of customer product quality complaints investigation is deficient in that it does not require practice of testing retention samples of respective lots for most frequent complaints. Since 2021, your firm has received US customer product quality complaints for Fibrin Sealant [VistaSeal] categorized as biologics thawing issue as follows: 2021, 46 complaints; 2022, 31 complaints; and 2023 (Q3), 14 complaints. For example, review of selected biologics thawing issue complaint investigations 800010433, 800010845, 800010963, 800011603, and 800011859 revealed that none of the complaints investigated were supported by testing the retention samples. There is no documented evidence that your firm retention samples were tested as part of the complaint investigation for biologics thawing issue.

Observation 2

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Observation 3

Deviations from written production and process control procedures are not justified.

Specifically, Your firm’s SOP IG_MSP.000577 Investigation Protocol of Analytical Deviation in the Quality Control Laboratories describes the procedure for investigating any deviation from approved procedure or specification. Analytical deviation investigation record is required, and a_ predefined testing plan is required to isolate and confirm OOS results. Flebogamma batch*(b) (4) was initially tested as QC sample — (b) (4) © on 31 January 2020 and retested as QC sample “"(b) (4) on 07 February 2020. There is no documented evidence of a laboratory OOS investigation opened for the initial test result. The initial test result met the Method specification. No predefined test plan was approved for retesting Flebogamma batch . There was no justification documented for conducting a retest on Flebogamma batch . Consequently, there is no justification for the average ofPee within specification test values reported in (0) (4) for Flebogamma batch— (b) (4) the assay results should be reported as single test value result for the batch.

Observation 4

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Observation 5

The written stability testing program is not followed.

Specifically, The Protocol # BIG-RD-SOP-000282, titled “Deviations General Procedure for Stability Studies ( (b) (4) | Barcelona, Scientific Innovation Office)” (Version 2.0, Effective from 6-Oct-2023; Section 7.2.1 Notification) is inadequate because it permits you to not open out of specification (OOS) investigations for reoccurring OOS at different time-points and different batches, if “the notification has been created” for the first OOS result (“i.e analytical incidents under accelerated conditions that have expected results due to previous studies”). Specifically, only one OOS investigation was opened for Fibrin Sealant Batch A04G03174 as Deviation # 300116307 for the 4 ml produced at (b) (4) with OOS result 3.6% fores (°) h C.) ee However, the reoccurring OOS results from the following batches and time-points from the same Stability Study at (b) (4). 0 hours were not investigated. All results were out of specification limit (b) (4) fores (2) C9 (document # IG_ESP-00030-ING): Batch #Time PointResult,% ee A0AGO3I7AI AOAGOSITAI 6 ADAGOSET2I _

See all 5 findings in this document
[FDA 483 observation · FDA]Center for Translational Medicine — GLP reporting and archiving failures
FDA483

FDA issued a Form 483 to Center for Translational Medicine, a nonclinical laboratory, after an inspection ending 07/11/2025. The five observations cover a final report that omitted circumstances affecting data, clinical observations (alopecia) recorded in source records but left out of the report, no SOP for test system observations, no master schedule, and raw data and protocol amendments not transferred to the archives, spanning GLP operations as a whole.

Published 2026-10-27 · Inspection date 07/11/2025 · Nonclinical Laboratory · FEI 3029067611

Key facts · Basis: official index plus supporting sources
  • Observations: 5
  • Citation: Study director and quality assurance unit duties not met; SOPs not established
  • Detail: Alopecia observations in source records were missing from the final report; no master schedule kept
Insight · Editorial insight

Clinical observations kept in source records but missing from the final report, together with no master schedule, suggest that oversight by both the study director and the quality assurance unit broke down. Sponsors who outsource nonclinical studies may want to check how their contractor reconciles source records with reports and archives study materials.

Check points
  • Reconciliation of source record observations against the final report
  • Whether the quality assurance unit keeps a master schedule
  • Records of transfer of raw data and protocol amendments to the archives after study completion
Observation detail · 5 observations · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

The final study report did not include a description of all circumstances that may have affected the quality or integrity of the data.

Specifically, (b) (4) as well as any instruments used to monitor temperature during (b) (4) and (b) (4) were not identified in the source records for any of the subjects for the (b) (4) study.

Observation 2

The study director failed to assure that the protocol, including any change, was approved and was followed.

Specifically,(0) (4) clinical observations related to alopecia were documented in the source records for) (4) ut of i ® subjects but were not included in the (b) (4) Report of the (b) (4) Final Report as required by the protocol. For example, Subject ID Abnormal Finding Recorded Dates ©) (b) (4) (b) (4) - at (b) (4) (b) (4) “— (b) (4) (b) (4) al (b) (4) (b) (4) | | (b) (4) b) (4 b) (4 ‘e) ( (b) (4)

Observation 3

Standard operating procedures have not been established for test system observations and handling of (b) (4) (b) (4) or (®) (4) during study.

Specifically, for the (6) (4), (10) (4) , and () (4) studies, the firm completed test system observations and took actions for (b) (4) or (6) (4) However, no standard operating procedures were established that describe these processes.

Observation 4

The quality assurance unit failed to maintain a copy of a master schedule sheet that contained all required elements for all nonclinical laboratory studies conducted by the testing facility.

Specifically) (4) procedures including(®) (4) preparation, (b) (4) , test system observations (©) (4) (6) (4) data collection, and sample collection were performed by the firm for the ( (4) © @ ang () (4) studies. However, no master schedule was maintained listing these ©) studies.

Observation 5

The study director failed to assure that all raw data, documentation, protocols, specimens, and final reports were transferred to the archives during or at the close of the study.

Specifically, (b) (4) and the (b) (4) signed Amendment” of the protocol for the (1) (4) study were not transferred to the archives after the study was completed on (1) (4) . A copy of (b) (4) (b) (4) was not (b) (4) as reported in the Compliance section of the (b) (4) Final Report, until (10) (4)

See all 5 findings in this document
[FDA 483 observation · FDA]MD Tox Laboratory — No CGTP quality program established
FDA483

FDA issued a 483 with 5 observations to MD Tox Laboratory, a testing laboratory. The citations included no quality program and procedures addressing the core CGTP requirements for HCT/P and inadequate record retention.

Published 2026-10-27 · Inspection date 01/28/2025 · Testing Laboratory · FEI 3011213917

Key facts · Basis: official index plus supporting sources
  • Observations 1 and 2: Quality program and step-by-step procedures addressing core CGTP requirements not defined or followed
  • Observations 3 and 4: Insufficient records of work performed, 10 years retention period after creation not met
  • Observation 5: CGTP recordkeeping system not maintained
Insight · Editorial insight

Citing the lack of a CGTP quality program for HCT/P at a testing laboratory signals that core requirements are expected to be applied according to the steps the laboratory performs. With record detail and the 10 years retention period also cited, it is worth checking the recordkeeping system.

Check points
  • Scope of CGTP procedures defined for each step performed
  • Detail of work records and compliance with the retention period
  • Documentation of the recordkeeping system
Observation detail · 5 observations · From the source

Inspectors: Celeta S Coves

Observation 1

A quality program which addresses all of the core CGTP requirements, appropriate for the HCT/Ps manufactured and the manufacturing steps performed, has not been defined and followed.

Specifically, your firm’s quality program has not been defined or followed for the following: 1.The following temperature/humidity excursions occurred in the refrigerators or FDA Testing areas below: 5 (b) (4) a. Fridge (Sample Storage) b. Fridge one (Sample Storage) . (b) (4) c. Fridge 1 (Reagents Storage) d. (b) (4) Room e. (b) (4) Room Nonconformances were not documented or investigated addressing the excursions above. According to procedure entitled, “Temperature Log Procedure, Version 1.0, Effective Date: 04/01/2024” Section 6.4 states: “Normal refrigerator temperature range for refrigerators is 7 (4 . considered between is | °C)/).” Sections 6.6 — 6.6.3 state: “6.6. IMPORTANT: If the temperature is out of range, proceed to the following steps: 6.6.1. Close the fridge/freezer s ” S (b) (4) door and tag the instrument as “Do Not Open”. 6.6.2. Leave the instrument closed for at least . 6.6.3. After (b) (4) , recheck the temperature, if the temperature is still abnormal,

Observation 2

Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not defined and followed.

Specifically, Your firm has not defined in your procedure entitled, “Procedure for repeating and reporting (B) (4) samples ( (b) (4) ), Version 1.0, Effective Date: 07/31/2023” the following manufacturing steps regarding review, sign-off, and release of final test results to a client are captured. For example, data entry and/or transfer into your (D) (4) system was not described. The (b) (4) review and documentation of the performed reviewed were also not described.

Observation 3

Records were not detailed as necessary to provide a complete history of work performed.

Specifically, during the inspection when I reviewed quality control and preventative maintenance records from August 2023 — December 2024 for the equipment and areas below, the following were missing documentation of review by signature and date: a. (b) (4) b. (b) (4) Oe we) d. e. (b) (4) f(b) (4) Qc (b) (4) Log g.Refrigerator (b) hRefrigerator (4) i.Refrigerator jf) (4) Room k(b) (4) Room

Observation 4

Records were not retained for the appropriate length of time, 10 years after their creation.

Specifically, your firm’s _(b) (4) is programmed to store test results for (b) (4). Your firm does not have the original testing data prior to (BD) (4) , THIS IS A REPEAT OBSERVATION.

Observation 5

A records management system relating to core CGTP requirements was not maintained and documented.

Specifically, during the inspection I reviewed quality control records regarding refrigerator temperature, room temperature, and humidity, however your firm was unable to provide quality control records for the following: a.Refrigerator"(Sample Storage) b.Refrigerator' (Sample Storage) : (b)(4) c.Refrigerator (Reagent Storage) d(b) (4) Room e(b) (4) Room

See all 5 findings in this document
[FDA 483 observation · FDA]Cangene Corporation — Inadequate process interruption investigation
FDA483

FDA issued a 483 to the Cangene Corporation manufacturing site. The citations included an inadequate investigation of process interruptions for VIGIV bulk lots, no reject rate criteria by defect category, inadequate retesting of lots that failed AQL, and inadequate document and deviation control.

Published 2026-10-27 · Inspection date 06/21/2012 · Manufacturer · FEI 3003153579

Key facts · Basis: official index plus supporting sources
  • Excerpt Observation 1: Inadequate investigation of process interruptions for VIGIV bulk lots (substance causing fouling not identified)
  • Observations 2 and 3: No reject rate criteria by defect category, no retesting at tightened criteria for lots that failed AQL
  • Observations 9 and 10: Replacement interval not defined for product-contact flexible hoses, incubation time not specified for growth promotion testing of environmental monitoring media
Insight · Editorial insight

An interruption investigation that did not identify the substance causing fouling, together with an inspection criterion with only a cumulative reject rate, signals that investigations stay on the surface unless defect data is broken down by cause. The inspection date of 06/21/2012 makes this a past record, but it is worth checking the visual inspection reject rate criteria and the replacement intervals for consumable contact parts.

Check points
  • Setting separate reject rate criteria for each defect category
  • Criteria and scope for retesting after an AQL failure
  • Defined replacement intervals for consumable parts such as product-contact hoses
Observation detail · 9 observations · From the source
Observation 2

There are no individual reject rates established for each defect category that is classified as(D)(4) The reject rate established is cumulative for all (b)(4) defects.

Change Control 219756 dated June 11, 2012 was implementedto change the cumulative reject rate for (b)(4) _ defects, such as associated with Microbial contamination” from oO a cumulative reject rate of or the WinRho (liquid formulation), HepGamB (Liquid), and Vaccinia Immune Globulin (VIG) products. A. are categorized as defects as opposed to “ is categorized as a Defect.

Observation 3

Not all lots ofproduct that fail the Acceptable Quality Limit (AQL) after the initial (B)(4) inspection is performed are reinspected under tightened limits for both the additional (6)(4) reinspection performed by production or the AQL performed by Quality.

For example: Deviation 212555 was initiated on May 29, 2012 for HepaGamB lot (b)(4) using 3mL Vial Lot"on having an atypical number of(6)(4) defects (classified as a (6)(4) defect), detected during the initial (6)(4) inspection process. The Acceptable Quality Limit for this inspection also failed the acceptance criteria as a vial with the(AVE) defect was detected. The lot was 100% reinspected for this defect. There were noreject limits established for this 2nd reinspection and there was no AOL performed for this reinspection. This lot was reinspected a third time under a tightened limit of (MAY dy land failed to meet this criteria with additional defects being found. Additional lots ofproduct that were affected by this deviation were also reinspected and failed either the reinspection and/or the AQL for the(b)(4) defect of here are no procedures in place which address the criteria for the reinspection of lots that fail the initia nspection or an AQL. Additionally, there are no procedures in place which address the limit for the number ofreinspections that can be performed on any given lot. .

Observation 4

There is a lack of assurance that there is adequate control over critical documents including, but not limited to, Policies, Standard Operating Procedures (SOPs), Work Instructions (WIs) Forms, Electronic Templates (ETs) Drawingsand Manuals.

The firm’s Record and Information Denartment (R41) dictribntac aantentlos documents}, »|, inwhich documents are to be returned is not always effective in that numerous incidences were o bserved where obsolete documents have been used by operators and technicians and have resulted in deviation investigations. Examples include, but are not limited to: [ - EMPEDYEE(S) SIGNATGRE on

Observation 5

SOP 25.026.0002.01.00 defines a On Oiled JO Ment A The printing, and circulation of such documents are not always controlled: A.

The firm uses(b)(4) software as a system for maintenance ofcontrolled documents. This allows for documents to be(0)(4) te use in various departments. There is a lack ofassurance that there is adequate control over controlled documents available to operators on(b)(4) Users who have access to the system are allowed to print offany of the effective controlled forms and procedures without accountability for these documents.

Observation 6

The firm’s deviation control system is inadequate in that it fails to adequately assess the classification of .

deviations that may affect product quality. Specifically, during manufacture of Liquid WinRho lot (b)(4) and HepaGamB lot(BVAYo ithe was exceeded. There is a lackofassurance that the product impact for these lots was adequately addressed in that iati i Deviations” that are use Per SOP 10.060.0023.20.19, QA Batch Record Revi eviations require

Observation 7

Deviation 109218 was initiated on June 7, 2010 for HepaGamB Finished Goods lot (b)(4) having been EMPEYEE(S) SIGHATURE——Z

Observation 8

Written procedures are not always followed.

The(D)(4 treatment module of the batch record (Document number 24.5002.08, step 17,

Observation 9

There is no defined change out period for product contact flexible hoses used in manufacturing.

Observation 10

The SOP for Growth Promotion of media used for’environmental monitoring is incomplete in that it does not specify the length oftime test articles should be incubated.

See all 9 findings in this document
[Warning Letter · FDA]TSP Solutions Pte. Ltd. — Release and ingredient identity testing missing
FDACGMP

FDA CDER issued a Warning Letter to TSP Solutions Pte. Ltd. on 10/22/2026. The violations cited were no finished product testing before release, no identity testing of each component, and inadequate fulfillment of quality unit responsibilities.

Published 2026-10-27 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/22/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: Identity and strength testing before release, and testing for objectionable microorganisms, not performed for each batch (21 CFR 211.165(a), (b))
  • Violation 2: Identity testing of each component not performed and reliability of supplier test reports not validated (21 CFR 211.84(d)(1), (d)(2))
  • Violation 3: Quality unit responsibilities not adequately fulfilled (21 CFR 211.22)
  • Issued by: CDER, 10/22/2026, FEI 3023093622
Insight · Editorial insight

This is a case where FDA tied a setup that skipped release testing and component identity testing and relied on supplier certificates to a quality unit responsibility problem. Manufacturers using outsourced or imported materials should re-examine the basis for accepting certificates and the scope of their own identity testing.

Check points
  • Whether identity testing of each component is done on receipt of materials
  • Frequency of verifying the reliability of supplier test certificates
  • Completeness of pre-release specification testing for each finished product batch
Violation detail · 3 items · From the source
Violation 121 CFR 211.165(a)

Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).

Violation 221 CFR 211.84(d)(1)

Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).

Violation 321 CFR 211.22

Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).

See all 3 findings in this document
[Warning Letter · FDA]Northland Nuclear Medicine, LLC — Failed-batch investigation and equipment gaps
FDACGMP

FDA CDER issued a Warning Letter to Northland Nuclear Medicine, LLC on 10/22/2026. The inspection of May 26 to 29, 2026 cited two violations: inadequate investigation and corrective action for batches that failed specifications (21 CFR 212.20(d)) and procedures for equipment cleanliness and suitability not adequately followed (21 CFR 212.30(b)).

Published 2026-10-27 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/22/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: No adequate investigation and corrective action when a production batch or component fails specifications (21 CFR 212.20(d))
  • Violation 2: Procedures for equipment cleanliness, suitability and maintenance not adequately followed (21 CFR 212.30(b))
  • Inspection period: May 26 to 29, 2026
  • Issued by: CDER, 10/22/2026, FEI 3005334016
Insight · Editorial insight

It shows that even under PET drug CGMP (21 CFR Part 212), investigation of specification failures and the link to CAPA are a core axis of enforcement. For processes such as short half-life products, where investigation happens after release, the scope of failure investigations and the basis for closing them should be checked.

Check points
  • Scope and closure criteria for investigations of batches that fail specifications
  • Records linking failure investigations to CAPA
  • Records showing equipment cleanliness and suitability procedures are followed
Violation detail · 2 items · From the source
Violation 121 CFR 212.20(d)

Your firm failed to conduct adequate investigations and take appropriate corrective action when a failure of a production batch or any component of the batch failed to meet any of its specifications (21 CFR 212.20(d)).

Violation 221 CFR 212.30(b)

Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed. (21 CFR 212.30(b)).

[Warning Letter · FDA]Sanrace Biotechnology Co., Ltd. — No ingredient identity tests or process procedures
FDACGMP

FDA CDER issued a Warning Letter to Sanrace Biotechnology Co., Ltd. on 10/22/2026. The violations cited were no identity testing of components, no written production and process control procedures, and an inadequate quality control unit.

Published 2026-10-27 · Issuing office / date Center for Drug Evaluation and Research (CDER) · 10/22/2026

Key facts · Basis: official index plus supporting sources
  • Violation 1: Identity testing of each component not performed (21 CFR 211.84(d)(1))
  • Violation 2: No written production and process control procedures (21 CFR 211.100(a))
  • Violation 3: No adequate quality control unit established (21 CFR 211.22(a))
  • Issued by: CDER, 10/22/2026, FEI 3016897521
Insight · Editorial insight

This is a case where FDA judged a site with no procedures and no quality control unit to lack a basic CGMP system. Where such an overseas manufacturer is in the supply chain, supplier assessment should first confirm that identity testing and process control procedures exist.

Check points
  • Confirmation that process control procedures exist during supplier assessment
  • Whether identity testing of each component is performed
  • Authority and structure of the supplier's quality control unit
Violation detail · 3 items · From the source
Violation 121 CFR 211.84(d)(1)

Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).

Violation 221 CFR 211.100(a)

Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).

Violation 321 CFR 211.22(a)

Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).

See all 3 findings in this document
[FDA 483 observation · FDA]Sunrise Pharmaceutical, Inc. — No scientific basis for temperature monitoring
FDA483

FDA cited 1 observation at Sunrise Pharmaceutical, Inc. (Manufacturer): drugs were not stored under appropriate temperature conditions. The firm was recorded as having no data or scientific justification for its routine temperature monitoring decisions.

Published 2026-10-26 · Inspection date 03/31/2026 · Manufacturer · FEI 3004813394

Key facts · Basis: official index plus supporting sources
  • Number of observations: 1
  • Citation: Inadequate temperature storage conditions for drugs
  • Detail: No data or scientific justification for routine temperature monitoring decisions
Insight · Editorial insight

The key signal is that the problem cited was the lack of data behind the monitoring method and not the storage temperature itself. It is worth checking whether the link between warehouse temperature mapping results and the choice of monitoring points and intervals can be explained.

Check points
  • Whether temperature mapping data for storage areas is available
  • Documented scientific basis for monitoring points and intervals
Observation detail · 1 observation · From the source

Inspectors: Alisha B Patel

Observation 1

Drug products are not stored under appropriate conditions of temperature so that their identity, strength, quality, and purity are not affected.

Specifically, Your firm lacked data and scientific rationale for determining the routine temperature monitoring . : - - oe . - oe . : location in the warehouses of Building and Building which store finished drug products such as (b) (4) Tablets, (B) (4) Tablets, and (b) (4) Capsules, raw materials, and packaging materials. Building™® current warehouse layout has only been mapped during winter months (b) (4) with no summer temperature mapping performed. Building (b) (4) : . ; tor eatin : has only been mapped during summer months ((b) (4) _), with no winter temperature mapping performed. Current temperature mapping studies do not account for seasonal variations when determining the worst-case location of the monitoring probe.

[FDA 483 observation · FDA]Pliva Croatia Ltd. c/o Teva Pharmaceuticals, USA — Test article stability during dialysis not shown
FDA483

FDA cited, at Pliva Croatia Ltd. (Analytical facility), that the stability of the test article was not demonstrated in relation to particle size distribution (PSD) data reported in a study. Stability at room temperature during the dialysis experiment was recorded as not demonstrated by the analytical method.

Published 2026-10-26 · Inspection date 05/31/2018 · Analytical facility · FEI 3002807904

Key facts · Basis: official index plus supporting sources
  • Number of observations: 1
  • Data concerned: Particle size distribution (PSD) data reported in a study
  • Citation: Stability of test article at room temperature during dialysis experiment not demonstrated
Insight · Editorial insight

It signals that at an analytical facility, demonstrating sample stability during the test conditions was treated as a precondition for data reliability. It is worth checking that the temperature and time range to which samples are exposed in long experiments is supported by stability data.

Check points
  • Data demonstrating sample stability during the test period
  • Scope of analytical method validation for long room temperature experiments
Observation detail · 1 observation · From the source
Observation 1

Stability of test product was not demonstrated, specifically: a) Stability was not demonstrated for during the dialysis experiment using an analytical assay at ambient temperature for the duration ofthe study.

b) Stability ofthe dialyzed solution stored before dynamic light scattering (DLS) analysis using an analytical assay was not demonstrated under storage conditions at ambient temperature to cover the duration that samples were stored before analysis.

[FDA 483 observation · FDA]Qilu Pharmaceutical (Hainan) Co., Ltd. — No process validation control procedures
FDA483

FDA cited 3 observations at Qilu Pharmaceutical (Hainan) Co., Ltd. (Finished Drug Product Manufacturer). They included no control procedures for process performance validation, inadequate size of manufacturing equipment, and use of laboratory instruments that did not meet specifications.

Published 2026-10-26 · Inspection date 08/22/2025 · Finished Drug Product Manufacturer · FEI 3008250362

Key facts · Basis: official index plus supporting sources
  • Number of observations: 3
  • Observation 1: No control procedures for performance validation of processes that may cause variation in product characteristics
  • Observations 2 and 3: Inadequate size of manufacturing equipment, use of laboratory instruments not meeting specifications
Insight · Editorial insight

Citing process variability control together with equipment and instrument suitability at a finished drug product manufacturer signals that the foundation of overall manufacturing capability was addressed. Consistency between batch size and equipment capacity, and whether laboratory instruments in use meet specifications, should be checked together.

Check points
  • Control procedures for performance validation of processes that cause variation
  • Fit of manufacturing equipment capacity to batch size
  • Control of laboratory instrument specification compliance and use restrictions
Observation detail · 3 observations · From the source
Observation 1

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics ofdrug products.

Specifically, a review of master batch records and validation batch records for) (»)(4)Capsules strengths(®) @) mg noted the following: 1) During the numerous®@ ~~) processes of ®)@) performed in the@@ samples are not taken to determine the ®) @ ofthe@ contained onthe®@) Only the amount®)@ at different time periods was documented. )@) (b) (4) are applied to @) and the actual amounts contained on the (»)(4) was not determined. 2) Numerous critical processing steps that require®)@) only documents the ®)@))))of the ()4)) obtained from the ®)@ The®@ > of the material that is larger or smaller in size is not measured and no specifications or limits for these materials have been established.

Observation 2

Equipment used in the manufacturing of drug products is not of adequate size.

Specifically, a review of validation manufacturing batch records for © Capsules strengths ©@ mg noted numerous® @ are performed during production for these products. These@ (0) (4) are performed on the ©@ Equipment ID #@@ used for the@ and ©@) Equipment ID #®@ used for)@ These two pieces of equipment do not have the capacity to process these jn a single operation. Multiple are performed to obtain the desire quantity ofOM and these additional steps increase the likelihood of operational errors and product quality variations.

Observation 3

The use of laboratory instruments not meeting established specifications was observed.

Specifically, on 8/20/2025, I inspected the firm’s QC laboratories located in Buildingand I observed three Dissolution Tester instruments that had asymmetrical basket apparatus rotation. 1) Instrument 1D #PDT2709A/PDT5103B which was used to perform dissolution testing on (©) 4) Capsules was observed to have 2 basket apparatus units out of(@ that had asymmetrical basket apparatus rotation. The last in-house verification for this instrument was on 3/17/2025. 2) Instrument ID #PDT2709B/PDT5103A which was used to perform dissolution testing on ©) 4) Capsules was observed to have 4 basket apparatus units out of hat had asymmetrical basket apparatus rotation. The last verification/calibration for this instrument was on 3/19/2025. 3) Instrument ID #PD5103A which was used to perform dissolution testing on ©@ (b) (4) Capsules was observed to have 2 basket apparatus units out of @) that had asymmetrical basket apparatus rotation. The last verification/calibration for this instrument was on 7/16/2025. / DA VEO

See all 3 findings in this document
[FDA 483 observation · FDA]Eugia Steriles Private Limited — Weak sterile contamination control and validation
FDA483

FDA cited 4 observations at Eugia Steriles Private Limited (Sterile Drug Product Manufacturer). The targets were procedures to prevent microbial contamination of sterile drugs, aseptic process validation, quality control unit procedures, and deviation investigation records.

Published 2026-10-26 · Inspection date 06/19/2026 · Sterile Drug Product Manufacturer · FEI 3027357163

Key facts · Basis: official index plus supporting sources
  • Number of observations: 4
  • Observations 1 and 2: Procedures to prevent microbial contamination of sterile drugs not established or followed, aseptic process validation insufficient
  • Observation 3: Quality control unit responsibilities and procedures not documented or not followed
  • Observation 4: Records of investigations into unexplained discrepancies lack conclusions and follow-up
Insight · Editorial insight

Citing contamination prevention procedures and aseptic process validation together at a sterile manufacturer signals that the foundation of the sterility assurance system was addressed. It is worth checking that microbiology-related deviation investigations are closed with conclusions and follow-up, since this may be reviewed alongside aseptic process evaluation.

Check points
  • Adequacy of aseptic process validation
  • Documentation of and compliance with microbial contamination prevention procedures
  • Completeness of conclusions and follow-up records in deviation investigations
Observation detail · 4 observations · From the source

Inspectors: Guerlain Ulysse

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, A. A®@@ trial run was conducted on June 16 - 17, 2026 to simulate the aseptic i (b) (4) (b) (4) eee Fe) ; filling anc process for injection, USM?) mg/vial and ©) (4) injection®@) mg/vial. The following deficiencies were observed: 1. The vial sampling tray used to conduct manual fill weight verification of©) filled vials were removed from the GradeA filling area after hand sanitization at approximately |2:03:21 on June 16, 2026, using © intervention. The vial sample tray located in the Grade B environment was moved to a) @) then to the sampling weighing station located at ©)@ (b) (4) and then returned until approximately 14:54:38 (almost 3 hours later). The vial sampling tray comes into direct contact with forceps stationed on the filling line for unplanned interventions of stoppered/unsealed vials. However, there is no detailed cleaning procedure ensuring that each of the ®@ in the sample vial tray are adequately sanitized prior to reentry in the Grade A filling line. Guerlain Ulysse, Investigator are wssue0

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation ofthe aseptic process.

Specifically, A. According to the Quality Head, the following ©)@ sensors, identified as part of the vial (b) (4) process, have not been calibrated or verified: There is no calibration record for such sensors involving the ()(4) and () (4) built in as part of the stoppering process foil)@ -45 and ®)(4) 20, In addition, there is no sensor challenge test for the ®)@) process and sensor locations. According to the Quality Head, ©)@)stoppering is dependent on )@) being maintained for (0) (4) B. There is no formalized Operation Qualification protocol or report detailing quality unit and production review of (®)(4) alarm events, any challenges, and final outcomes. This includes the lack of detailed review for sensor and alarms used for ©) @) signals, (©) (4) sensors used as (®)(4) sensors. C. There is no detailed justification by the quality unit as to why planned media fill interventions dictated by the Aseptic Process Simulation (APS) master batch record are not uniformly performed for al] ©)(4) campaign batches, For example: Guerlain Ulysse, Investigator Cy. DATE 1ssueO

Observation 3

The responsibilities and procedures applicable to the quality control unit are not writing or fully followed, Specifically, A.

During my walkthrough on June 10, 2026, I observed that two (2) CCTV cameras were offline. In addition, | observed an outlined circle on the filling machine®)@) The Quality Head stated that this was due to future plans to install an additional camera inside the Grade A environment. The firm's CAPA report further states that some of the interventions, which are performed from filling to © @ joading/unloading are not clearly visible from CCTV camera and there is no feasibility of view panel to verify aseptic intervention execution (behaviour and technique). However, activity is now monitored by real time reviewer from aseptic area. Based on the above evaluation, below are the actions to be taken for clear visibility of interventions throughCCTV: aa ; Room Name and No. Camera Adjustment /New Camera Vial Filling and Stoppering area and |New CCTV Camera required at stoppering station (b) (4) Guerlain Ulysse

Observation 4

Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.

Specifically, A. PNC-EP5-EN-25-0006 was initiated on June 07, 2025 due to power failure for all plant loads and during the ®)@4) process involving (©)@) injection me/vial, batch No. (0)(4) However, the investigation report did not include details surrounding the change in (o)(4) ___ and its effect on the ®@ process. In addition, there is no software limitation, internal limit, or study as to how long a ®@) cycle can remain interrupted prior to continuation as per MSAT Manager. According to the Quality Head, batch No. (>) (4) ‘was initiated after the power failure incident. However, the batch No was ultimately rejected due to observed solution leakage from the product transfer line filling area. There was no attempt to repeat the © @ batch thereafter. _ B. OOS Number ESOOS240002 was initiated for R&D ©@ Injection UsP @ me/Vial, Test: Gross Content by HPLC, Date Initiated: February 03, 2024,, Batch Nowa) | Results: ©@ mg/vial (Specification Limit: NLT ®@ and NMT ®@. The manufacturing investigation attributed the most probable root cause to potential issues with connections to manufacturing vessels during ®@ —_calibration that may not have been accounted for during Guerlain Ulysse

See all 4 findings in this document
[FDA 483 observation · FDA]Fagron Analytical Services, LLC — No backup of pH meter electronic data
FDA483

FDA cited 1 observation at Fagron Analytical Services, LLC (Contract Laboratory): backup files of data entered into computerized systems were not maintained. Digital data and results generated by a Mettler Toledo pH meter in the chemistry laboratory were recorded as not backed up.

Published 2026-10-26 · Inspection date 03/26/2026 · Contract Laboratory · FEI 3033031230

Key facts · Basis: official index plus supporting sources
  • Number of observations: 1
  • Citation: Backup files of computerized system data not maintained
  • Instrument concerned: Mettler Toledo pH meter in the chemistry laboratory
Insight · Editorial insight

It signals that even a small stand-alone instrument such as a pH meter falls under backup requirements once it generates digital data. Firms that use contract testing laboratories should check that the scope of electronic data retention for each instrument also bears on the sponsor's data integrity.

Check points
  • Whether stand-alone laboratory instrument electronic data is included in backups
  • Confirmation of how the contract testing laboratory retains raw data
Observation detail · 1 observation · From the source

Inspectors: Fy Bowles

Observation 1

Failure to maintain a backup file of data entered into the computer or related system.

Specifically, The Mettler Toledo pH meter used in the chemistry laboratory creates digital data and results that are not backed up. The instrument can store up to 250 results, but there is no system in place to preserve this electronic data before it is overwritten or lost. Additionally, the pH meter does not have unique usernames and logins for individual operators. Instead, a shared username, "Analyst," is used by personnel. This shared login system does not allow for attribution of specific test results to individual operators and does not provide adequate controls to ensure that only authorized personnel are accessing and using the equipment. There is no assurance that pH test data generated by this equipment is complete, accurate, and attributable to specific individuals, or that historical data can be retrieved for batch record review or investigation purposes. The pH meter is used for release testing on the following products: Product (b) (4)

[FDA 483 observation · FDA]Banner - University Medical Center Tuscon — Emergency transfusion physician signature gaps
FDA483

FDA cited two observations at Banner - University Medical Center Tuscon (Transufusion Service). Requesting-physician signatures and justification records for emergency transfusions were not maintained, and investigation and documentation of unexplained discrepancies were inadequate.

Published 2026-10-26 · Inspection date 04/22/2026 · Transufusion Service · FEI 3004445465

Key facts · Basis: official index plus supporting sources
  • Observations: 2
  • Observation 1: Requesting-physician signature and emergency justification records not maintained for emergency transfusion
  • Observation 2: Inadequate thorough investigation of unexplained discrepancies and recording of conclusions and follow-up
Insight · Editorial insight

This signals the expectation that emergency exceptions at transfusion services be justified in documentation after the fact. It is worth checking whether exceptions that bypass normal procedure, such as urgent release, carry after-the-fact approval and a recorded rationale.

Check points
  • Approver signature and justification records for exception or emergency handling
  • Conclusion and follow-up records for discrepancy investigations
Observation detail · 2 observations · From the source

Inspectors: Emily S Mcgann

Observation 1

Records including signature by the physician requesting the procedure are not maintained of all emergency transfusions including complete documentation justifying the emergency action.

Specifically, while reviewing available emergency release documents for blood components released between June 2025 and April 2026, it was noted that: 1. The Emergency Transfusion Request Form (LSA Transfusion Medicine Form 1840) does not contain documentation for the justification for the emergency release of blood products or the date of physician signature. 2. Approximately 30 ofthe 4) Emergency Transfusion Request Forms reviewed were signed by individuals who are not physicians. Since 2025, your firm has emergency released approximately ®) units of blood components

Observation 2

Failure to perform a thorough investigation and makea record of the conclusions and follow-up of an unexplained discrepancy.

Specifically, when reviewing your firm's variances the documentation does not include information need to demonstrate a thorough investigation was completed. This includes a lack of description of issue with detail (i.e. units involved), all corrective actions taken, employee(s) involved and product suitability review.

[FDA 483 observation · FDA]Laboratoires Anios — Weak specification basis, no stability program
FDA483

FDA cited two observations at Laboratoires Anios (Drug Manufacturer). Scientifically sound specifications, sampling plans and test methods were not established for components, in-process materials and finished products, and there was no written testing program to assess drug stability characteristics.

Published 2026-10-26 · Inspection date 09/12/2024 · Drug Manufacturer · FEI 3004094142

Key facts · Basis: official index plus supporting sources
  • Observations: 2
  • Observation 1: Specifications, sampling plans and test methods for components, in-process materials and finished products lacked scientific soundness
  • Observation 2: No written testing program to assess drug stability characteristics
Insight · Editorial insight

Citing specifications and the stability program together suggests that the basis for release decisions and for expiry dating was undermined at once. It is worth checking that expiry dating is supported by stability data and that the basis for specifications is documented.

Check points
  • Documented basis for component and finished-product specifications
  • Written stability testing program and basis for expiry dating
Observation detail · 2 observations · From the source

Inspectors: Joohi Castelvetere

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components, in- process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, A) Your firm failed to establish specifications requiring testing of raw material pe with the respective USP Monographs for Identification™® — Limit of (b) (4) a -,. & . - . . ; This raw material is received and approved for release without testing for impurity limits. is used in your drug product”™ B) Your firm has not established specifications requiring testing of the incoming raw material ahi within the respective USP Monographs for Identification of "™ These raw materials are received and approved for release without testing for impurity lunits. iad is : (4) used in your drug product” Since 01/01/2022, approximately) batches of drug product have been manufactured and shipped to the US.

Observation 2

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, Your firm has not established a stability testing program for your drug product to confirm and ensure that these products maintain their efficacy and quality attributes throughout the established shelf life? In addition, your stability program is deficient in that: Your most current stability study, study number 16/275ANA, was completed in 2018 and signed off in 2020. This study was performed under the requirements of the European Good Laboratory Practices (GLPs), and not the U.S. Current Good Manufacturing Practices (CGMPs). There have been no ongoing stability studies performed since, and stability samples included in your 2018 study did not include microbiological testing, and/or testing for impurities. Additionally, stability chambers used in the study for accelerated and real-time conditions were not controlled for relative humidity.

[FDA 483 observation · FDA]Tan-Alize Kozmetik ve Temizlik Urunleri Sanayi ve Ticaret A. — Seven observations across GMP areas
FDA483

FDA cited seven observations at Tan-Alize Kozmetik ve Temizlik Urunleri Sanayi ve Ticaret A.S. (OTC Drug Manufacturer). They span laboratory specifications and methods, non-adherence to the stability program, microbial control for non-sterile products, air filtration and manufacturing records.

Tan-Alize Kozmetik ve Temizlik Urunleri Sanayi ve Ticaret A.S. · Published 2026-10-26 · Inspection date 02/27/2026 · OTC Drug Manufacturer · FEI 3004135088

Key facts · Basis: official index plus supporting sources
  • Observations: 7
  • Main findings: Inadequate laboratory specifications and test methods; written stability testing program not followed
  • Microbiological and environment: Procedures to prevent objectionable microorganisms in non-sterile drugs not followed; inadequate air filtration system in production areas
  • Records: Batch production and control records incomplete
Insight · Editorial insight

Findings spread evenly across testing, stability, microbiology, environment and records point to immaturity of the GMP system as a whole rather than one specific defect. When assessing contract manufacturers, check that even non-sterile products are controlled for objectionable microorganisms and production-area air handling.

Check points
  • Adherence to procedures against objectionable microorganisms in non-sterile products
  • Adequacy of the air filtration system in production areas
  • Contemporaneous entry and completeness of batch records
Observation detail · 7 observations · From the source

Inspectors: Saleem A Akhtar

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that components, drug product containers and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, you failed to verify the identity and purity of the active pharmaceutical ingredients and packing materials that are used to manufacture OTC drugs intended for the US market. For example: ; . - (bo) (4) A. The firm manufactures OTC drugs including ahi using various active pharmaceutical ; ; (b) (4) ingredients such as (4) p On 2/25/2026, the QC Manager stated the firm does verify the purity and strength of these APIs to what is stated in the manufacturer’s certificate of analysis. The site routinely ships batches of OTC drugs manufactured with these APIs. (4) : : 4) B. The firm uses ° for primary packing of? (b) (4) (b) (4) (b) (4) and to pack 4) : aha On 2/25/2026, the QC Manager stated the firm does verify the identity of9 packing materials that are sourced from a 3" party supplier. "™ ai are used as primary packing materials to pack all the OTC drugs that are routinely

Observation 2

The written stability testing program is not followed.

REPEAT OBSERVATION Specifically, you failed to follow your Stability control procedure (FRMS SOP QC 023) to ensure the quality of the distributed batches for entire shelf life. On 2/25/2026, following deficiencies were observed pertaining to stability testing of OTC drug products: A. The site approved stability study protocol for Lot? on 12/9/2025 to conduct long-term (25°C/60%RH), accelerated (40°C/75%RH), and intermediate (30°C/65%RH) stability studies. However, on 2/25/2026, no sample for this batch was observed in the stability chambers intended to store stability samples under long-term, mtermediate, and accelerated stability studies. On p the firm shipped? units of Lot (b) (4) to the US. B. The firm approved stability study protocols for batch and bho batch on 1/12/2026 and 2/10/2026 to conduct stability studies under long-term, intermediate, and accelerated storage conditions. As per study protocols, the stability samples required to be tested as per following intervals for both products: Product Name [Long-term testing [Intermediate Accelerated schedule in esting Schedule [Testing Schedule

Observation 3

Determinations of conformance to appropriate written specifications for acceptance are deficient for in- process materials.

Specifically, since 12/8/2025, you have not tested ad fo.” On 1/10/2026, you used pe of this” to manufacture "™ bulk batch bahia (Packing batch °™ (b) (4) ; ; ; On 2/25/2026, the QC Manager stated the equipment (equipment ID: QA-QC-EQ-011) is out of order as of 12/8/2025 due to malfunction of an electronic component. The firm raised deviation DV-25- 001 to investigate the equipment malfunction and repair. The firm has not closed the deviation as the equipment repair is still pending. The QC Manager stated even the "® is not being tested for there is no risk to the products as they are meeting the finished product testing specifications. (b) (4) ww Since the equipment failure the firm manufactured package batch aie and shipped this batch on two dates, pe units) and p units) to (b) (4)

Observation 4

Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not followed.

Specifically, you failed to follow your control procedure SOP-QCM-011, Microbiological Control of o@ to ensure used to manufacture OTC drugs is free from objectionable microorganism. For

Observation 5

The production area air supply lacks an appropriate air filtration system.

Specifically, the air supply in the core manufacturing areas used to manufacture drug products does not provide assurance that it is free from dust and/or other undesirable particulates. : b) (4 . : : For example, core drug manufacturing areas such as p filling, and packing are shared with the areas used to manufacture cosmetic products without appropriate airlock system. The firm’s QA Manager confirmed on 2/27/2026 that these areas are not maintained as classified areas and/or minimally Grade D areas. The firm’s air circulation system does not provide any assurance that is suitable for intended use.

Observation 6

Written production and process control procedures are not followed in the execution of production and process control functions and documented at the time ofperformance.

Specifically, batch manufacturing and testing records are not documented/signed and/or verified at the time activity is performed. For example: A. Equipment use logbook for balance in the sampling room indicated that the balance was used three times on 2/23/2026 to sample various material such as” saa However, this sampling activity was not documented on Sampling Room Use Logbook as required under Raw Material Sampling control procedure FRMS-SOP-QC-019. (b) (4) . . . . B. The QC Lab used the equipment (equipment ID: QA-QC-EQ-011) approximately eight times to analyze 1 for between the dates of 10/14/2025 to 10/23/2025. Review of the equipment use logbook indicated, as of 2/24/2026, the equipment use entries were not checked/verified by the 24 person as required under Records System control procedure FRMS-SOP-QA-003.

Observation 7

Batch production and control records do not include complete information relating to the production and control of each batch.

See all 7 findings in this document
[FDA 483 observation · FDA]DiAgam Societe Anonyme (S.A.) — Inadequate validation of unverifiable processes
FDA483

FDA cited four observations at DiAgam Societe Anonyme (S.A.) (Manufacturer). They include inadequate validation of a process whose results cannot be fully verified by subsequent inspection, manufacturing equipment not meeting requirements, and no established acceptance procedures for finished and in-process product.

Published 2026-10-26 · Inspection date 12/18/2025 · Manufacturer · FEI 3003749380

Key facts · Basis: official index plus supporting sources
  • Observations: 4
  • Observation 1: Inadequate validation of a process that cannot be fully verified by subsequent inspection
  • Observation 2: Findings on adequacy of manufacturing equipment design and installation and on meeting requirements
  • Observations 3 and 4: Inadequate finished-product acceptance procedures and in-process product acceptance and control procedures
Insight · Editorial insight

This shows that for processes whose results cannot be confirmed by later inspection, validation and stage-by-stage acceptance are the only basis for quality assurance. It is worth checking that in-process and finished-product acceptance criteria are linked to validation results.

Check points
  • Identification of processes that cannot be verified afterwards and their validation status
  • In-process product acceptance and control procedures
  • Finished-product acceptance procedures
Observation detail · 4 observations · From the source

Inspectors: Naakesh N Gomanie

Observation 1

A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.

Specifically, your firm’s process validation procedures: Validation et modification des processus et des équipments DGM-QAA-SOP-023 Rev 00 (dated JAN-25-2019) to Rev 03 (dated JULY-23-2024) and Quality Management, SOP-IMP-04 Ver 1 (dated MAY-26-2025) are inadequate. Between| _... | your firm has distributed approximately | - | |(A2M-1) and|-__| (A2M-2) apha2 Macroglobulin immunoturbidimetry IVD kits (Class ID, IVD calibrator Kits (Class II), and| - IVD control kits (Class I). Your firm failed to adequately validate the process of: A.Capping the IVD, Control, and Calibrator vials specific to Bouchoneuse | ‘Capper 1’. Specifically, your firm’s validation Qualification et Validation de la Visseuse a bouchon semi- automatique, DGM-R+D-NOT-14011b (dated FEB-25-2014) fails to provide any assurance that the: 1.Machine TB440.4 is capable ofproducing product that meets specifications. Specifically, your firm failed to include any protocol, testing instructions, acceptance criteria, and results for the installation/qualification of the capping machine. 2.Process was challenged utilizing worst case process parameters which include but are not

Observation 2

The appropriate design, construction, placement, and installation ofmanufacturing equipment have not been ensured and equipment used in the manufacturing process does not meet specified requirements.

Specifically, your procedures which govern capping Short-term maintenance Bouchonneuse, FOR-INF- 02_BOUCHONEUSE Rev 01 (dated JULY-01-2025) and Maintenance et métrologie Rev 35 (dated JULY-30-2024) and Rev 34 (dated OCT-27-2022) are inadequate. For example: A. Your firm consistently operates outside the validated parameters for capping height processed. Of the 5 DHRs reviewed the following was observed: Head Capper sags Height in Observed Height No. No. validation Validation Range | 2 |1s] SSDGM-R+D-NOT-14011IB_— [|00 | 2) | | ~DGM-R+D-NOT-14011B_ |__| || | 3 | | DGM-R+D-NOT-14011B_ |_| P| 3 || DGM-R+D-NOT-14011B_ | || | 3 | dt |S DGM-R+D-NOT-14011B_ [| | | | 3 | |=DGM-R+D-NOT-14011B_ |_| || | 2) | | ~DGM-R+D-NOT-14011B || | 2) | | ~DGM-R+D-NOT-14011B_ |_| || B. Your firm has not defined the end-of-life characteristics and maintenance requirements of your custom capping heads #2, #3, #6, #7, #10, #11 used in the manufacturing ofthe Alpha2

Observation 3

Procedures for finished device acceptance have not been adequately established.

Specifically, your firm’s Procedure de controle final des commades *** diagnostics GMBH, DGM- QAC-SOP-030 Rev 08 (dated JAN-31-2023) fails to require any testing of the capping process for the Alpha2-Macroglobulin immunoturbidimetry IVD kits (Class I), [VD calibrator Kits (Class II), and [VD control kits (Class I).

Observation 4

Procedures for the acceptance and control of in-process product have not been established.

Specifically, your firm has not established any in-process inspection procedures for the Alpha2- Macroglobulin immunoturbidimetry IVD kits (Class II), [VD calibrator Kits (Class I), and [VD control kits (Class I).

See all 4 findings in this document
[FDA 483 observation · FDA]KCI POLYMEDICS BV — Inadequate process parameter monitoring procedures
FDA483

FDA cited two observations at KCI POLYMEDICS BV (Manufacturer). Validation of a process whose results cannot be fully verified by subsequent inspection was inadequate, and procedures for monitoring and controlling parameters of validated processes were not sufficiently established.

Published 2026-10-26 · Inspection date 12/11/2025 · Manufacturer · FEI 3003775292

Key facts · Basis: official index plus supporting sources
  • Observations: 2
  • Observation 1: Inadequate validation of a process that cannot be fully verified by subsequent inspection
  • Observation 2: Inadequate procedures for monitoring and controlling parameters of validated processes
  • Related document: Validation Master Plan, PRO 38.E.00 Rev 1 (dated 04/16/2009)
Insight · Editorial insight

The mention of a validation master plan revised in 2009 signals that review may focus on whether old procedures have been updated to current expectations. It is worth checking that there is a system to keep monitoring process parameters after validation and so maintain the validated state.

Check points
  • Revision cycle and currency of the validation master plan
  • Continuous monitoring of process parameters after validation
Observation detail · 2 observations · From the source

Inspectors: Naakesh N Gomanie

Observation 1

A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.

Specifically, your firm’s procedures Validation Master Plan, PRO 38.E.00 Rev 1 (dated 04/16/2009); Validation Procedure, SOP 38.E Rev 00 (dated 10/21/2010) to Rev 02 (dated 05/13/2013); and Process Validation, SAT-QP-09-05 Rev 13 (dated 05/29/2015) to Rev 36 (dated 09/04/202 e inadequate. Between| —. | your firm has distributed a total of) au, class II sterile V.A.C. Whitefoam devices sua Your firm failed to adequately validate the: A.Cleaning process using the worst-case product. This includes but is not limited to the highest allowable levels of { wi Your firm categorized washing as medium risk in your process risk files: Manufacturing PFMECA - V.A.C. Whitefoam, PFMECA- 05-839542 Rev 5 (dated 06/11/2025) and Risk Management Assessment, RM-A-05-839518 Rev 4 (dated 10/30/2025). This applies to the: 1)In-process wash: Process Qualification (PQ)for WhiteFoam Production, Protocol DOC- 0000023933 Rev A (dated 10/05/2010) and Report DOC-0000023934 Rev A (dated 10/25/2010). 2)Final wash: Final wash process Process Qualification Protocol for. _?washing

Observation 2

Procedures for monitoring and control ofprocess parameters for a validated process have not been adequately established.

Specifically, your firm failed to establish procedures to document start up temperatures and pressure settings for sealers #234, #235, and #236. The PO report sealers, SAT-PQ-RPT-05-899324 Rev | (dated 12/21/2022) defines in section 6.0 the nominal temperature as 140 °C and force/pressure as 100N. However, your firm’s DHRs fail to document this parameter during start-up. For example: In both batched a | lie | devices, (dated, wn ) andjG |devices, (dated your firm fails to document the start-up parameters for both temperature and pressure

[FDA 483 observation · FDA]NanoHive Medical LLC — Inadequate complaint handling records
FDA483

FDA cited one observation at NanoHive Medical LLC (Manufacturer): complaint handling records were not properly maintained. Complaint files were recorded as not sufficiently documented in accordance with the firm's complaint handling procedure SOP-032-Rev A.

Published 2026-10-26 · Inspection date 03/05/2026 · Manufacturer · FEI 3013462427

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Finding: Complaint handling records not properly maintained
  • Related procedure: Complaint Handling procedure, SOP-032-Rev A (Effective Date: 7/21/2017)
Insight · Editorial insight

A procedure existed, but actual complaint files were not prepared as it required, so the gap between procedure and records is the focus. It is worth sampling complaint files against the required items in the procedure to check for omissions.

Check points
  • Whether complaint files meet the required items in the procedure
  • Current suitability of old complaint handling procedures
Observation detail · 1 observation · From the source

Inspectors: Nabil Nakhoul

Observation 1

Complaint handling records were not adequately maintained.

Specifically, your complaint files have not adequately documented as required per your Complaint Handling procedure, SOP-032-Rev A; Effective Date: 7/21/2017, per the following: A.3 of 11 complaint records reviewed did not include necessary signatures and dates indicating review. B.2 of 11 complaint records reviewed did not include complete documentation for regulatory reporting as required by Section 6.5.4 of SOP-032. C.2 of 11 complaint records reviewed did not include reference to the corrective action record that was initiated in response to the complaint or include a justification for no corrective action as required by Section 6.8 of SOP-032. D.4 of 11 complaint records reviewed were not processed in a timely manner.

[FDA 483 observation · FDA]Grifols Diagnostic Solutions Inc. — Verification used in place of validation
FDA483

FDA found the rationale inadequate for applying verification instead of process validation to manufacture of the licensed antigen HCV c100-3 at Grifols Diagnostic Solutions Inc. (Licensed Antigen Component Manufacturer for IVDs). It also cited the absence of a CPV report analyzing process data across all antigen types to evaluate validation status.

Published 2026-10-26 · Inspection date 12/13/2024 · Licensed Antigen Component Manufacturer for IVDs · FEI 1000124057

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Subject: Manufacturing process of the licensed antigen HCV c100-3
  • Finding: Inadequate rationale for excluding process validation, and no analysis of process data for all antigens using a CPV report
Insight · Editorial insight

This shows that when verification is chosen over validation, the rationale for excluding validation is itself subject to inspection. It is worth checking whether continued process verification (CPV) data are analyzed across the whole product family to judge the validated state of the process.

Check points
  • Documented rationale when process validation is excluded
  • Whether CPV data are analyzed across the whole product family
Observation detail · 1 observation · From the source

Inspectors: Nisha C Patel · Gene D Arcy

Observation 1

Licensed Antigen Component Manufacturer for IVDs Your firm has not appropriately ruled out process validation for manufacturing of licensed antigen HCV c100-3 instead of using a verification approach, and your firm has not analyzed process data across all antigen types using your firm's CPV (b) (4) Reports to assess that manufacturing processes are in a qualified/validated state.

A.Process Validation Master Plan, GDSE-VAL-VMP-000005, V21 & 22, indicates in part in section 9.3 that a verification approach is an alternative to re-validation in which manufacturing process performance is monitored and evaluated. Your firm used a process verification approach to address (b) (4) for HCV c100-3 antigen (bb) (4) manufacturing (yeast (b) (4) , and yeast (6) (4) (b) (4) , as indicated by Process Verification Report GDSE-VAL-REP-000973. The Master Plan also indicates in part that a risk assessment will determine if a verification is appropriate. This was done as per Risk Assessment for (®)(4) HCV c100-3 (b) (4) in (©) (4) GDSE-MFG-RSKA- 000652. The risk assessment indicates that “Run (b) (4) ot (b) (4) runs used for evaluation of risk) did not pass certain assays. This apparent failure was not addressed to substantiate the decision to perform a process verification (i.e., (b) (4) run) instead of a full re-validation (i.e., PPQ) of the HCV c100-3 process (b) (4) B.Your firm’s SOP, Process Validation Stage 3 — Continued Process Verification, GDSE-MFG-SOP-000071, Ver 17 and 18 requires, in part, the trend analysis of process output parameters and critical quality attribu

[FDA 483 observation · FDA]Neurotech Pharmaceuticals, Inc. — Management quality system responsibility unmet
FDA483

FDA cited three observations at Neurotech Pharmaceuticals, Inc. (Drug Substance and Drug product Manufacturer): management responsibility for establishing the quality system, quality oversight of the NT-501 combination product, and the ability of the visual inspection program to detect turbidity, precipitate and particles.

Published 2026-10-26 · Inspection date 07/26/2024 · Drug Substance and Drug product Manufacturer · FEI 3012545799

Key facts · Basis: official index plus supporting sources
  • Observations: 3
  • Observation 1: Management did not ensure an adequate and effective quality system was established
  • Observation 2: Inadequate quality oversight of the NT-501 combination product
  • Observation 3: Visual inspection program inadequate to identify turbidity, precipitate and particles
Insight · Editorial insight

Management responsibility was raised as the first observation, signaling that management involvement in quality is directly assessed beyond individual defects. It is worth checking that the visual inspection capability to identify turbidity, precipitate and particles is verified and that management review covers such quality indicators.

Check points
  • Reflection of quality indicators in management review
  • Verification of visual inspection program detection capability
  • Quality oversight system for combination products
Observation detail · 3 observations · From the source
Observation 1

Management with executive responsibility has not ensured that an adequate and effective quality system has been established.

For example: a. Management with executive responsibility has not ensured that the quality policy is established, understood, and maintained at all levels of the organization. Specifically, implementation and training of the quality policy within draft document QM -0001.01 "Neurotech Quality Manual" has not been performed. Additionally, F10404.01 "Quality Policy" was Ibt1 as of June 8,2021. b. Management with executive responsibility has not appointed a management representative to ensure that quality system requirements are met, and to report to management on the performance of the quality system. Specifically: 1. There is no documentation for the appointment of the management representative. ii. The management representative is not defined as required to attend the management review meetings as per SOP -1040.03 "Quality Management Review". iii. Per SOP -1040.03 "Quality Management Review", the QA Executive Management reviews and approves the presentation on the quality system performance for the management review meetings.

Observation 2

Inadequate quality oversight to assure that the NT -501 combination product has the identity, strength, quality, and purity it purports or is represented to possess.

For example: a Written procedures are not followed. For example: i. There are no approved quality agreements between Neurotech and suppliers of materials including the endothelial serum free media, gripper, scaffold yarn, hollow fiber membrane, titanium anchor loop,1181 adhesive, and primary container closure as required per SOP -1021.12 "Supplier Qualification & Monitoring".

Observation 3

The manual visual inspection program is inadequate to identify turbidity, precipitate, and particulates in the NT -501 combination product.

For example: a. Written procedure to inspect the NT -501 combination product is inadequate or not established. i. SOP -2188.02 "Visual Inspection of NT -501 Final Product" does not include instructions on how to inspect the parameters (e.g., turbidity, seal leaking, implant seating, precipitates, particles, label) using the ii. SOP -2188.02 does not specify how operators should set up the visual inspection station to maintain consistent inspection performance. Since the is not adjustable and nor was there an adjustable 01(41 on July 24, 2024, it was observed that an operator was not consistently on the same level as the NT -501 combination product during the manual visual inspection. b. Written procedures are not followed. Specifically, on July 24, 2024, it was observed that the operator did not the product before assessing each parameter as per step 3.2 of SOP -2188.02 "Visual Inspection of NT -501 Final Product".

See all 3 findings in this document
[FDA 483 observation · FDA]2seventy bio, Inc. — Incomplete reference standard testing records
FDA483

FDA cited one observation at 2seventy bio, Inc. (Viral Vector Testing Lab): records of testing and standardization of laboratory reference standards were not complete.

Published 2026-10-26 · Inspection date 03/20/2025 · Viral Vector Testing Lab · FEI 3013427685

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Finding: Records of testing and standardization of laboratory reference standards incomplete
Insight · Editorial insight

A stand-alone finding on reference standard records at a viral vector testing lab signals that traceability of the standards, the reference point for test results, is a key inspection item. It is worth checking that qualification and re-standardization history of reference standards are linked in the records.

Check points
  • Reference standard qualification and standardization records
  • Traceability of reference standard use and re-standardization history
Observation detail · 1 observation · From the source

Inspectors: Scott T Ballard

Observation 1

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.

Specifically, your firm has not adequately qualified the DNA plasmid reference standard’ (b) (4) used in the test method TM-0059 Determination of Lentiviral Vector Titer by (b) (4) (6) (4) in Quality Control. This test method relates to the viral vector Anti-BCMA02 CAR aLVV used in manufacturing drug product ABECMA. Three testing reports speak to the structure of the DNA Plasmid (lot ®) (4)) expected to be (6) (4) bp in length but give conflicting data: 1.Report (b) (4) dated (Bb) (4) _— for (b) (4) with size of(6) (4) bp 2.BioInformatics Report dated) (DB) (4) — shows (b) (4) total size of (b) (4) bp 3.Report #RPT-2265 dated _(b) (4) shows (b) (4) plasmid with size greater than or equal to (b) (4) bp. This plasmid reference standard lot has been used in all testing of viral vector batches with TM-0059 since prior to 2021.

[FDA 483 observation · FDA]MSD International GmbH — Multiple 483 inspection records released
Evidence BFDASignal High · T3483

FDA OII FOIA Electronic Reading Room released 11 Form 483 inspection records. The original PDFs are public, but the individual observation text could not be obtained automatically, so only the list of facilities and inspection dates is summarized.

Published2026-10-26
Document no.fda483-195404
Site / companyMSD International GmbH · FEI 3002808087
Site · typeDrug Substance Manufacturer · 483
Inspection date04/11/2025
All 4 items
  • MSD International GmbH · FEI 3002808087 · 실사 04/11/2025
  • Sanofi Pasteur Limited · FEI 3002888623 · 실사 03/18/2025
  • Baxter Pharmaceutical Solutions LLC · FEI 10000115571 · 실사 07/26/2024
  • Victory Medical Center Pharmacy · FEI 3010485868 · 실사 09/10/2026
Key facts · Basis: official index plus supporting sources
  • Records released: 11 (observation text not obtained automatically; original PDFs are public)
  • Representative facility: MSD International GmbH, FEI 3002808087, plus 10 others
  • Source: FDA OII FOIA Electronic Reading Room
Insight · Editorial insight

Release of inspection records without the observation text is not in itself a signal for action. Domestic firms should check whether any facility in their supply chain appears on the list and, if so, read the original PDF directly.

Check points
  • Whether any facility in your supply chain or sourcing appears on the list
  • If so, read the original FDA FOIA PDF directly
[FDA 483 observation · FDA]Omrix Biopharmaceuticals Ltd. — Test data and contemporaneous recording gaps
FDA483

FDA cited four observations at Omrix Biopharmaceuticals Ltd. (Manufacturer): scientific soundness of test methods, complete recording of test data, real-time recording of laboratory control activities, and labeling material records per batch.

Published 2026-10-26 · Inspection date 03/05/2020 · Manufacturer · FEI 3008640339

Key facts · Basis: official index plus supporting sources
  • Observations: 4
  • Observation 1: Scientifically sound test methods not established
  • Observations 2 and 3: Incomplete recording of test data; time of performing laboratory control activities not recorded
  • Observation 4: Batch records incomplete for labeling control, such as labeling specimens and copies
Insight · Editorial insight

Completeness of test data and contemporaneous recording were cited together, suggesting the assessment took a laboratory data integrity view. Because labeling material control in batch records was also included, check that record completeness holds in both the laboratory and production.

Check points
  • Retention of all raw test data
  • Contemporaneous entry of laboratory records when performed
  • Retention of labeling specimens and copies for each batch
Observation detail · 4 observations · From the source

Inspectors: Mihaly S Ligmond · Steven E Bowen · Chava Kimchi Sarfaty

Observation 1

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, Per Procedure-96247 / 05 “Procedure for Cutting 2”x4” Fibrin Pad”, EVARREST Patch samples (6) (4) testing are cut into . Per Form-02596 / 01, “Logbook for EVARREST Visual Assessment and Cutting” cut from are designated for specific tests; e.g. thrombin activity, clottable protein, calcium, and total protein. There is no written justification for assigning these (b) (4) Wotthe patch to specific tests.

Observation 2

Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.

Observation 3

Established laboratory control mechanisms are not documented at the time ofperformance.

Specifically, Laboratory procedures do not ensure the control and accountability of samples received by the QC laboratory. For example: A. Final drug product samples are logged into the(b) (4) system. Entries are not made in this system when samples are removed.

Observation 4

Batch production and control records do not include complete labeling control records, including specimens or copies of all labeling used for each batch of drug product produced.

Specifically, A specimen of the Instructions for (b) (4) is not routinely included in the EVARREST batch record.

See all 4 findings in this document
[FDA 483 observation · FDA]PCAS Finland Oy — API equipment and workspace maintenance gaps
FDA483

FDA cited three observations at PCAS Finland Oy (API Manufacturer). Unknown results from an in-house analytical method were not investigated, and repair and maintenance of API manufacturing equipment and of the workspace for the bioburden-controlled process were inadequate.

Published 2026-10-26 · Inspection date 06/07/2024 · API Manufacturer · FEI 3003469991

Key facts · Basis: official index plus supporting sources
  • Observations: 3
  • Observation 1: Unknown results from in-house analytical method not investigated
  • Observation 2: API manufacturing equipment not adequately maintained
  • Observation 3: Inadequate repair and maintenance of workspace and equipment for the bioburden-controlled process (two holes observed 05 JUN 2024)
Insight · Editorial insight

Physical damage in a bioburden-controlled area was observed directly during the inspection, linking facility maintenance to API quality. It is worth checking that unknown items in in-house method results feed into an investigation system and that facility damage and repair history are managed.

Check points
  • Investigation procedure for unknown results from in-house methods
  • Inspection and repair of facility damage in bioburden-controlled areas
  • Preventive maintenance of API manufacturing equipment
Observation detail · 3 observations · From the source

Inspectors: Lewis K Antwi · Gene D Arcy

Observation 1

Your firm has not investigated unknown (including one known as indicated by an in-house analytical method.

An "in-house" method is indicated in SOP titled Method Analysis, DOC-00010295, among other tests (e.g., other in-house and API release tests), under product code Results of the in-house method is reported to the sponsor (product owner). The reference indicates unknown as the in-house method indicates more resolved vs. the official API release method for your firm. Many of the unknown have remained consistent across commercial lots but with changes in percentages, which include increases relating to process validation lots and commercial lots, and many of which have acceptable LOD (Limit of Detection) and LOQ (Limit of Quantitation) for the in-house method. However, your firm has not investigated unknown per SOP Vaatimuksesta poikkeavien (00S/00T) laboratoriotulosten keisittely jaraportointi, DOC-00002873 (English: Processing and reporting of non- conforming laboratory results (00S/00T)). In addition, one major known can only be seen using the in-house method. This is expected but has not been investigated as to whether the amount is an acceptable output of the manufacturing process. The following most recent API batches have been released and distributed

Observation 2

Failure to maintain equipment used for the manufacturing of API.

Specifically, your firm has not established procedures for the maintenance of (equipment ID: and (equipment equipment used for the manufacturing of Active Pharmaceutical Ingredient (API). There is no written procedure for inspection, component replacement, calibration or other maintenance frequency/schedule for this equipment.

Observation 3

Your firm has not repaired and maintained manufacturing spaces & equipment in which bioburden- controlled manufacturing processes are conducted for API On 05 JUN 2024, the following conditions were observed: a)Two holes (apparently about the diameter of a U.S.

quarter) were observed in an exhaust vent which is (Equip reported as meeting an standard), and which continues as part of the air system. The (located in room is used to conduct key bioburden-controlled steps in of your firm's manufacturing process (e.g., processes such as b)Regarding the condition of room (in which of manufacturing occur and in which certain steps in the of manufacturing occurs; and reported as meeting an standard).

See all 3 findings in this document
[FDA 483 observation · FDA]Reading Scientific Services Ltd — Inadequate investigation of failing batches
FDA483

FDA cited one observation at Reading Scientific Services Ltd (Control Testing Laboratory): specification failures of a batch or its components were not thoroughly reviewed, whether or not the batch had been distributed.

Published 2026-10-26 · Inspection date 06/16/2025 · Control Testing Laboratory · FEI 3002808041

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Finding: Inadequate thorough review of specification failures of batches or components
Insight · Editorial insight

A stand-alone finding on specification failure investigation at a testing laboratory signals that thorough handling of OOS results is a core axis of laboratory assessment. When outsourcing testing, check whether OOS investigation results and root cause conclusions are shared with the sponsor.

Check points
  • Contract laboratory OOS investigation procedure and how results are shared
  • Review of specification failures identified after release
Observation detail · 1 observation · From the source

Inspectors: Burnell M Henry · Gene D Arcy

Observation 1

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically, TM-578, titled “The Determination of (b) (4) (b) (4) by Inductively Coupled Plasma — Mass Spectroscopy (ICP-MS),” requires that internal quality control and standard performance characteristic tests (b) (4) (b) (4) criteria (b) (4) to performing ICP-MS metal analysis. Failed instrument performance checks have been documented on the “Test Batch Report Sheet for Metals” across client data packages. In response, new standard controls were prepared and failed controls re-analyzed to confirm reliable instrument operation before proceeding with the sample analysis. However, you did not initiate or complete laboratory investigations to determine the root cause of the initial instrument performance failures observed during preliminary testing for the following client batches. A Batch # (B) (4) — On 12/21/2023, there was a (b) (4) ICP-MS instrument (part # ©) (4) failure for (Bb) (4) B.Batch # (6) (4) - On 02/20/2024 there was a (b) (4) (6) (4) TCP-MS instrument (part #)@)) failure for (1b) (4)

[FDA 483 observation · FDA]Kite Pharma, Inc. — Adverse events not reported within 15 days
FDA483

FDA cited one observation at Kite Pharma, Inc. (Finished Product Drug Manufacturer): not all adverse events were reported within 15 days of initial receipt of information.

Published 2026-10-26 · Inspection date 11/01/2024 · Finished Product Drug Manufacturer · FEI 3016888173

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Finding: Adverse events not reported within 15 calendar day of initial receipt
Insight · Editorial insight

A stand-alone finding on adverse event reporting timelines, rather than a manufacturing defect, signals that post-market safety reporting systems are also within inspection scope. It is worth checking that the date of initial receipt of information is recorded and the reporting deadline calculated consistently.

Check points
  • Recording of initial receipt date and deadline calculation for adverse events
  • Monitoring of compliance with the 15-day reporting deadline
Observation detail · 1 observation · From the source

Inspectors: Peng Zhou · Richard L Bartlett · Lizaida Perez

Observation 1

All adverse experiences were not reported within 15 calendar day of initial receipt of the information.

Specifically, From 04 MARCH 2022 through 14 OCTOBER 20724, 11 serious and unexpected adverse experiences were not reported to FDA within 15 calendar days of initial receipt of the information. These adverse experiences were reported to FDA from 17 to 159 calendar days of initial receipt of the information, including the following adverse experiences: Initial Date a ; Date of Date Between Initial Case Number [Received by er : ‘ae ubmission Receipt to Submission Manufacturer |May12,2023 89 [April 26, 2023 [April 26, 2023 pune 8, 2023 uly 5, 2023 b 4 August 18, 2023 October 27, 31 2023 August 7,2024 48 [April 2, 2024

[FDA 483 observation · FDA]Nelson Laboratories, LLC — Eleven observations: HCT/P contamination, controls
FDA483

FDA cited 11 observations at Nelson Laboratories, LLC (Testing Laboratory) related to HCT/P processing. They include unmet in-process control requirements, prevention of contamination and cross-contamination, environmental control, personnel training, lot status identification and laboratory records.

Published 2026-10-26 · Inspection date 07/30/2025 · Testing Laboratory · FEI 3000233845

Key facts · Basis: official index plus supporting sources
  • Observations: 11
  • Process and contamination: In-process control requirements not met; inadequate prevention of contamination and cross-contamination during HCT/P processing; inadequate control of environmental conditions
  • Quality program: No monitoring system established; training of personnel for key GTP activities not ensured
  • Records and identification: Incomplete work history records; quarantine, approval and rejection status of component lots not identified
Insight · Editorial insight

A testing laboratory that also performs HCT/P processing drew 11 observations across GTP requirements, revealing the risk of contractors combining testing services and processing work. When a contractor's scope goes beyond testing, check that the regulations applying to that work are also evaluated.

Check points
  • Applicable regulations for each part of the contractor's scope of work
  • Control of contamination and cross-contamination in HCT/P processing environments
  • System for identifying component lot status
Observation detail · 11 observations · From the source

Inspectors: Emily B Camire · Laurissa S Flowers

Observation 1

Specified requirements for in-process controls were not met.

Specifically, while reviewing amended test results, the following studies were not properly resulted ensuring that in-process controls were met: Bioburden Testing ° (b) (4) had ten human tissue samples submitted for bioburden testing. Sample three (3) showed 4 cfu in the aerobic material, sample four (4) showed 12 cfu and sample one (1) showed 4 cfu growth in the anaerobic media. The client was contacted and confirmed that they wanted the organisms identified. The samples were transferred internally to the organism identification department. The department was unable to recover cells from the samples. As a result, the final bioburden report was amended to reflect that samples one (1) four (4) and three (3) showed no growth for their respective medias. The original report showed a bioburden average of <4.0 for the aerobic media and <8.1 for the anaerobic media. The amended report showed a bioburden average of <4.0 for aerobic media and a lower average of <7.3 for anaerobic media. Sterility Testing ° (b) (4) , human tissue rinsate (wash), had an amended test result from growth to no growth. The following was observed: e The test was initiated on August 14, 2023

Observation 2

Records were not detailed as necessary to provide a complete history of work performed.

Specifically, during the review of SOP NEL-STP-0077 Product Sterility, dated November 7, 2024, we noted that section 19.3.4 states (b) (4) . During the review of(b) (4) data for (b) (4) , It was noted that one unit was marked for secondary review, (b) (4) . The (b) (4) data contained result comments for the secondary review (_ (BD) (4) _ ), however no result comments were documented for the initial preliminary review ( (b) (4) ) or the final review( (b) (4) Na Since 2023, your firm has conducted approximately (B) (4) Sterility Assurance tests on (BD) (4) samples.

Observation 3

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.

Specifically, while observing a testing procedure, the test was not performed in such a way as to prevent potential contamination of the article. The following was observed: 2 © (b) (6). (b) (7XC) a9 5 = ‘i e On 7/16/2025, Lab Technician conducted product sterility testing on 20 bone family i z - os ©)6). &) 7) samples received under (b) (4) . During the process, Technician was observed performing the following: e Dropping bone pieces onto the surface of the Biological Safety Cabinet (BSC) hood during processing. (b) (4) . In accordance with best practices, the technician (b) (4) (b) (4) Bsc (b) (4) , which included 20 samples. (b) (4) BSC (b) (4) e During this observation, your lab technician had to exit the clean room multiple times to (b) (4) . At no point during the processing of 20 tissue samples did the technician’ (D)(4) Since 2023, your firm has conducted approximately (b) (4) Sterility Assurance tests on| (B) (4) samples.

Observation 4

The quality program has not established and maintained appropriate monitoring systems.

Specifically, procedures have not been established or maintained to ensure proper monitoring and control of Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) lot identification

Observation 5

Procedures were not designed to prevent circumstances that increase the risk of communicable disease introduction, transmission and spread through the use of HCT/Ps.

Specifically, your firm receives tissue fromm® tissue manufacturing facilities to include but are not limited to powders, gels, liquids, and whole tissue pieces. Incoming tissue type is not required on the sample submission form that accompanies the tissue to the laboratory. The disposition of tissue received is also not included on the incoming sample submission forms. During the review of SOP NEL-STP- 0077 Product Sterility, dated November 7, 2024, we noted that the procedure lacks tissue-specific instructions for sterility testing performed by the firm. Neither the (b) (4) nor the NEL-STP-0077 Product Sterility procedure describe in detail how to complete sample transfer into the media for the different tissue types. These additional steps, which are inherent to tissue sample handling, are not addressed in any current Standard Operating Procedures or (b) (4)

Observation 6

Environmental conditions existed in which contamination or cross contamination of HCT/Ps or equipment could occur, and environmental conditions were not adequately controlled.

Specifically, during the review of (b) (4) , your firm identified an action level excursion in the (b) (4) floor on May 1, 2023, associated with the recovery of Bacillus cereus. The investigation, which spanned from May to October 2023, documented a progressive contamination event of a spread ofBacillus cereus throughout multiple classified cleanroom areas. Although your firm implemented enhanced cleaning activities and modified disinfection procedures in response to repeated alert and action level excursions, environmental monitoring data continued to yield positive results for Bacillus cereus in critical areas. These included the ISO Class (b) (4) (b) (4) Iso Class (b) (4) . The persistence of contamination suggests the cleaning and disinfection methods employed were ineffective in eradicating the microorganism or preventing its spread.

Observation 7

The quality program has not ensured the proper training and education of personnel involved in core GTP activities.

Specifically, personnel responsible for performing sterility testing and cleaning were observed to lack documented, tissue-specific training related to the proper handling of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). During review of records and observational walk-throughs, deficiencies were noted in employees' ability to carry out routine duties for which they were reportedly trained, including the incomplete cleaning of spills in classified cleanroom areas and improper handling of quarantined media lots. These gaps indicate that the firm has not ensured personnel possess the education, training, and experience necessary to perform their functions in compliance with established procedures and current good tissue

Observation 8

In-process inspections, tests, or other verification activities and approvals were not documented.

Specifically, while reviewing test results the following was observed: Endotoxin Testing e On 05/21/2025, Bacterial Endotoxin Test (BET) (b) (4) had two samples from (©) @) (b) (4) and one sample from (b) (4) that resulted with the %CV values above the acceptability limit (D) (4). Procedure NEL-STP-0046 “Bacterial Endotoxins Test” states, inant A new test was not performed. The data was reviewed and accepted by the study director on 05/27/2025 and the results were sent to the clients on the same day. e (b) (4) __. two devices were combined and tested in a (1D) (4) solution during Bacterial Endotoxin Testing, however, the validation test method specifies the use of one device per (b) (4) . The pooling of two devices in the (b) (4) , violating the established test parameters. Despite this deviation, the results were reported to the client and considered valid.

Observation 9

Each lot of components was not appropriately identified as to its status in terms of being quarantined, approved or rejected.

Specifically, on 7/23/2025, during review ofNEL - FRM-0211 (Steam Sterilizer Log and Cycle Review) the following was observed: e (b) (4) underwent an out-of-specification (OOS) sterilization cycle on (b) (4), which exceeded the validated cycle duration by 33 minutes and 11 seconds. Upon inquiry, va ooo indicated that this lot was in quarantine pending QC review and release. However, the media was found (b) (4) —not in a designated, clearly labeled quarantine area, nor secured in a (b) (4) to prevent premature access or use. The lack of appropriate labeling and physical controls compromised the integrity of the quarantine process.

Observation 10

Laboratory records are deficient in that they do not include a complete record of all data obtained during testing.

Specifically, during the review of(D) (4) data for (b) (4) (human amniotic fluid), it was noted that two units were marked for secondary review, unit (b) (4) . The (D) (4) data contained result comments from the initial reviewer for unit (b) (4) ). No result comments from the initial reviewer were documented for unit (B) (4) as required by the firm’s sterility procedure (SOP NEL-STP-0077 Product Sterility). Since 2023, your firm has conducted approximately (B) (4) Sterility Assurance tests on (BD) (4) samples.

Observation 11

Deviations from written production and process control procedures are not justified.

Specifically, during the review of SOP NEL-STP-0077 Product Sterility, dated November 7, 2024, we

See all 11 findings in this document
[FDA 483 observation · FDA]ABO Holdings, Inc. — Centrifuge performance qualification inadequate
FDA483

FDA stated at ABO Holdings, Inc. (Plasmapheresfa Center), inspected 11/21/2024, that performance qualification (PQ) of centrifuges in use was not performed correctly and that each donation was not tested for evidence of RTTI infection.

Published 2026-10-26 · Inspection date 11/21/2024 · Plasmapheresfa Center · FEI 3027619751

Key facts · Basis: official index plus supporting sources
  • Observation 1: Performance Qualification of Centrifuges in use not performed adequately
  • Observation 2: Each donation not tested for evidence of RTTI infection
Insight · Editorial insight

Citing centrifuge PQ and per-donation RTTI testing together signals that FDA looks at equipment qualification and infection safety of source plasma at once. If you receive plasma-derived material, check the collection facility's equipment qualification and infection testing history within supplier controls.

Check points
  • Adequacy of collection equipment (centrifuge) PQ protocol and results
  • Records of RTTI testing for each donation
  • Whether supplier evaluation of plasma sources covers equipment qualification
Observation detail · 2 observations · From the source

Inspectors: Carmelita F. Bibby

Observation 1

Thefirm did notcorrectly perform the Performance Qualification studies for the’...

| i Centrifuges in use at the establishment. Specifically, when selecting the aie assay values from the manufacturer package insert, the firm selected assay values intended for - instruments usingoo — i The firm shouldhaveselectedtheassay values intended fo i Centrifuges using we | The correct assay values are listed in a different table on the same manufacturer package insert. The acceptable ranges for the reference control material are significantly different forthe, —,,~==-s-/»-—s/ofinstruments. They, a Centrifuges are used in the qualification of donors. Proper execution of Performance Qualification is necessary to demonstrate the instruments perform as intended and to ensure compliance with Source Plasma manufacturing requirements.

Observation 2

The firm is not testing each donation for evidence of infection due to relevant transfusion transmitted infections (RTTI).

Specifically, when a donor tests reactive for an RTTI on one donation, additional donation(s) made after that donation and prior to the time the donor is permanently deferred are not tested for RTTI. Samples from some subsequent donations are not shipped to the firm's contact testing laboratory after a reactive test result is obtained and testing orders are cancelled. Blood establishments that collect blood and blood components for use in further manufacturing must test each donation for evidence of infection due to RTTI. For example: a.Donor# ° ___|tested) -—-- | on donation : | collected| = . The donor's subsequent donation, 4 © collectedon = was not tested for RTTI because the samples from that donationwere not shipped to the testing laboratory, =| b. Donor# * | tested | == si jon donation # = * |, collected) = . The donor's subsequent donation, # : collected on) * | was not tested for RTTI because the samples from that donation were notshipped to the testing laboratory. c.Donor# * tested --- ——ijondonation# — collected * The donor's subsequent) = ldonations,# | collected on! = pand# collected on) * !

[FDA 483 observation · FDA]Biomay AG — Contamination control lapses, no airflow study
FDA483

FDA issued a Form 483 to Biomay AG, a manufacturer in Austria, after an inspection ending 07/27/2023. Two observations were legible: contamination control procedures were not followed, including equipment repair and storage rules for a room, and a classified area was qualified without an in-operation airflow visualization study.

Published 2026-10-26 · Inspection date 07/27/2023 · Manufacturer · FEI 3004536648

Key facts · Basis: official index plus supporting sources
  • Observations legible: 2 (1 contamination control, 2 equipment qualification)
  • Citation: Contamination control procedures not followed; equipment not adequately qualified
  • Detail: No airflow visualization study under in-operation conditions
Insight · Editorial insight

An in-operation airflow visualization study is a basic part of qualifying a classified area, and running the area without one was cited as an equipment qualification gap. Parts of the scanned text are illegible, so the specific area and stored items need to be checked in the original PDF.

Check points
  • Whether in-operation airflow visualization studies exist for classified areas
  • Compliance with equipment repair and room storage rules in production areas
Observation detail · 2 observations · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

Procedures for contamination control are not followed.

Specificall a. Equipment is not in state of good repair. Specifically, visibleYA were observed() 4) the Grade juring manufacturing operations. b. Cleaning ere found stored nderga melthe room According to sop-©) @)06, room must be kept clear at all times and must not be covered at any time.

Observation 2

Equipment is not adequately qualified.

Specifically, an air visualization study under in-operation conditions has not been performed to qualify the Grade 0 adequately demonstrate appropriate air flow is maintained during manufacturing operations.

[FDA 483 observation · FDA]Labcorp Early Development Laboratories, Inc. — Study data not transferred to archives
FDA483

FDA cited one observation at Labcorp Early Development Laboratories, Inc. (GLP), inspected 05/07/2025: the study director did not ensure transfer of raw data, documentation, protocols, specimens and final reports to the archives during or at the close of the study.

Published 2026-10-26 · Inspection date 05/07/2025 · GLP · FEI 2128592

Key facts · Basis: official index plus supporting sources
  • Observation 1: Study director did not ensure transfer of raw data, protocols, specimens and final reports to archives
Insight · Editorial insight

A stand-alone finding on the study director's duty to transfer data signals that completeness of nonclinical record retention bears directly on the reliability of submission data. When outsourcing nonclinical studies, check how transfer of raw data and specimens to archives is confirmed after the study ends.

Check points
  • Records confirming transfer of raw data and specimens to archives at study end
  • Whether outsourced nonclinical study contracts assign data archiving responsibility
Observation detail · 1 observation · From the source

Inspectors: Carmen Y Fisher

Observation 1

The study director failed to assure that all raw data, documentation, protocols, specimens, and final reports were transferred to the archives during or at the close of the study.

Specifically, Per regulation, the study director has the overall responsibility for technical conduct of a GLP study, and the transfer of study documentation to archives at the close of the study. In addition, per SOP "*e** Archive Use and Security*** version: 3.0*** p. 3 of 10***", "***Studies that are claiming compliance to FDA-GLP or EPA-GLP regulations, must transfer all study data into the custody of archives no later than the Study Completion date. ***". Raw data for protocol 8463057 was submitted and archived on 12/19/23 and 1/8/24. The study report for protocol 8463057 was signed by the study director on 1/11/24. The study director failed to ensure the required Quality Control (QC) performance and review of Immunology and Immunotoxicity (I&I) raw data, (b) (4) study closure, and subsequently failed to ensure the submission of this I&I raw data to the (b) (4) . QC has not been performed on this data and it was not archived with additional raw study data as required. The I&I data currently remains unsubmitted to the archival unit.

[FDA 483 observation · FDA]Octapharma Dessau GmbH — Biological deviation reports not submitted
FDA483

FDA cited four observations at Octapharma Dessau GmbH (Packaging and Labeling), inspected 11/08/2024, including failure to submit biological deviation reports, investigation records without conclusions and follow-up, insufficient documentation of key steps in batch records, and a quality control unit lacking authority to approve procedures and specifications.

Published 2026-10-26 · Inspection date 11/08/2024 · Packaging and Labeling · FEI 3008923644

Key facts · Basis: official index plus supporting sources
  • Observation 1: Failure to submit biological deviation reports (related SOP 0170-SOP-00084 "Assessment and process for issuing BPDRs")
  • Observation 2: Investigation records of unexplained discrepancies lacked conclusions and follow-up
  • Observation 4: Quality control unit lacked authority to approve or reject procedures and specifications
Insight · Editorial insight

Failure to submit BPDRs, cited as the first observation at a packaging and labeling site, signals that the procedure for deciding whether quality complaints and deviations are reportable to the authority is itself inspected. It is worth checking that the complaint handling procedure and the deviation reporting decision procedure are linked.

Check points
  • Criteria for deciding whether complaints and deviations require a BPDR
  • Whether discrepancy investigation records state conclusions and follow-up
  • Confirmation that key steps are performed in batch packaging records
Observation detail · 4 observations · From the source

Inspectors: Lewis K Antwi · Travis S Bradley

Observation 1

Failure to submit biological deviation reports.

Specifically, your current standard operating procedures 0170-SOP-00084 (ver. 2.0) titled “Assessment and process for issuing BPDRs,” 0170-SOP-00068 (ver. 2.0) titled “Handling of Product Quality Complaints,” and SOP6006/13 (ver. 13) titled “Deviation Control” are not aligned to support Biological Product Deviation Reporting (BPDR) requirements. On O7NOV2024, your Qualified Person (QP) stated that your current process for managing potential BPDRs relating to complaints follows complaint procedure 0170-SOP-00068 and (b) (4) contacting the (b) (4) (b) (4) , who is responsible for classifying the event as reportable or non-reportable. This practice does not follow current BPDR and Deviation procedures 0170-SOP-00084 and SOP6006/13 which identify that your (b) (4) has responsibility for classifying potential reportable events related to complaints and deviations. From 2021 to the present, the following events were observed: ° On O08NOV2023, you received complaint #R/US/2023/017 pertaining to a missing vial label from one package of (b) (4) from the U.S. Market. This complaint was investigated and assessed by your (b) (4) and not identified as a reportable event (Db) (4) to assure compl

Observation 2

Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.

Specifically, the following was observed: * CAPA #204728 was initiated on 14MAY2024 in response to deviation #201944 pertaining to rework of batch (b) (4) to (b) (4) (b) (4) involving the identification of two product vials with missing labels from ) @) total packages during repackaging on 283MAR2024 (identified as major deviation). As a corrective action, procedure 0170-SOP-00004 (ver. 1.0) titled “Tasks of © packaging during manufacturing” was implemented (17SEP2024) (b) (4) . No effectiveness check was assigned within the CAPA to verify effectiveness of the corrective action and to prevent future reoccurrence of the deviation. No justification was documented as required per procedure SOP6006/13 (ver. 13) titled “Deviation Control.” ° CAPAs #157434 and 157435 were initiated on 12DEC2021 in response to deviation 156341 (critical deviation) pertaining to the wrong (Db) (4) content printed on a label and folding carton of (b) (4) for the U.S. market (units distributed to U.S. customers and returned/destroyed). This deviation was reported to the agency as a BPDR on 24NOV2021 (b) (4) . As corrective actions, CAPA #157434 implemented the

Observation 3

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and packing.

Specifically, your current process for handling in-process, rejected unlabeled vials from the (b) (4) (©) (4) for all licensed biological products ( (b) (4) ) you package for distribution to the U.S. market, is to (b) (4) procedure 0170-SOP-00004 (ver. 3.0) titled “Tasks of ® packaging during manufacturing”). This process was implemented as a corrective action (CAPA 204728) in response to deviation #201944 pertaining to rework of (b) (4) (b) (4) when two vials from (9) (4) packages were found with missing labels identified

Observation 4

The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the quality of drug products.

Specifically, you failed to include the (b) (4) (b) (4) for your. (b) (4) __ visual inspection (B) (4) during the initial qualification or re-qualification of your (1B) (4) _ visual inspection (b) (4) Your Quality Control unit approved parameters in your procedure ( (b) (4) ) for various (Bb) (4) were not included in the initial qualification or re-qualification of the ©) visual inspection (Bb) (4) . Your (b) (6), (b) (7)(C) confirmed that the (1) (4) of your’ (6) (4) visual inspection (B) (4) are critical parameters that helps in detecting defective© and that the (b) (4) should have been included in the initial qualification and re-qualification. (b) (4) visual inspection (1) (4) have been in use for over 7“ years and have been utilized to perform visual inspections of licensed biological drug products shipped to the U.S market.

See all 4 findings in this document
[FDA 483 observation · FDA]Premier Laboratory, LLC — Deviation, OOS and CAPA management inadequate
FDA483

FDA cited five observations at Premier Laboratory, LLC (Contract testing facility), inspected 05/14/2025: inadequate management of deviations, OOS and CAPAs, weak quality oversight, lack of ongoing CGMP training, inadequate control of suppliers and service providers, and inadequate equipment qualification and monitoring.

Published 2026-10-26 · Inspection date 05/14/2025 · Contract testing facility · FEI 3006369552

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate management of deviations, OOS and CAPAs
  • Observation 5: Equipment not adequately qualified for intended use or monitored
Insight · Editorial insight

OOS and CAPA management and equipment qualification were cited together, signaling that the reliability of results a sponsor receives depends on the contract laboratory's own quality system. When outsourcing testing, check the laboratory's OOS handling and equipment qualification status in supplier evaluation.

Check points
  • Contract laboratory OOS investigation and notification procedure
  • Status of equipment qualification at the contract laboratory
  • CGMP training cycle at the contract laboratory
Observation detail · 5 observations · From the source
Observation 1

Management of deviations, out-of-specifications (OOS), and corrective and preventive actions (CAPAs) is inadequate.

For example: a. In Section 12.7 of(6) (4)-0013.11, client is to be notified as soon as possible of any issues with staining events through email or fax. However, DEV-24-006 indicates that the deviation was notified to client© 14 days after discovery. This deviation was related to use of an incorrect antibody concentration that : affected 27 of client© @”s studies initiated from January 17, 2024 to May 23, 2024. Client classified | the deviation as (b) (4). b. Written procedures are not established to monitor or trend OOS to re-initiate a CAPA. For example, QA-0018.5.01, CAPA Effectiveness and Deviation Trend Review performed on August 27, 2024, indicates | corrective action performed by CAPA-23-002 to address OOS-23-001 for non-specific staining during (b) (4) staining did not resolve the issue as the same root cause was identified in OOS-23-005, and the CAPA effectiveness proposed to monitor the issue for further action. c. The entries in logbooks are not in chronological order and predate the issuance of the logbooks. For example: i. QA-0018.4.01, Corrective and Preventative Action Log, Volume 2 was issued on October 25, 2023. The second CAPA entry in the logbook was for CAPA-23-

Observation 2

Quality oversight is inadequate to assure (b) (4) has the identity and purity it purports or is | represented to possess.

For example: a. Written procedures for QA’s final review of documentation associated with batches for histology sample preparation, staining, and scanning for the identity and purity tests for (b) (4) are not established. : b. Quality does not have control of work instructions (WIs). For example, i. No document control is performed on WIs. There are five work instructions (WI(b) (4)-0017.00, WI- | (b) (4)-0019.00, WI-(5) (4)-0021.00, WI-(®) (4)-0025.01, and WI-(©) (4)-0026.01) that are associated with client °s study, but none ofthe work instructions have been reviewed or approved by QA. ii. No documentation for revision history is performed for revised WIs. For example, procedure #16 of WI-() (4)-0026.01 was inserted with yellow highlights without a revision history to include timing of | preparation and equilibrium time for reagents based on| (b)(4) , which was related to non-specific | binding of(b) (4) antibody. iii. On May 13, 2025, the Laboratory Manager stated that an operator can change WI-(6) (4)-0026.01 without any quality oversight. Additionally, the operator overwrote the previous version of WI- (b) (4)-0026.01. iv. WI-(6) (4)-0026.01 is not referenced by the correspond

Observation 3

Good manufacturing practice training is not conducted on a continuing basis to assure employees remain familiar with Current Good Manufacturing Practice (CGMP) requirements applicable to them.

For example: a. As ofMay 12, 2025, “GLP, GMP, QSR Training” has not been completed according to™®-0010.1.01 Employee Training Plan, established for the Laboratory Aide/Archivist who was hired in (b) (6), (b) (7)(C) |

Observation 4

Management of suppliers and service providers is deficient.

For example: a. Suppliers of critical materials (e.g., laminin antibody for the identity release test for _ (b) (4) : (b) (4) have not been qualified, and the critical materials continue to be used for identity and purity release tests for (b) (4) Planned deviation PD-24-004 was opened on February 19, 2024, | to track and ensure supplier approvals occur over time. PD-24-004 hada target closure date ofJanuary 3, | 2025, which is an 11-month duration. However, PD-24-004 remained open as ofMay 14, 2025, which has an approximately 15-month opening period from initiation, and no extensions were documented. b. The (b) (4) spreadsheet provided on May 11, 2025, for current suppliers associated with identity and purity testing of (b) (4) did not include the service provider for the preventive maintenance ofthe (b) (4) that are used for (b) (4) sample thaw and (b) (4)... c.@@-0001.01, Purchase Controls and Management specifies that suppliers will be reassessed every®@) | (b) (4) However, the frequency or extent of control and reassessment is not based on criticality, or the products or services provided.

Observation 5

Equipment is not qualified or monitored for its intended use.

Specifically, refrigerators/freezers system numbers ‘(b) (4) and (6) (4) and ultra-low (UTL) freezer system number (6) (4) were not qualified and are not continuously monitored. Critical reagents used for the identity and purity release tests for (b) (4) (b) (4) are stored in refrigerators/freezers system numbers |(b) (4) and (b) (4) : samples and antibody aliquots for the identity and purity release tests for (b) (4) are stored in | UTL freezer system number (b) (4).

See all 5 findings in this document
[FDA 483 observation · FDA]Protherics UK Ltd. — Weak QC test methods and calibration checks
FDA483

FDA issued a Form 483 to Protherics UK Ltd., a manufacturer in the UK, after an inspection ending 06/23/2022. One observation (deficient QC testing procedures) was legible. It covers a lack of study support for endotoxin analysis, cultures not qualified before use, and no check that instruments were still calibrated at the end of an analysis. A calibration failure led to CroFab and DigiFab release test results being invalidated and retested.

Published 2026-10-26 · Inspection date 06/23/2022 · Manufacturer · FEI 3001417487

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Citation: QC testing procedures are deficient
  • Detail: No calibration check at the end of analyses; release tests invalidated and retested after a calibration failure (Quality Event 55795)
Insight · Editorial insight

Without a calibration check at the end of an analytical sequence, a later calibration failure forces all results in between to be invalidated, and this case shows that happening. Much of the scanned text is illegible, so the details need to be checked in the original PDF.

Check points
  • Whether analytical sequences end with a system suitability or calibration check
  • Procedures for qualifying test cultures and media before use
Observation detail · 1 observation · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

QC testing procedures are deficient.

Specifically, A. There is a lack ofstudy to support the uy sisample, for endotoxin analysis per ra 13.160, v7, section 6.12.3. ee are not being compared to previously tested and approved batch ofthe same media type. Instead, they are being compared tol = jobtainedi ae -13.015, v15, section 6.7.1. C. There is a lack 0 we lander_w__ |conditions despitewm qualification requires the assessment ofHg Recovery PET) ww -13.002, v7, section 2. Dou prepared ws ultures are not qualified prior to release for use| cultures are E. Drug samples are nomT Te analytical sequences to verify _.,, control. A|- isanalyzed| sample and does not confirm that the ‘an instrument is in a Calibrated state upon the completion of the analysis. Asa result, drug product results were invalidated and retested, due to ar_palibration test failure. For example, i). Quality Event 55795 - Thewe | calibration for the Quality Control ints was conducted perSOP| ....——_—_— entitled,‘ * ai ” on June 29, 2020, and failed the! ccuracy test during the calibration. Consequently, all CroFab and DigiFab es drug product release tests that were performed. | wa were invalidated and retested. All sample retests had passing results.

[FDA 483 observation · FDA]Replimune, lnc — Late deviation closure, weak quality agreements
FDA483

FDA issued a Form 483 to Replimune, lnc, a US manufacturer, after an inspection ending 04/24/2025. Two observations were legible: 25% of 660 deviations were not closed within the SOP deadline, and quality agreements with a contracted storage site and a testing laboratory did not accurately specify the services provided.

Published 2026-10-26 · Inspection date 04/24/2025 · Manufacturer · FEI 3022984544

Key facts · Basis: official index plus supporting sources
  • Observations: 2 (1 deviation closure timelines, 2 quality agreements)
  • Citation: Investigations not closed in time; deficient quality agreements
  • Detail: 25% of 660 deviations not closed on time, including some critical ones
Insight · Editorial insight

A quarter of deviations, some of them critical, ran past the firm's own SOP deadline, which was cited as a failure in managing investigations. The case also shows inspectors checking whether quality agreements with storage and testing contractors cover the services actually provided.

Check points
  • On-time closure rate for deviation investigations and tracking of overdue reasons
  • Whether quality agreements with storage and testing contractors define the full scope of services
Observation detail · 2 observations · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

Investigations are not closed in a timely manner as required by the SOP “1161-0007: Deviation Management” that states (b) (4) are to be completed within" (b) (4) __ from the observed date.

25% of 660 deviations, including some critical deviations, were not closed within (b) (4)

Observation 2

Quality agreements are deficient in that they do not accurately specify the services provided by the supplier.

Specifically, a. The quality agreement for a contracted storage site does not include provisions for (b) (4) b. The quality agreement for a contracted testing laboratory does not specify the (b) (4)

[FDA 483 observation · FDA]Bio-Rad Medical Diagnostics GmbH — Inadequate risk analysis
FDA483

FDA cited five observations at Bio-Rad Medical Diagnostics GmbH (Manufacturer), inspected 06/14/2024: inadequate risk analysis, inadequate validation of a process that cannot be fully verified by subsequent inspection, inadequate control of nonconforming product, no CAPA procedure established, and document control procedures not maintained.

Published 2026-10-26 · Inspection date 06/14/2024 · Manufacturer · FEI 3002806595

Key facts · Basis: official index plus supporting sources
  • Observation 1: Risk analysis is inadequate
  • Observation 2: Inadequate validation of a process whose results cannot be fully verified by subsequent inspection or testing
  • Observation 3: Inadequate control of product not meeting specifications
Insight · Editorial insight

Citing weak validation of unverifiable processes together with inadequate risk analysis suggests risk assessment results may not have fed into deciding validation scope. It is worth checking that the risk analysis documents are linked to the list of processes subject to validation.

Check points
  • Whether risk analysis results are reflected in selecting processes for validation
  • Identification, segregation and disposition records for nonconforming product
  • Revision and distribution history of document control procedures
Observation detail · 5 observations · From the source

Inspectors: Cody D Rickman · Kaarin M Slotte · Kimberly M Bigler · Meihong Liu

Observation 1

Risk analysis is inadequate.

Specifically, According to your document ®) @)-0061/00, titled Risikoanalyse fiir Herstellung der IH, page 74,°® On 06/10/2024, during a tour of the facility, sublots ofIH Gel card (B) (4) were discovered in (Bb) (4) (b) (4) These gel (Bb) (4) are Your firm has failed to performa risk analysis regarding these gel (b) (4) (6) (4) contained within the (b) (4)

Observation 2

A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.

Observation 3

Products that do not conform to specifications are not adequately controlled.

Specifically, On 01/03/2022, your firm discovered AHG Anti-IgG gel cards, lot number (b) (4) distributed to the United States was out of specification with a negative specificity (false positive test results) of 20% equivalency (= 10 out of 50 samples). Your established specification for product release is less than or equal to ™) equivalency. On 01/03/2022, your firm discovered AHG Anti-IgG gel cards, lot number (D) (4) distributed to the United States was out of specification with a negative specificity (false positive test results) of 20% equivalency (= 10 out of 50 samples). Your established specification for product release is less than or equal to equivalency.

Observation 4

Procedures for corrective and preventive action have not been adequately established.

Specifically, your firm’s standard operating procedure for Global Procedure Corrective and Preventive Action (CAPA), fails to address initiating a CAPA investigation regarding trending significant consumer complaints. The following consumer complaints were not initiated as a CAPA investigation: A.Approximately 24 consumer complaints for ABO/D (DVI-) +Rev A1,B gel cards involving approximately 7 different lots with false positives test results. B.Approximately 12 consumer complaints for AHG Anti-IgG + Anti-C3d lot 8749190-03, including false negative testing results. C.Approximately 2 consumer complaints for AHG Anti-IgG 48 IH card lot (b) (4) , including questionable or equivocal results and weak false positive results. D.Approximately 3 consumer complaints for AHG Anti-IgG 48 IH card lot 8923050, including false negative test results and dried cards. E.Approximately 2 consumer complaints for IH-Card AHG Anti-IgG lot (b) (4) , including false positive test results.

Observation 5

Document control procedures have not been adequately maintained.

See all 5 findings in this document
[FDA 483 observation · FDA]Noble Life Sciences, Inc — Staff understanding of duties not ensured
FDA483

FDA stated at Noble Life Sciences, Inc (Nonclinical Laboratory), inspected 06/20/2025, that the testing facility management did not ensure personnel understood their duties, animal cages, racks and accessory equipment were not cleaned and sanitized at appropriate intervals, and the QAU did not verify unauthorized deviations from protocols and SOPs.

Published 2026-10-26 · Inspection date 06/20/2025 · Nonclinical Laboratory · FEI 3004760616

Key facts · Basis: official index plus supporting sources
  • Observation 2: Animal cages, racks and accessory equipment not cleaned and sanitized at appropriate intervals
  • Observation 3: QAU did not verify unauthorized deviations from approved protocols and SOPs
Insight · Editorial insight

Citing animal housing hygiene and the QAU's failure to verify deviations together signals that the condition of the test system is tied to judging the validity of study data. When outsourcing nonclinical studies, check how the QAU verifies and documents deviations from the protocol.

Check points
  • Records of cleaning and sanitizing intervals for animal cages and racks
  • QAU records of checks for deviations from protocols and SOPs
  • Records of job-duty training for study personnel
Observation detail · 3 observations · From the source

Inspectors: Hugh M Mcclure · Christine M Smith · Amanda M Szucsik

Observation 1

Testing facility management failed to assure that all personnel clearly understood the functions they were to perform.

Specifically, Facility personnel have not adequately maintained the testing facility as evidenced by: A. Significant accumulations ofpotential pest harborage including cage racks designated for _ (DB) (4) (b) (4) as well as leaves and plant overgrowth were observed (b) (4) dines © and?” Buildings and B. In Building” Large Animal Holding area (®)@), Bam), holes have been chewed in the (b) (4) with evidence of animal nesting material in the chewed holes. C. In Building” Room ™™the (b) (4) contained significant accumulations of dirt and hair. D. In Building on the clean side of the cage wash area, clean/sanitized cage racks were observed being stored with significant accumulations of dirt and hair under them. “44° 4) ee E. In Building Lab (b) (4) a (b) (4) of the building was observed with a (b) (4) of the () (4)

Observation 2

Not all animal cages, racks and accessory equipment were cleaned and sanitized at appropriate intervals.

Specifically, A. In Building ™on the clean side of the cage washer, at least ® clean/sanitized rodent feeders were observed with significant accumulations of encrusted feed residue inside of the feeders. B. In Room © Radiographic Development Room, clean rodent cage boxes were observed being stored in (b) (4)

Observation 3

The quality assurance unit failed to determine whether any deviations from approved protocols or standard operating procedures had been made without proper authorization and documentation.

Specifically, A. Sop )(4)-008/2. (b) (4) , Section 6.6.8 states that (b) (4) may be (b) (4) only at the time of dispensing. On 6/10/2025, (b) (4) _ labeled as (b) (4) with no expiration date or date of preparation were found in the (b) (4) in the necropsy room (6) (4). B. In Building™Room ®® (immunocompromised Animal Room), rodent feed Lot # (b) (4)

See all 3 findings in this document
[FDA 483 observation · FDA]SciVac LTD — Sterile contamination procedures lacking
FDA483

FDA cited one observation at SciVac LTD (Sterile Drug Manufacturer), inspected 03/27/2023: procedures to prevent microbiological contamination of drugs purporting to be sterile were not established, documented or followed.

Published 2026-10-26 · Inspection date 03/27/2023 · Sterile Drug Manufacturer · FEI 3012695367

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures to prevent microbiological contamination of drugs purporting to be sterile not established, documented or followed
Insight · Editorial insight

Establishment, documentation and compliance were all questioned in a single observation, signaling shortfalls at every stage from existence of the procedure to its execution on the floor. It is worth checking step by step that aseptic process procedures cover the actual work completely and are followed as written.

Check points
  • Coverage of actual work by aseptic process contamination prevention procedures
  • Match between on-the-floor aseptic practice and the written procedure
Observation detail · 1 observation · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, . .. . ow. . A. You do not routinely employ the use of sporicidal agent(s) in your Grade__ filling environments to include the inside and outside of your (D) (4) Grade You have 48 documented recoveries of various spore forming microbes to include molds and bacillus species over the previous approximate two years. These spore forming recoveries are documented in your open(b) (4) . ; (b) (4) .. filling enclosure, surrounding Grade areas as well as throughout your facility. i. You documented Deviation(®) (4) regarding the recovery of (b) (4) (b) (4) on(b) (4) sampled (6) (4) of filling operations inside the (b) (4) door during batch (b) (4) Your CAPA does not address operator error while the investigation includes operator error as a root cause. Sporicide use was not employed on the outside of the (b) (4)doors before filling operations were started for batch (D) (4) dated (b) (4) B. Your environmental and personnel monitoring plan to include sampling locations and times lack : : : (b) (4) . : scientific support in your Grade formulation and filling areas as follows

See all 4 findings in this document
[FDA 483 observation · FDA]Seqirus Inc — Quality unit duties and procedures undocumented
FDA483

FDA stated at Seqirus Inc (Manufacturing), inspected 06/05/2025, that quality control unit responsibilities and procedures were not documented, the deviation procedure did not ensure timely documentation and impact assessment of quality events, and written production and process control procedures were not adequately established.

Published 2026-10-26 · Inspection date 06/05/2025 · Manufacturing · FEI 3007867647

Key facts · Basis: official index plus supporting sources
  • Observation 1: Quality control unit responsibilities and procedures not documented (deviation procedure does not ensure timely documentation and impact assessment of quality events)
  • Observation 2: Inadequate establishment of written production and process control procedures
Insight · Editorial insight

The deviation procedure's failure to record and assess quality events in time was used as evidence that quality unit duties were undocumented, signaling that delays in deviation handling are read as a structural quality system problem. It is worth checking that procedures set time limits from occurrence of a deviation to registration and impact assessment.

Check points
  • Time limits for deviation registration and impact assessment
  • Documentation of the scope of quality control unit responsibilities
  • Whether production and process control procedures cover assurance of quality attributes
Observation detail · 2 observations · From the source
Observation 1

The responsibilities and procedures applicable to the quality control unit are not in writing.

Specifically, your firm’s procedure for deviation management does not ensure timely documentation and assessment of quality events to determine potential impact on product quality. The current procedure does not require quality events to be recorded in the quality system at the time of the occurrence or upon initial discovery. Instead, a quality event record is (b) (4) the Quality Unit (b) (4) . Additionally, the procedure lacks defined timeframe requirements for the Quality Unit to evaluate and determine whether a quality event should be classified as a deviation once it is reported. For example: e A quality event occurred on August 20, 2020, but the associated deviation QE-081374 was not initiated until March 27, 2025, more than four years later. e <A quality event occurred on January 12, 2022, but the associated deviation QE-077007 was not initiated until February 21, 2025, more than three years later. e A quality event occurred on June 6, 2024, but the associated deviation QE-084962 was not initiated until April 25, 2025, more than eight months later. e A quality event occurred on September 22, 2022, but the associated deviation QE-073262 was not initiated until November 6, 202

Observation 2

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically, your firm utilizes the ()@) electronic system to (b) (4) . While current practice permits production personnel to request materials (b) (4) for drug manufacturing during (b) (4) outages, your firm has not established written procedures governing how these requests are (b) (4) during unplanned system outages.

[FDA 483 observation · FDA]Biotest AG — Inadequate quality oversight of Yimmugo
FDA483

FDA cited multiple observations at Biotest AG (Drug Substance and Drug product Manufacturer), inspected 12/15/2023, including inadequate quality oversight of Yimmugo, deviation management, labeling material control, facilities to prevent contamination and mix-ups, scope of process validation, and the manual visual inspection program.

Published 2026-10-26 · Inspection date 12/15/2023 · Drug Substance and Drug product Manufacturer · FEI 3001034985

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate quality oversight to assure identity, strength, quality and purity of Yimmugo drug product
  • Observation 7: Process validation did not cover the proposed range of critical process parameters
  • Observation 9: Manual visual inspection program inadequate to identify foreign matter and physical defects
Insight · Editorial insight

The finding that process validation did not cover the proposed range of critical process parameters signals that a gap between the applied operating range and the validated range is found at inspection. Because visual inspection and labeling material control were also cited, check final product stage controls as well.

Check points
  • Whether validation covers the operating range of critical process parameters
  • Evaluation of detection capability of the manual visual inspection program
  • Records reconciling issuance, use and remaining labeling materials
Observation detail · 9 observations · From the source
Observation 1

Inadequate quality oversight to assure that the Yimmugo drug product has the identity, strength, quality, and purity it purports or is represented to possess.

For example: a. There is no quality oversight of unplanned maintenance events to assess the qualification/validation status and product impact. Specifically: i. SOP-T-00386 v. 5.0 “Maintenance of technical systems” does not require the quality unit’s approval for any unplanned maintenance or repairs to the facility. ii. Work order 5031880, which was opened to repair a door to formulation room ©)@) where the open final formulation operation for Yimmugo is performed, was not approved by the quality unit. A product impact assessment was not performed to assess the room’s environment status while the door was not properly closed. b. Written procedures for production and process control are inadequate. For example: i. SOP-Q-00431 v. 5.0 “Review and release of plasma deliveries” does not contain the process on how to inspect plasma (b) (4) ii. (B) (4) -00488 v. 4.0 “Aseptic final (6)(4) ofIgG Next Generation (BT595) and (b) (4) (b) (4) on the) (b) (4) line,” which is used for (6) (4) does not require the removal of documents including batch records. Line clearance was not performed in capping and crimping room 4 where batch records for (b) (4) were found during the manufacture ofYimmugo

Observation 2

Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and does not adequately identify, document, or investigate the impact to drug product.

For example: a. Failure to thoroughly investigate deviations. For example: i. Deviation 200183029 occurred on April 20, 2023, when a) (6) (4) was incorrectly installed after (6)(4) Yimmugo lot (6) (4). An associated corrective and preventive action (CAPA) 200184757 was implemented to revise SOP-P-00135 “Description and operation of the (b) (4) line (6) (4) and the batch record to include the) (6) (4) assembly on (6) @) line (©) 4). Due to this CAPA, change contro] (6)(@)-2023-0494 was implemented to include a (b) (4) batch record. However, an investigation was not conducted to assess if any previous lots were affected by the incorrectly installed (6) (4) as the procedure did not describe how to correctly assemble the (6) (4) operators were not properly trained, and there was no (b) (4) for this step. ii. Deviation 200162802 initially occurred on August 30, 2021, when! (6) (4) were observed during the evaluation of the W(BY(4™) of the WH(BY(4)) ofbatch (6) (4) , and a laboratory technician performing the test noticed unusual strong \(b) (4) during mixing. However, an investigation into the root cause for the unusual (6) (4)) of the (6) (4) was not performed, and a product quality im

Observation 3

Strict control is not exercised over labeling materials issued for use in the Yimmugo drug product labeling operations.

For example, the labeling materials used to label Yimmugo 10%, 100 mL, iot (b) (4) on December 7, 2023, were (1b) (4) on November 27, 2023, in room (b) (4) which can be accessed by over ®@ individuals including external contractors. 4, Procedures designed to monitor microbiological contamination are not established. For example, bioburden samples are not collected from (b) (4) such as the Yimmugo pH treated _(b) (4) — and (b) (4) after (b) (4).

Observation 5

Manufacturing buildings used in the manufacture ofYimmugo do not have the suitable controls to prevent contamination.

For example: a. There is no disinfectant efficacy study to support the use of (b) (4) surfaces. Specifically, (Bb) (4) did not provide a (b) (4) a facility (b) (4)

Observation 6

Manufacturing building™®, where the Yimmugo drug product is manufactured, does not contain sufficient space to prevent mix-ups and to secure the product.

For example: a. Yimmugo drug product (B)(4) are (0) ll (4) in an4) (4) where other drug products are concurrently (b) (4) b. The Yimmugo drug product (by G4) are labeled with the lot number (©)(4) | crimp. This lot number can be removed from the crimp usinga(BD) (4) ENN that is near the(BY

Observation 7

Process validation is deficient as it does not cover the proposed range for process parameters that are critical.

For example, the U(B)(4)INl range for [(B)(A)N| which is used for the (UECD) has not been validated. Batch record (6) (4) -00490 “Final (6) (4) pools [gG Next Generation (BT595) and(0) (4) hE without support of the [TT (OY) HNN specifies 4 {IY GH range of ~() (4) however, on December 5, 2023, you stated that the (by (4) is— (b)(4).

Observation 8

Process controls are not established from validated manufacturing processes.

Specifically, as a result of Deviation 200161821, the {(6)\(4)) alarm during nanofiltration was modified to prevent an alarm from a 4 The modified alarm permits the routine performance ofthe critical nanofiltration step to occur atee (°)0 C) which is (6)(4) the validated |(b)(4)) range for nanofiltration.

Observation 9

The manual visual inspection program is inadequate to identify))(b) (4) matter and physical defects.

For example: a. Written procedures to fully inspect the crimping cap for defects are not established in SOP™®-00405 v. 12.0 “Implementation and test criteria for the visual inspection.” b. Employees engaged in the visual inspection of a drug product lack the training required to perform their assigned functions. Specifically, employees are not trained to fully inspect the product and crimping cap and, in the technique, to avoid | (b) (4) that can interfere with the detection of (b)(4) . ENPLOYEE(S)

Observation 10

The (6)(4) sampling process for routinely monitoring the (b) (4) is deficient.

Chemical sampling for total organic carbon, conductivity, and nitrogen is (b) (4) bioburden sampling. _ ra a Pd ““ , “ 2 a eb 4 ! a< \ : ] EMP OVEE(S)

See all 9 findings in this document
[FDA 483 observation · FDA]Octapharma Produktionsgesellschaft Deutschland mbH. — Batch release protocol not established
FDA483

FDA stated at Octapharma Produktionsgesellschaft Deutschland mbH. (Drug Substance Manufacturer), inspected 03/21/2023, that a batch release protocol including key product testing was not established, and also listed inadequate deviation and CAPA procedures, manufacturing area environmental monitoring and cleaning validation program.

Published 2026-10-26 · Inspection date 03/21/2023 · Drug Substance Manufacturer · FEI 3016855360

Key facts · Basis: official index plus supporting sources
  • Excerpted observation: Yield, identity and bioburden tests not performed to confirm quality of released batches
  • Observation 3: Inadequate system for monitoring environmental conditions in manufacturing areas
  • Observation 5: Cleaning validation program inadequate
Insight · Editorial insight

The absence of yield, identity and bioburden tests in the release protocol signals that the testing basis for drug substance release decisions was itself questioned. With cleaning validation and environmental monitoring also cited, check whether release testing items reflect the contamination risk of the process.

Check points
  • Whether the drug substance release protocol includes yield, identity and bioburden tests
  • Environmental monitoring system for manufacturing areas
  • Scope of the cleaning validation program
Observation detail · 3 observations · From the source
Observation 2

Procedures for deviations and corrective and preventive actions are not adequately established or implemented.

Specifically, A. Deviations are not closed in a timely manner. For example, Procedure A SOP 054 018, effective 20FEB2023, - «55 : a a) “Deviation, CAPA, and Task Handling” requires that deviations be closed within days. In the year 2022, approximately 50% of deviations were not closed within this timeframe, with seventeen percent open up to®™™@ days, eleven percent open up to © @days, and twenty three percent open over (/@Hays. B. The late closure or extension of deviations from written production and process control procedures are not always adequately justified. The same reason, i.e., late completion of the deviations has no negative impact on product quality, was repeatedly used for extension ofthe deviations including but not limited to: a. Deviation 169048 (10) (4), Overrun of temperature during ® @yeasurement (6) date opened 06JUL2022. b. Deviation 167652| (b) (4) Exceeding the (b) (4) ‘temperature , date opened 09JUN2022. c. Deviation 169447 (1) (4) Use of wrong batch protocols for the (b) (4) date opened 13JUL2022. d. Deviation 163933 (1) (4) Total duration (1B) (4) exceeded, date opened 06APR2022. e. Deviation 164077| (1) (4) Falling below the (1) (4) of the! (10) (4) (b)

Observation 3

Manufacturing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, A. The environmental monitoring frequency of Grade ®nanufacturing areas where open processing is performed is not adequately justified. For example, in Grade®™@reas | (0) (4) air particulates are monitored (6) (4) (6) (4) and viable air, surfaces and floors are monitored (b) (4) B. Maximum number of people allowed in Grade manufacturing areas is not determined.

Observation 5

Cleaning validation program is inadequate.

Specifically, Manual cleaning for small parts used in (1B) (4)ind (b) (4) (b) (4) does not include operator training qualification testing to ensure the cleaning is performed consistently and successfully by each operator. In addition, there is no routine monitoring of the manual cleaning performed by operations personnel to verify that cleaning acceptance criteria are continued to be met over time. a [

See all 3 findings in this document
[FDA 483 observation · FDA]ROSLIN CELL THERAPIES LIMITED — Inadequate aseptic operator gowning
FDA483

FDA stated at ROSLIN CELL THERAPIES LIMITED (Manufacturer), inspected 01/21/2025, that procedures to prevent microbiological contamination of drugs purporting to be sterile were not followed, citing inadequate aseptic operator gowning during production. Non-compliance with quality control unit responsibilities and procedures was also included.

Published 2026-10-26 · Inspection date 01/21/2025 · Manufacturer · FEI 3013416813

Key facts · Basis: official index plus supporting sources
  • Observation 1: Procedures to prevent microbiological contamination of drugs purporting to be sterile not followed (aseptic operator gown inadequate during production)
  • Observation 3: Quality control unit responsibilities and procedures partly not followed
Insight · Editorial insight

Gowning practice on the floor was presented as evidence of non-compliance with contamination prevention procedures, signaling that operator behavior is directly observed in aseptic production. It is worth checking that gowning qualification and in-process verification records reflect actual gowning.

Check points
  • History of aseptic operator gowning qualification
  • Records of in-process checks of gowning status
  • Execution of quality control unit responsibility procedures
Observation detail · 3 observations · From the source
Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, Inadequate aseptic operator gown was observed during the production of the following (b)(4) A total of} ... operators were observed on oa in the Grade. |manufacturing area wearing goggles thathad| Ss. ~— ~=———«s: exposing the operators’ skin. The goggles are part of the sterile gown worn by the operators in theGadd. operators include the Operator whose main duties are to perform process steps on the drug product in the Grade exe Biosafety Cabinet ,,, and the Assistant Operator who provides assistance to the Grade perator in the .. .

Observation 2

Appropriate controls are not exercised over.

or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel. Specifically,

Observation 3

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, A. Deviations are not always closed within the target dates defined by SOP) - /32 Version 15 “Deviation Management Section 10.3.16. Out of a total of 1144 deviations without extension: e Three out of four Critical deviations since CBER licensure were closed beyond the target of 45 days. The Critical deviations were open from| __|days. e A total of 119 Major deviations were closed beyond the target date of 30 or 45 days. The Major deviations were open from| _,,, days. e A total of 105 Minor deviations closed beyond the target date of 30 days. The Minor deviations were open from), days.

See all 3 findings in this document
[FDA 483 observation · FDA]Dynavax GmbH — Narrow endotoxin OOS investigation
FDA483

FDA issued a Form 483 to Dynavax GmbH, a bulk drug substance manufacturer, after an inspection ending 02/03/2023. One observation was legible: the root cause of an endotoxin OOS result was assigned to method interference, while the manufacturing investigation did not review the equipment sanitization cycle or its periodic requalification.

Published 2026-10-26 · Inspection date 02/03/2023 · Bulk Drug Substance Manufacturer · FEI 3010165220

Key facts · Basis: official index plus supporting sources
  • Observations: 1
  • Citation: Inadequate OOS and manufacturing investigation
  • Detail: Lab investigation #0202-001 and DEV-00031; sanitization cycle not evaluated
Insight · Editorial insight

Assigning the OOS root cause to the test method without recording why manufacturing causes such as sanitization were ruled out was cited as too narrow an investigation. For endotoxin OOS results, whether the investigation covered equipment sanitization history as well as the lab may be checked.

Check points
  • Whether OOS investigations that assign a lab cause record why manufacturing causes were ruled out
  • Whether sanitization cycle requalification history is reviewed in investigations
Observation detail · 1 observation · OCR reading of the scanned original

The public PDF of this inspection record is a scanned image, so the text was read by machine (OCR). Misreadings are possible; check the official PDF for the exact wording.

Observation 1

The investigation into the out of specification test result and the corresponding manufacturing investigation w inadequate in that the investigation did not extend into the review ofthe!

(6) (4) Sanitization of th Specifically, Laboratory investigation #0202-001 and deviation DEV-00031 were initiated on 2 é S endotoxin result for the . The investigation root cause was assigned to method due to interference with in the test sample. The manufacturing investigation failed to evaluate the sanitization cycle of the(D(A. Additionally, the periodic re-qualification of the (6)(4) sanitization ofthe was not reviewed as part of the investigation. a

[FDA 483 observation · FDA]Fin Vector Oy — Planned deviations allow departure from process
FDA483

At the Fin Vector Oy drug substance and drug product site (FEI 3010227150), inspected 09/27/2022, FDA cited as the first observation too few qualified personnel to perform and supervise manufacturing. Four extracted observations include inadequate equipment maintenance, a procedure allowing departures from the approved process as planned deviations, inadequate control of cleaning equipment, and incomplete labeling and packaging PQ.

Published 2026-10-26 · Inspection date 09/27/2022 · Drug Substance and Drug product Manufacturer · FEI 3010227150

Key facts · Basis: official index plus supporting sources
  • Observation 1 (excerpt): Insufficient qualified personnel to perform and supervise manufacturing
  • Observation 3: SOP version 16 (effective September 7, 2022) step 5.1 allows departure from the approved process as a planned deviation
  • Observation 6: Labeling and packaging PQ validation and documentation incomplete
Insight · Editorial insight

Citing a procedure that lets departures from the approved process be documented as planned deviations raises concern that matters needing change control may be handled as deviations. With insufficient qualified staff and weak equipment maintenance also cited, check how staffing and equipment conditions relate to deviation occurrence.

Check points
  • Boundary between planned deviation and change control
  • Level of qualified manufacturing supervision staff
  • Completion status of PQ for labeling and packaging processes
Observation detail · 5 observations · From the source
Observation 1

As evidenced by the following deviations, there does not appear to be an adequate number of qualified personnel to perform and supervise the manufacture and/or processing of the drug product.

Specifically, the following deviations were initiated due to operations personnel documenting the verification their own work: Deviation 21011, initiated January 12, 2021 Deviation 22263, initiated May 16, 2022 Deviation 22306, initiated May 30, 2022 Deviation 22309, initiated May 31, 2022

Observation 2

Equipment used to support the manufacturing process is not maintained at appropriate intervals to prevent malfunctions, making the equipment unavailable for its intended use for equipment (b) (4) I Specifically, a.

Between September 3, 2021 and July 4, 2022, multiple unplanned work orders were executed regarding breakdowns of (b)( in the (b) (4)area, room(b) (4) The Work Orders are as follows: WO -001063, WO -001755, WO -001802, WO -001886, WO -001891, WO -001948, WO -002183, WO -002887 and WO -003070. b. Due to the breakdown of (b) (4) it could not be used for equipment (b) 0) during the following dates: October 6-7 and 21-22, 2021 November 8-22 and 24-30, 2021

Observation 3

The Quality System procedure for deviations and incidents allows for planned deviations to document a departure from a previously approved process as stated below: SOP - version 16, effective September 7, 2022, states in step 5.1, deviation may also be raised to document planned departure from written procedure or previously approved process.

For example, continued use of an equipment pending completion of periodic maintenance or open breakdown not impacting performance of the equipment." Deviations 21457 (Occurrence date October 5, 2020) and 22315 (Occurrence date June 2,2022) were initiated related to the continual use of theE to r(b) (4) equipment needed for the Adstiladrin manufacturing process. The (b) ( facility and not part of the proposed commercial operations. 'NATURE,

Observation 5

requency to confirm the (b) (41= currently has no requirements for (b) (4) Equipment used to clean drug product not adequately maintained.

Specifically, (b) (4) was visible inside the (b) ( used to clean the 04 (4)for the drug product Adstiladrin. Any potential impact to the product is unknown.

Observation 6

Performance Qualification Validation and documentation required for the labelling and packaging of the filled drug product are not complete.

Specifically, the following equipment is not fully qualified: a. (b) (4) b. (b) (4) System including (b) (4)

See all 4 findings in this document
[FDA 483 observation · FDA]Intertek USA Inc. — Electronic records fail audit trail requirements
FDA483

FDA issued a Form 483 with two observations to Intertek USA Inc., a Control Laboratory. Electronic records did not meet audit trail requirements, and quality control unit responsibilities and procedures were not fully followed.

Published 2026-10-26 · Inspection date 03/07/2025 · Control Laboratory · FEI 1000151295

Key facts · Basis: official index plus supporting sources
  • Observation 1: Audit trail requirements not met for electronic records in use
  • Observation 2: Quality control unit responsibilities and procedures not followed
Insight · Editorial insight

Audit trail non-compliance as the first observation at a contract laboratory signals that data integrity is a core axis of assessing testing contractors. If you outsource analysis to external laboratories, check that laboratory's audit trail configuration for electronic records and whether it is reviewed.

Check points
  • Audit trail activation and review records for test instruments and systems
  • Scope of electronic record controls checked in contract laboratory audits
Observation detail · 2 observations · From the source

Inspectors: Lizaida Perez · Christian Lynch

Observation 1

Electronic records are used, but they do not meet audit trail requirements to ensure that they are trustworthy, reliable and generally equivalent to paper records.

Specifically, A. Procedure SOP-000012 (Version 13, Effective Date: JAN-14-2025), titled “Review and Release of Analytical Reports”, cludes Attachment 1, titled “Analytical Data Packages (ADP) Review Form’, which lists items to be reviewed during the peer and QA reviews. The list of items includes the review of audit trails. Section 3.2.1 of the cited procedure states that the review performance is documented in the ADP Review Form and stored with the Analytical Data Packages (ADP) generated for regulated analyses. However, Analytical Data Packages for testing of LUXTURNA “Lot (b) (4) ”, “Lot (b) (4) ”, and “Lot (b) (4) did not include Attachment 1. B. In addition, evaluation of audit trail records in the software of analytical equipment HPLC-CAD (Equipment Number (6) (4)) and ICP-MS Equipment Number (b) (4) for LUXTURNA Drug Substance Lot Number (b) (4) did not show access into the system by the personnel that signed for the responsibilities of QA Review, which includes audit trail review. Audit trail review is not done on the analytical equipment but reviewed using a non-validated software | (1b) (4) that pulls information from the audit trails log of analytical equipment. However

Observation 2

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically, A. Procedure SOP-000031(Version 16, Effective Date: JUN-02-2023), titled “Analytical Result Investigation”, requires that (BD) (4) of “Analytical Result Investigation Reports” (ARIR) be completed within ® business days of the discovery of the ARIR. During the inspection, three ARIR records (ARIR- 0000062, ARIR-0000096, and ARIR-0000100) were reviewed and found to exceed the ® business days requirement by 23 days, 18 days and 11 days, respectively. Each of these ARIRs was associated with testing ofLUXTURNA drug substance/product. B. Procedure SOP-000242 (Version 10, Effective Date: MAY-24-2023), titled “Cleaning Laboratory and Administrative Units” defines requirements for a (B) (4) cleaning that includes instructions for the disposal of expired reagents, solutions and solutions no longer required in the laboratory refrigerators and freezers. On March 03, 2025 during a walkthrough of laboratory areas, four expired solutions were identified in refrigerator (6) (4). Each of these solutions expired on DEC-8-2024. The logbook for (b) (4) cleaning, including the section of disposal of expired solution, had been initialed and dated for executed cleaning schedules for the per

[FDA 483 observation · FDA]Charles River Laboratories Inc — Facility and GMP operations SOPs not followed
FDA483

FDA issued a Form 483 to the Charles River Laboratories Inc manufacturing site. Non-compliance with SOPs on facility and GMP operations and an inadequate SOP were cited.

Published 2026-10-26 · Inspection date 08/25/2023 · Manufacturer · FEI 3006500433

Key facts · Basis: official index plus supporting sources
  • Observation 1 (excerpt): SOPs on facility and GMP operations not followed
  • Observation 5: Inadequate SOP
Insight · Editorial insight

Citing both non-compliance with SOPs and inadequacy of the SOP itself signals that procedure content and on-the-floor execution are verified together. It is worth checking that facility operations SOPs are revised regularly to reflect actual work.

Check points
  • Periodic review of facility and GMP operations SOPs for suitability to the floor
  • Deviation handling records for SOP non-compliance
Observation detail · 1 observation · From the source
Observation 5

Inadequate SOP.

Specifically, CRL SOP-0667 “Cold Storage Alarm ResponseBydoes not describe the temperature and the| (b) (4)time limit when stored material is required to be moved to a new storage location upon freezer failures. Observation 6. Facility is not in a state ofgood repair, leading to pest control issues. Specifically, timely facility repairs at the warehouse located at 5780 E Shelby Drive, Memphis TN have not been performed. umn(D)I@)in 1found rusted at the was left inadequately repaired since January 2023, alongwith) (b) (4) in the(6)(4) and a in Room(®)@). This caused an increase in insect and pest (rodent) infestations as described in pest control reports by pest control management vendor for the period covering April-June 2023. On August 24, 2023, during warehouse inspection, it was observed that the(VA tacked a and had an allowing insects to enter the warehouse. Rust and damage were noted onlc) a additionally a wasp nest was observed on theen (°)1 C.) Observation 7. Visual inspection process qualification is deficient. Specifically, the defect challenge set used in training and qualification of the inspectors is not representative of final filled drug product vials, including clari

[FDA 483 observation · FDA]August Reuchlen GmbH — CAPA activities poorly documented
FDA483

FDA issued a Form 483 with two observations to the August Reuchlen GmbH manufacturing site. Inadequate documentation of CAPA activities and results, and an undefined scope of control over external services and consultants, were cited.

Published 2026-10-26 · Inspection date 05/02/2025 · Manufacturer · FEI 4439

Key facts · Basis: official index plus supporting sources
  • Observation 1: Inadequate documentation of CAPA activities and results
  • Observation 2: Type and extent of control over external services and consultants not defined
Insight · Editorial insight

This shows that even when CAPA is carried out, it is cited if activities and results are not recorded. With the scope of control over external service providers also cited, check that the level of control over outsourced work is defined in documents.

Check points
  • Completeness of records of CAPA execution and effectiveness results
  • Definition of control type and extent for each external service and consultant
Observation detail · 2 observations · From the source

Inspectors: John A Sciacchitano

Observation 1

Corrective and preventive action activities and/or results have not been adequately documented.

Specifically, the following CAPAs were not adequately documented: CAPA 2024-006 CAPA 2024-007 CAPA 2024-008 CAPA 2023-001

Observation 2

The type and extent of control to be exercised over services and consultants was not clearly defined.

Specifically, the firm’s supplier controls procedures do not adequately establish the type and extent of control to be exercised over some contractors, and consultants, based on the evaluation results.

[Regulatory news · PIC/S]Adoption and Entry into force of PIC/S Recommendation (PI 05… — PIC/S PI 058-1 on Annex 1 key changes
PIC/SGMP News

PIC/S published Recommendation PI 058-1, an interpretation of the most important changes in Annex 1 (Manufacture of Sterile Products, 2022). Details require checking the original text.

Published 2026-10-28 · Issuing authority PIC/S · Topic Adoption and Entry into force of PIC/S Recommendation (PI 058-1) - Interpretatio…

Key facts · Basis: official index plus supporting sources
  • Document: Recommendation PI 058-1
  • Subject: Annex 1 on the Manufacture of Sterile Products (2022)
  • Issue date: 2026-10-28
Insight · Editorial insight

An official PIC/S interpretation of the key Annex 1 (2022) changes signals alignment of member inspectorates' criteria for assessing sterile manufacturing. Because the interpretation itself requires checking the original text, sterile manufacturers should compare it with their existing Annex 1 gap analysis.

Check points
[WHO · WHO]Styrax Life Science Pvt Ltd (Anakapalli) — WHO inspection report on an API manufacturer
WHOWHO

WHO published a public inspection report (WHOPIR) for Styrax Life Science Pvt Ltd (Anakapalli), inspected 2026-06-01. Under quality management, a Quality Unit independent of production and designated release approvers for intermediates and API were confirmed.

Inspection date 2026-06-01 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO

Key facts · Basis: official index plus supporting sources
  • Inspection date: 2026-06-01
  • Quality management: Quality Unit independent of production established
  • Release approval: Release approvers for intermediates and API clearly designated
Insight · Editorial insight

That the WHOPIR quality management section first confirmed Quality Unit independence and definition of release approval authority signals that these two elements are basic checkpoints in API manufacturer assessment. A company sourcing API from this manufacturer should read the full report as supplier evaluation material.

Check points
  • Independence of the Quality Unit from the production department
  • Designation of release approvers for intermediates and API and documentation of their authority
Inspection report detail · From the source · WHO · Item 14
Inspection outcome
Original · WHOPIR

Based on the areas inspected, the people met, and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Styrax Life Sciences Pvt. Limited, located at Plot No 5G, Rambili Mandal, Atchutapuram, Anakapalli, Andhra Pradesh, 531061; India was considered to be operating at an acceptable level of compliance with WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients Guidelines. The deficiencies observed during the inspection, as listed in the full report, were addressed by Styrax Life Sciences Pvt. Limited to a satisfactory level before the publication of the WHOPIR. This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.

1. Quality management
Original · WHOPIR

A Quality Unit, independent of production, was established. The persons authorized to release intermediates and APIs were clearly defined. Quality Assurance ensured compliance with quality standards across operations, products, and facilities. It managed and approved SOPs, batch records, and product release documentation, ensuring their accuracy and completeness. QA conducted audits, oversaw validations and qualifications, and provided GMP training. QA investigated deviations, out-of-specification results, and complaints, ensuring appropriate resolution. …

2. Personnel
Original · WHOPIR

Personnel qualification An adequate number of personnel with appropriate qualifications, training, and experience were available for the manufacture and supervision of intermediates and APIs, with defined responsibilities documented in their job descriptions. The CV and job description of one authorized QA personnel responsible for batch release were reviewed. The manufacturer had a documented training system in place. …

3. Buildings and facilities
Original · WHOPIR

Design and construction According to the production schedule for the week of the inspection, no manufacturing activities were ongoing in Production Blocks V (PB-V) and VI (PB-VI). Nevertheless, these areas were included in the inspection to verify their general condition, cleanliness, and maintenance status. The areas were found to be maintained in an orderly condition. The facility layout was reviewed and followed a structured grid design with clearly segregated functional areas. …

4. Process equipment
Original · WHOPIR

The manufacturer was observed to possess an adequate range and number of production equipment to support the manufacturing of APIs and intermediates. The installed equipment appeared to be generally appropriately selected in terms of capacity, design, and material of construction to meet process requirements and ensure product quality. A qualification and calibration schedule was available at the site. …

5. Documentation and records
Original · WHOPIR

All documents related to the manufacture of intermediates and APIs were prepared, reviewed, approved, and distributed in accordance with SOP on Good Documentation Practices (GDP), and were maintained in paper form. Measurements such as weighing were verified, and calculations were checked for accuracy. The issuance, revision, superseding, and withdrawal of documents were controlled in accordance with the respective SOP, and revision histories were appropriately maintained. …

6. Materials management
Original · WHOPIR

The manufacturer had established multiple SOPs governing the receipt, identification, quarantine, storage, handling, sampling, testing, and approval or rejection of materials, including SOP for Receipt, Inspection, Labelling and Handling of Raw Material and Packing Materials, and SOP for Sampling, Testing and Approval of Raw Material and Packing Material. All related activities were managed using a paper‑based system. Upon receipt and prior to acceptance, each container or grouping of containers of materials was visually examined. …

7. Production and in-process controls
Original · WHOPIR

Production operation Raw materials used in the manufacture of intermediates and APIs were weighed or measured. Critical weighing, measuring, and subdividing operations were verified. Prior to use, production personnel confirmed that materials corresponded to those specified in the batch records for the intended intermediate or API. Actual yields were compared with expected yields at designated stages of the production process in the BPR, and expected yield ranges were established during process development. …

8. Packaging and identification labelling of APIs and intermediates
Original · WHOPIR

General: Procedures were established describing the receipt, identification, quarantine, sampling, examination and/or testing, release, and handling of packaging materials. Preparation of product labels was performed in accordance with the respective SOP. Labels were generated using an application that generated a unique barcode. Labels were issued based on production requests, for the exact quantity required for each batch and for the designated number of containers, including both inner and outer containers. …

9. Laboratory controls
Original · WHOPIR

The independent Quality Unit had adequate laboratory facilities. Written procedures covered sampling, testing, approval or rejection of materials, and the management and storage of laboratory data. Laboratory records were maintained in accordance with established requirements. Sampling equipment was stored in the QC laboratory under the supervision of the QC unit. Non‑dedicated sampling tools were cleaned, packed, and labelled with the date of cleaning. …

10. Validation
Original · WHOPIR

Validation documentation A limited verification was performed, consisting of confirming the existence of the Validation Master Plan (VMP) and the calibration program. Process validation documentation Process validation ensured consistent manufacturing performance and product quality through defined and verified stages, including process design, process qualification, and continued process verification. It involved documentation of raw materials, equipment, process parameters, and calibration requirements. …

11. Change control
Original · WHOPIR

A formal change control system was established to evaluate changes that could impact the production and control of intermediates or APIs. The relevant SOP was in place and reviewed during the inspection and found to be satisfactory. The procedures covered the identification, documentation, review, and approval of changes related to raw materials, specifications, analytical methods, facilities, support systems, equipment (including computer hardware), processing steps, labelling and packaging materials, and computer software. …

12. Rejection and re-use of materials
Original · WHOPIR

Reprocessing and reworking SOP for Reprocessing and Reworking of Intermediates and APIs was established to define the requirements and controls governing reprocessing and reworking activities and was reviewed during the inspection and found to be adequate. The procedure clearly differentiated between reprocessing and reworking as controlled, non- routine activities intended to bring non-conforming intermediates or APIs into compliance. …

13. Complaints and recalls
Original · WHOPIR

All quality-related complaints, whether received orally or in writing, were recorded and investigated in accordance with the SOP for handling of market complaints. The documentation of one randomly selected complaint was reviewed. Complaint records included the name and address of the complainant, contact details of the person submitting the complaint, the nature of the complaint (including the API name and batch number), and the date of receipt. …

14. Contract manufacturers (including laboratories)
Original · WHOPIR

A list of testing laboratories and other service providers, included as Annexure III of the SMF, was available. The following documentation was reviewed: - SOP for approval procedures of contract manufacturers, testing laboratories, and other service providers; - The quality agreement with the contract testing laboratory, and it was verified that it included provisions for documentation retention, confidentiality, and the right to audit; - The onsite audit report to verify compliance with GLP procedures and practices. The corresponding audit checklist was also available and reviewed. …

[WHO · WHO]Styrax Pharma (Andhra Pradesh) — WHO inspection of a combined QA/QC unit
WHOWHO

WHO published a public inspection report (WHOPIR) for Styrax Pharma (Andhra Pradesh) from the 2026-05-26 inspection, noting that an independent Quality Assurance Unit performs both QA and QC functions.

Inspection date 2026-05-26 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO

Key facts · Basis: official index plus supporting sources
  • Inspection date: 2026-05-26
  • Quality management: independent Quality Assurance Unit in operation
  • Function: one unit performs both QA and QC functions
Insight · Editorial insight

A single independent unit covering both QA and QC was accepted in the WHOPIR, a sign that independence matters more than organizational form in the assessment. Where QA and QC are combined, check how checks and balances are kept between test result review and batch release decisions.

Check points
  • Checks and balances between QC test review and release decisions in a combined QA unit
  • Independence of the Quality Assurance Unit from production
Inspection report detail · From the source · WHO · Item 15
Inspection outcome
Original · WHOPIR

Based on the areas inspected, the people met, and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Styrax Pharma Pvt Ltd., located at Plot No. 27B, Jawaharlal Nehru Pharma City, Parawada, Anakapalli, Andhra Pradesh, 531021, India, was considered to be operating at an acceptable level of compliance with WHO Good Manufacturing Practices for Active Pharmaceutical Ingredients Guidelines. The deficiencies observed during the inspection, as listed in the full report, were addressed by Styrax Pharma Pvt Ltd. to a satisfactory level before the publication of the WHOPIR. This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive

1. Quality management
Original · WHOPIR

An independent Quality Assurance Unit was in place and fulfilled both quality assurance and quality control functions. The Quality Assurance department was responsible for ensuring overall compliance with product quality, operations, and facilities in accordance with established procedures and policies. QA oversaw the preparation, review, approval, and periodic revision of SOPs across all departments. It was responsible for the approval and control of master batch production records, the issuance and review of batch production records, and the maintenance of master documentation. …

2. Personnel
Original · WHOPIR

Personnel qualification There was an adequate number of personnel qualified by appropriate education, training, and/or experience to perform and supervise the manufacture of intermediates and APIs. The responsibilities of all personnel engaged in the manufacture of intermediates and APIs were specified in their respective job descriptions. Training was conducted regularly in accordance with the SOP, by qualified personnel and, at a minimum, covered: - the specific operations performed by the employee; and - GMP as it related to the employee’s functions. …

3. Buildings and facilities
Original · WHOPIR

According to the production schedule for the week of the inspection, no manufacturing activities were taking place in PB-I and PB-III. Nevertheless, these areas were included in the inspection to verify their general condition, cleanliness, and maintenance status, along with the warehouses, including the packaging and dispensing area, drum yard, and solvent farm. The premises consisted of different areas. Changing rooms were provided before each cleanroom in Clean Area Block II, with appropriate gowning instructions displayed. …

4. Process equipment
Original · WHOPIR

Design and construction The manufacturer was equipped with the necessary equipment required for the production of its products. All equipment in direct contact with products was constructed from suitable materials (SS316, borosilicate glass, or Hastelloy) to prevent any impact on product quality. Equipment used for manufacturing intermediates and APIs was labelled, designed, and located to facilitate proper operation, cleaning, and maintenance. Equipment maintenance and cleaning Product changeover cleaning procedures were in place, and equipment cleanliness was verified by QA prior to reuse. …

5. Documentation and records
Original · WHOPIR

Document control was managed in accordance with the applicable SOP. Approved documents were designated as “MASTER COPY” and served as the source for issuing controlled versions. Most of the company’s operations were paper-based. Copies distributed to relevant departments were stamped as “CONTROLLED COPY” to ensure traceability and prevent unauthorized use. Formats and documents were reproduced from the master copy and issued with appropriate company identification. …

6. Materials management
Original · WHOPIR

The manufacturer had established multiple SOPs governing the receipt, identification, quarantine, storage, handling, sampling, testing, and approval or rejection of materials. All processes were managed using a paper-based system. Upon receipt, raw materials were initially verified against the approved supplier list in the receiving area, cleaned, and subsequently transferred to the warehouse, where quarantine status labels were issued by warehouse personnel. …

7. Production and in-process controls
Original · WHOPIR

The facility operated under a structured shift system to ensure continuous production. The general shift ran from 09:00 to 17:30, while operations were supported by three rotating shifts: A shift from 06:00 to 14:00, B shift from 14:00 to 22:00, and C shift from 22:00 to 06:00. This arrangement enabled uninterrupted 24/7 operations to meet market demand and customer timelines. Production operation Raw materials for the manufacture of intermediates and APIs were weighed or measured under appropriate conditions. Weighing and measuring devices were of suitable accuracy for their intended use. …

8. Packaging and identification labelling of APIs and intermediates
Original · WHOPIR

Materials were transferred using scoops into pre-weighed, food-grade white LDPE bags (primary packaging), which were then placed into black LDPE bags (secondary packaging) within HDPE or fiber drums. Both primary and secondary bags were twisted and sealed with pilfer-proof seals. The containers were subsequently closed with lids and secured using electroplated metal rings, which were locked with tamper-evident stainless-steel seals embossed with the company logo and serial number, ensuring traceability and integrity.

9. Storage and distribution
Original · WHOPIR

Refer to previous sections for storage.

10. Laboratory controls
Original · WHOPIR

Quality Control activities included the preparation and review of specifications and analytical methods for raw materials, packaging materials, in-process samples, intermediates, and finished products. The department was responsible for sampling and testing at all stages of production, including stability and holding time studies. …

11. Validation
Original · WHOPIR

Validation documentation Validation Master Plan was reviewed. Systems and processes were periodically evaluated to verify that they continued to operate in a validated state. Where no significant changes had been made to the system or process, and quality reviews confirmed consistent production of materials meeting specifications, revalidation was not required. Validation and qualification of critical systems, including computerized systems, processes, and analytical methods, were considered essential to ensure the reliability and integrity of the data generated and managed by these systems. …

12. Change control
Original · WHOPIR

A formal change control system was established in accordance with the applicable SOP. The SOP defined procedures for documenting, reviewing, assessing, implementing, and controlling all proposed changes related to documents, procedures, processes, raw materials, vendors, equipment, and facilities used in the manufacture of APIs and intermediates. A list of change categories was included in the SOP; however, it was specified that the list was not exhaustive and that other changes could also be subject to the change control procedure. Change control requests were randomly selected and reviewed. …

13. Rejection and re-use of materials
Original · WHOPIR

Rejection Intermediates and APIs that did not meet established specifications were identified and quarantined. Reprocessing and reworking The manufacturer had SOP for Re-Processing and Re-Working of Intermediates and APIs, in place. The procedure described the requirements and processes for reprocessing and reworking activities and was reviewed during the inspection and found to be adequate. Both reprocessing and reworking were defined as controlled, non-routine activities used to bring non-conforming intermediates or APIs into compliance, with clear distinction between the two. …

14. Complaints and recalls
Original · WHOPIR

All quality-related complaints, whether received orally or in writing, were recorded and investigated in accordance with the SOP on Handling of Complaints. Complaint records included the name and address of the complainant, contact details of the person submitting the complaint, the nature of the complaint (including API name and batch number), the date of receipt, details of initial and follow-up actions (including dates and responsible personnel), the response provided to the complainant (including the response date), and the final decision regarding the intermediate or API batch or lot. …

15. Contract manufacturers (including laboratories)
Original · WHOPIR

A list of contractors was available as Annexure V of the Site Master File. Contract manufacturers, including contract testing laboratories and service providers, were evaluated by the contract giver to ensure GMP compliance for the specific operations performed at the contract sites, in accordance with the corresponding SOP. A written and approved contract or formal agreement was in place between the contract giver and the contract acceptor, defining the GMP responsibilities and quality requirements of each party. …

[WHO · WHO]Hetero Labs (Unit III Jeedimetla - FPP) — WHO inspection of a finished product site
WHOWHO

WHO published a public inspection report (WHOPIR) for Hetero Labs (Unit III Jeedimetla - FPP) from the 2026-04-27 inspection, noting a documented quality assurance system with procedures covering the main quality elements.

Inspection date 2026-04-27 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO

Key facts · Basis: official index plus supporting sources
  • Inspection date: 2026-04-27
  • Site type: FPP
  • Quality system: documented QA system with procedures covering main quality elements
Insight · Editorial insight

A finished pharmaceutical product (FPP) site WHOPIR opening with confirmation of a documented quality system signals that a complete procedural framework is a baseline expectation in WHO inspections. A company sourcing finished products from this site should check the rest of the report as part of contract manufacturer oversight.

Check points
  • Whether the WHOPIR for the contract finished-product site has been obtained and reviewed
  • Whether quality system procedures cover the main quality elements
Inspection report detail · From the source · WHO · Item 16
Inspection outcome
Original · WHOPIR

Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Hetero Laboratories Limited (Unit-III) located at Survey No. 51, Plot 22-110, Industrial Development Area (I.D.A.), Jeedimetla, Hyderabad-500055, Telangana State, India was considered to be operating at an acceptable level of compliance with WHO GMP Guidelines. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR. This WHOPIR will remain valid for three years, provided that the outcome of any inspection con- ducted during this period is positive.

1. Pharmaceutical quality system
Original · WHOPIR

A documented system for quality assurance was established, with procedures covering key quality elements in place. The Quality Department was divided into QA and QC and were separate from the Production Department. Operations were specified in written form and critical GMP requirements were essentially being met. The procedures reviewed and discussed during the inspection were generally of an acceptable standard. Annual Product Quality Review (APQR) The company had a procedure in place for performing annual product quality reviews. …

2. Good manufacturing practices for pharmaceutical products
Original · WHOPIR

Good manufacturing practices were generally implemented. Necessary human and physical resources with adequate premises, equipment and utilities were provided for the current operational level of FPP activity. Manufacturing processes were generally adequately defined. The manufacturing processes follow procedures as defined and documented in the BMRs and BPRs. The personnel were appropriately qualified and adequate training is conducted.

3. Sanitation and hygiene
Original · WHOPIR

Premises and equipment in the FPP production area were maintained at a satisfactory level of cleanliness at the time of inspection. Personal hygiene and sanitation appeared satisfactory. Areas were cleaned frequently in accordance with an approved written programme. Personnel at the site were seen to be performing their duties in an organized and diligent manner.

4. Qualification and validation
Original · WHOPIR

Validation master plan An approved VMP was available and reviewed. The company qualification and validation policy and programme were defined and documented. Process validation Process validation was performed following approved written procedures. The following PVs were reviewed and discussed.

  • HA486 Zidovudine Oral Solution, USP 50mg/5mL
  • HA757 Darunavir/Ritonavir Tablet, Film-coated 400mg/50mg
  • HA758 Darunavir/Ritonavir Tablet, Film-coated 800mg/100mg The procedure for holding time study was available. The holding time for uncoated and coated tablets were defined upon the study data. …
5. Complaints
Original · WHOPIR

Product quality complaints were handled according to the procedure “Handling of market complaints and Quality defects”. There were three reportable classifications of Quality complaints: Critical, Major and Minor. For WHO products, the information was provided that there were no complaints for the period of October 2020 to April 2026. Additionally, the current list of complaints for 2026 was reviewed and discussed. It was the responsibility of QA to investigate complaints and implement CAPA if necessary. …

6. Product recalls
Original · WHOPIR

The SOP for “Product recalls” was reviewed. Recall was classified as Class I, Class II or Class III defect, and the action was required to be initiated within specified time. No batches of WHO products have been recalled in the last five years. Recall simulation was required to be performed for all markets every year if no real recall occurs. The mock recall performance was checked and discussed.

7. Contract production, analysis and other activities
Original · WHOPIR

The SMF and company presentation indicated that all products are manufactured exclusively at Unit-III. No products were outsourced for contract manufacturing, including the WHO prequalified FPPs under inspection. The list of contract laboratories, including their addresses and contact information were documented. This list indicated that external laboratories were used where specialized analytical equipment or capabilities are required.

8. Self-inspection, quality audits and suppliers’ audits and approval
Original · WHOPIR

Self- Inspection A self-inspection plan and SOP was in place. This was spot-checked in management review and not reviewed in detail. Vendor/Supplier qualification and approval The supplier qualification and approval were managed following SOP “Vendor qualification”. An approved vendor list was maintained and covered all starting materials including APIs, Excipients and packing materials. Vendor audit, auditor’s qualification and audit procedure were addressed.

9. Personnel
Original · WHOPIR

An organization chart was available. Key personnel responsibilities were defined in job descriptions. The key personnel in various departments had pharmaceutical qualifications and were well experienced in pharmaceutical manufacturing. In general personnel met during the inspection were aware and followed the GMP principles with appropriate qualifications and experience.

10. Training
Original · WHOPIR

QA was responsible for training of personnel. Training was required for newly appointed and job specific training and re-training in the event of personnel errors, resulting in a CAPA event. Training programme was not reviewed in detail during the inspection.

11. Personal hygiene
Original · WHOPIR

Personnel hygiene requirements were documented in written procedures. The procedure for entry and exit through change room was reviewed. The requirements for entering the Grade D cleanrooms were clearly documented and included pictorial drawings in the changing rooms. Staff observed in these areas were dressed in the appropriate protective clothing.

12. Premises
Original · WHOPIR

The production facility was consisted of three blocks i.e. Block A, Block B and Module IX, Block B. The production blocks were multi-product and non-dedicated to the products manufactured in the block. Central warehouse The warehouse, located about 6 km away from Unit III was used for receipt and storage of excipients, packaging materials and finished goods, including sampling of excipients / packing materials and dispensing of packing materials. QC laboratories The laboratory areas were separate from the production areas. …

13. Equipment
Original · WHOPIR

Equipment installed in the production blocks was multi-purpose and each piece of equipment had a unique identification number. The equipment viewed appeared to be of suitable design and construction for the allocated process in general. Equipment maintenance The equipment viewed during the inspection appeared to have been suitably maintained and in good condition. Equipment status labels were available. The procedure for equipment preventive maintenance was available. Equipment cleaning Equipment cleaning followed approved procedures. …

14. Materials Management
Original · WHOPIR

Incoming materials and finished products were quarantined after receipt until released for use or distribution. The starting material and finished goods were managed by SAP system. Starting material, packaging material and FPPs were stored in different warehouses under the specified conditions. The warehouses onsite and the Central warehouse were visited during the inspection. The raw material warehouse was equipped with sampling booths and dispensing booths under LAF with separate entrances for materials and personal. …

15. Documentation
Original · WHOPIR

Documentation was designed, prepared, reviewed and distributed according to an approved procedure. Computerised systems were used for management of quality system and handling of documents. Approved, signed and dated testing procedures and specifications were available for starting and packaging materials and for finished products. Batch numbering system and BMR management The procedure for product batch numbering and management was reviewed. The procedure included a list which addressed assignment of batch numbers in different scenarios. …

16. Good practices in production
Original · WHOPIR

The manufacturing processes were performed and recorded according to instructions in the batch production records. Production of several batches of Dolutegravir (Sodium)/Lamivudine/Tenofovir disoproxil fumarate (DLT) Tablet, Film-coated, 50mg/300mg/300mg and oral liquid product were in operation at the time of inspection. Tablets and oral liquids manufacturing steps were briefly inspected. In-process controls were conducted inside of the processing room in the production blocks. Appropriate testing equipment was available. The frequency and limits were defined in the BMRs. …

[WHO · WHO]Hetero Labs (Unit 5 Polepally) — Quality system with separate QA and QC
WHOWHO

WHO published a public inspection report (WHOPIR) for Hetero Labs (Unit 5 Polepally) from the 2026-04-21 inspection, noting a documented QA system and QA/QC units separate from production.

Inspection date 2026-04-21 · Outcome Acceptable · Valid for 3 years · Issuing authority WHO

Key facts · Basis: official index plus supporting sources
  • Inspection date: 2026-04-21
  • Quality system: documented QA system with procedures covering main quality elements
  • Organization: Quality Department split into QA and QC, separate from production
Insight · Editorial insight

The WHOPIR stating that the quality department is split into QA and QC and separated from production signals that organizational role separation is the starting point of PQS assessment. A company procuring from this site should check whether the report's follow-up items feed into supplier evaluation.

Check points
  • Separation of QA and QC functions and independence from production
  • Documentation coverage of procedures for the main quality elements
Inspection report detail · From the source · WHO · Item 16
Inspection outcome
Original · WHOPIR

Based on the areas inspected, the people met and the documents reviewed, and considering the findings of the inspection, including the observations listed in the Inspection Report, Hetero La- boratories Limited (Unit-V) located at Survey No. 439, 440, 441 & 458, TSIIC Pharma SEZ, Polepally Village, Jadcherla Mandal, Mahaboobnagar District, Telangana State – 509301 was considered to be operating at an acceptable level of compliance with WHO GMP Guidelines. All the non-compliances observed during the inspection that were listed in the full report as well as those reflected in the WHOPIR, were addressed by the manufacturer, to a satisfactory level, prior to the publication of the WHOPIR. This WHOPIR will remain valid for three years, provided that the outcome of any inspection con- ducted during this period is positive.

1. Pharmaceutical quality system
Original · WHOPIR

A documented system for quality assurance was established, with procedures covering key quality elements in place. The Quality Department was divided into QA and QC and were separate from the Production Department. Operations were specified in written form and critical GMP require- ments were essentially being met. Annual Product Quality Review The company had a procedure in place for conducting annual product quality reviews. The APQR schedule was prepared at the beginning of each year. The 2025 schedule and 2026 schedule were available. …

2. Good manufacturing practices for pharmaceutical products
Original · WHOPIR

Good manufacturing practices were generally implemented. Necessary human and physical resources with adequate premises, equipment and utilities were provided for the current operational level of FPP activity. Manufacturing processes were generally adequately defined. The manufacturing processes follow procedures as defined and documented in the BMRs and BPRs. The personnel were appropriately qualified and adequate training is conducted.

3. Sanitation and hygiene
Original · WHOPIR

The premises and equipment in the FPP production area were clean and well-maintained at the time of inspection. Personal hygiene and sanitation also appeared satisfactory. Areas were cleaned fre- quently in accordance with an approved written programme. Personnel at the site were seen to be performing their duties in an organised and diligent manner.

4. Qualification and validation
Original · WHOPIR

Validation master plan An approved VMP was available and reviewed. The company qualification and validation policy and programme were defined and documented. Process validation Process validation was performed following approved written procedures. The process validation of HP029 Sofosbuvir and Velpatasvir Tablets 400 mg/ 100 mg and HA696 Dolutegravir (Sodium)/Lamivudine/Tenofovir disoproxil fumarate Tablet, Film-coated 50mg/300mg/300mg were checked and discussed. Computerised System (CS) validation Additional VMP was generated for the computerised systems. …

5. Complaints
Original · WHOPIR

Product quality complaints were handled according to the procedure “Handling of market com- plaints and Quality defects”. There were three reportable classifications of Quality complaints: Crit- ical, Major and Minor. For WHO products a list of complaints was provided. Additionally, the cur- rent list of complaints for the year 2026 was checked and discussed. It was the responsibility of QA to investigate complaints and implement CAPA if necessary. …

6. Product recalls
Original · WHOPIR

The SOP for “Product recalls” was reviewed. Recall was classified as Class I, Class II or Class III defect, and the action is required to be initiated within specified time. No batch of WHO products has been recalled in last three years. Recall simulation was required to be performed for all markets every year if no real recall occurs. A class I mock recall was performed in Feb/2026. It was concluded that the recall procedure was robust and fit to handle the real time recall situation.

7. Contract production, analysis and other activities
Original · WHOPIR

Hetero Labs has confirmed that all products are manufactured on-site by Unit-V only. No product has been given for contract manufacturing. The list of contract laboratories, including the addresses and contact information was available. The details were not reviewed during this inspection.

8. Self-inspection, quality audits and suppliers’ audits and approval
Original · WHOPIR

Self- Inspection A self-inspection plan and SOP was in place. This was spot checked in management review and not reviewed in detail. Vendor/Supplier qualification and approval The supplier qualification and approval were managed following SOP “Vendor qualification”. An approved vendor list was maintained and covered all starting materials including APIs, Excipients and packing materials. Vendor audit, auditor’s qualification and audit procedure were addressed. Vendor requalification schedule 2026 was available and monitored.

9. Personnel
Original · WHOPIR

An organization chart was available. Key personnel responsibilities were defined in job descrip- tions. The key personnel of the various departments had pharmaceutical qualifications and were well experienced in pharmaceutical manufacturing. In general personnel met during the inspection are aware and follow the GMP principles with appropriate qualifications and experience.

10. Training
Original · WHOPIR

QA was responsible for training of personnel. Training was required for newly appointed and job specific training and re-training in the event of personnel errors, resulting in a CAPA event. Training programme was not reviewed in detail during this inspection.

11. Personal hygiene
Original · WHOPIR

Personnel hygiene requirements were documented in written procedures. The requirements for en- try Grade D cleanrooms were well documented, including pictorial drawings in change rooms. Staff observed in these areas were dressed in appropriate protective clothing.

12. Premises
Original · WHOPIR

Production blocks were multi-product and not dedicated. Manufacturing areas were of a good stand- ard and suitable for the activities conducted therein. Exposed surfaces were smooth, impervious and unbroken to minimize the shedding or accumulation of particles or microorganisms and permitted the repeated application of cleaning. The classified areas were monitored for temperature and relative humidity with BMS system for environmental control. Pressure differentials were monitored manually based on the differential pressure indicators installed. …

13. Equipment
Original · WHOPIR

Equipment installed in the production blocks was multi-purpose and each piece of equipment had a unique identification number. The equipment viewed appeared to be of suitable design and con- struction for the allocated process in general. Equipment maintenance The equipment viewed during the inspection appeared to have been suitably maintained and in good condition. Equipment status labels were available. Equipment cleaning In general, the production facilities were well maintained, and equipment was free of dust and resi- dues at the time of inspection.

14. Materials Management
Original · WHOPIR

Incoming materials and finished products were quarantined after receipt until released for use or distribution. Status of raw material was indicated, with respect to material under quarantine, ap- proved, and retest etc. The starting material and finished goods were managed by SAP system. Starting material, packaging material and FPPs were stored in different warehouses under the spec- ified conditions. The warehouses in Blocks V and VA were visited during the inspection. The codes and locations for starting material and finished goods were available in the SAP system and spot checked. …

15. Documentation
Original · WHOPIR

Documentation was designed, prepared, reviewed and distributed according to an approved proce- dure. Computerised systems were used for management of quality system and handling of docu- ments. Approved, signed and dated testing procedures and specifications were available for starting and packaging materials and for finished products. Analytical work sheets were generated from the LIMS. Batch numbering system and BMR management The SOP “Allotment of batch numbers” and SOP “Issue and control of BPR through batch record issuance management system application” were reviewed. …

16. Good practices in production
Original · WHOPIR

The manufacturing processes were performed and recorded according to instructions in the batch production records. Production of several tablets was in operation at the time of inspection. Tablet’s manufacturing steps including material dispensing, granulation, compression, coating and primary, secondary packaging areas were inspected. In-process control was conducted inside of processing room in the production blocks. Appropriate testing equipment was available. Recovery and reprocessing were handled following SOP “Procedure for handling if rejects during packing operation”. …

Korea 7 cards

Guidance
[Guidance · MFDS]바이오 무균의약품 제조 규정 적용 사례집 — Case book on biologic sterile manufacturing rules
MFDSGuidance

MFDS issued a case book on applying biologic sterile medicinal product manufacturing rules on 2026-10-30. Review of the original text is needed.

Published 2026-10-30 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: case book on applying biologic sterile medicinal product manufacturing rules
  • Issue date: 2026-10-30
Insight · Editorial insight

Issued as a case book rather than a rule commentary, it signals how MFDS interprets biologic sterile manufacturing rules in practice. Review of the original text is needed, and the included cases should be compared against the company's own aseptic process operation.

Check points
  • Comparison of the included cases with in-house biologic aseptic process operation
  • Identification of items that need to be reflected from the case book
[Guidance · MFDS]의약품등 회수·폐기 처리 운영 지침 — Operating guideline for recall and disposal
MFDSGuidance

MFDS posted an operating guideline on recall and disposal handling of medicinal products. Details require review of the original text.

Published 2026-10-30 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: operating guideline on recall and disposal handling of medicinal products
  • Issue date: 2026-10-30
Insight · Editorial insight

The guideline covers administrative operating standards for recall and disposal and can serve as a reference point for company response procedures when a recall occurs. Whether it is a revision and its detailed requirements need review of the original text, so check alignment with the recall response system.

Check points
  • Alignment of recall plan and reporting forms with the guideline requirements
  • Record keeping for disposal of recalled products
[Guidance · MFDS]일본뇌염 백신 품질평가 가이드라인 — Japanese encephalitis vaccine quality guide
MFDSGuidance

MFDS posted a quality evaluation guideline for Japanese encephalitis vaccines. Details require review of the original text.

Published 2026-10-30 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: quality evaluation guideline for Japanese encephalitis vaccines
  • Issue date: 2026-10-30
Insight · Editorial insight

Quality evaluation standards for a specific vaccine category are now set out, which can be a reference point for test item setting by manufacturers and importers of such vaccines. Detailed evaluation items need review of the original text, so check differences from current specifications.

Check points
  • Comparison of current standards and test methods for the vaccine with the guideline
  • Test method validation status for each quality evaluation item
[Guidance · MFDS]한약(생약)제제 GMP 질의응답집(민원인 안내서) — GMP Q&A for herbal medicine preparations
MFDSGuidance

MFDS posted a GMP question-and-answer booklet for herbal (crude drug) preparations, written as a guide for applicants. Details require review of the original text.

Published 2026-10-30 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: GMP Q&A booklet for herbal (crude drug) preparations (applicant guide)
  • Issue date: 2026-10-30
Insight · Editorial insight

The applicant guide organizes GMP interpretation for herbal preparations in Q&A form and can serve as reference material for reducing interpretation gaps during inspections. The specific questions need review of the original text, so a herbal preparation manufacturer should compare them with its existing interpretation.

Check points
  • Consistency between the Q&A items and current herbal preparation GMP interpretation
  • Need to reflect raw herbal material control items in in-house standards
[Guidance · MFDS]오가노이드 기반 세포치료제의 임상시험 시 품질 및 비임상 평가 가이드라인 — Organoid therapy quality and nonclinical guide
MFDSGuidance

MFDS posted a guideline on quality and nonclinical evaluation of organoid-based cell therapy products in clinical trials. Details require review of the original text.

Published 2026-10-30 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: guideline on quality and nonclinical evaluation of organoid-based cell therapy products in clinical trials
  • Issue date: 2026-10-30
Insight · Editorial insight

A separate clinical-stage evaluation standard for organoid-based cell therapies signals that regulatory expectations in advanced biologics are becoming more specific. Detailed requirements need review of the original text, so developers with related projects should check their characterization data plans.

Check points
  • Quality characterization items for organoid cell therapy development projects
  • Composition of nonclinical evaluation data for clinical trial applications
[Guidance · MFDS]의약품등 품목별 사전 GMP 평가 운영지침 — Product-level pre-GMP evaluation guideline
MFDSGuidance

MFDS posted an operating guideline on product-level pre-GMP evaluation of medicinal products. Details require review of the original text.

Published 2026-10-29 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: operating guideline on product-level pre-GMP evaluation of medicinal products
  • Issue date: 2026-10-30
Insight · Editorial insight

The guideline covers operating standards for pre-GMP evaluation at the marketing approval stage and may affect new product approval timelines and inspection preparation. The scope of changes needs review of the original text, so check changes in the evaluation procedure for products awaiting approval.

Check points
  • Whether upcoming approval products are subject to pre-GMP evaluation
  • Readiness of submission data for pre-GMP evaluation
[Guidance · MFDS]박테리오파지 치료제의 임상시험 시 품질 및 비임상 평가 가이드라인 — Bacteriophage therapy quality guideline
MFDSGuidance

MFDS posted a guideline on quality and nonclinical evaluation of bacteriophage therapeutics in clinical trials. Details require review of the original text.

Published 2026-10-29 · Issuing authority MFDS

Shown in the original Korean: 1 value in this table.

Key facts · Basis: official index plus supporting sources
  • Subject: guideline on quality and nonclinical evaluation of bacteriophage therapeutics in clinical trials
  • Issue date: 2026-10-29
Insight · Editorial insight

Clinical-stage quality and nonclinical evaluation standards for bacteriophage therapeutics, a new modality, signal that regulatory expectations for developers are becoming concrete. Detailed requirements need review of the original text, so companies with related pipelines should check how their quality data are composed.

Check points
  • Response of bacteriophage therapeutic projects to quality evaluation items
  • Composition of nonclinical data for clinical trial applications

Recall 20 cards

[Recall / sales suspension · MFDS](주)화림제약 — Recall for buprofezin pesticide residue
MFDS▫️ OtherRecall

MFDS ordered a recall of a Lycium fruit herbal product from a domestic pharmaceutical company due to pesticide residue (buprofezin).

Published 2026-10-30 · Product 화림구기자

Original text
잔류농약(뷰프로페진)
Key facts · Basis: official source record kept by the collector
  • Reason: pesticide residue (buprofezin)
  • Product: a Lycium fruit herbal product
  • Mandatory: Y
  • Recall order date: 20261030
Insight · Editorial insight

Naming a specific pesticide, buprofezin, as the reason signals that pesticide use history at the raw material production stage bears directly on quality decisions. Those handling Lycium fruit material should check whether buprofezin is included in incoming residual pesticide testing.

Check points
  • Scope of residual pesticide test items for incoming materials
  • Verification of pesticide use history at raw material suppliers
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS](주)현진제약 — Recall for chlorpyrifos pesticide residue
MFDS▫️ OtherRecall

MFDS ordered a recall of an Alisma rhizome herbal product from a domestic pharmaceutical company due to pesticide residue (chlorpyrifos).

Published 2026-10-30 · Product 현진택사

Original text
잔류농약(클로르피리포스)
Key facts · Basis: official source record kept by the collector
  • Reason: pesticide residue (chlorpyrifos)
  • Product: an Alisma rhizome herbal product
  • Mandatory: Y
  • Recall order date: 20261030
Insight · Editorial insight

A residual pesticide recall naming chlorpyrifos signals that control variation at the growing origin and cultivation stage can lead to nonconforming finished products. Those handling Alisma rhizome material should check lot-by-lot residual pesticide test results and supplier control status.

Check points
  • Chlorpyrifos test results for each Alisma rhizome material lot
  • Re-evaluation of residual pesticides when the material supplier changes
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS](주)나음제약 — Recall for foreign matter (seeds) in purity test
MFDS▫️ OtherRecall

MFDS ordered a recall of a Zanthoxylum fruit herbal product from a domestic pharmaceutical company due to foreign matter (seeds) in the purity test.

Published 2026-10-30 · Product 나음산초

Original text
순도시험 1) 이물 가) 씨
Key facts · Basis: official source record kept by the collector
  • Reason: purity test, 1) foreign matter, a) seeds
  • Product: a Zanthoxylum fruit herbal product
  • Mandatory: Y
  • Recall order date: 20261030
Insight · Editorial insight

The seed limit under the foreign matter item of the purity test being the reason signals that physical control of sorting and cleaning, rather than chemical testing, is the issue. Such nonconformities can generally relate to sorting process control, so check foreign matter confirmation records after sorting.

Check points
  • Records confirming foreign matter (seeds) after the sorting process
  • Testing frequency for the foreign matter item of the purity test
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS](주)허브팜 — Recall order for sulfur dioxide
MFDS▫️ OtherRecall

MFDS issued a mandatory recall order (Mandatory: Y) for a galangal herbal product from a domestic pharmaceutical company, citing sulfur dioxide.

Published 2026-10-30 · Product 허브팜고량강

Original text
이산화황
Key facts · Basis: official source record kept by the collector
  • Product: a galangal herbal product
  • Reason: sulfur dioxide
  • Mandatory: Y
  • Recall order date: 20261030
Insight · Editorial insight

A mandatory recall over sulfur dioxide signals that residual sulfur dioxide control can be a direct release issue. Sulfur dioxide can generally relate to drying and preservation treatment history of the material, so check the reliability of material-stage test results.

Check points
  • Whether sulfur dioxide testing is performed on incoming material and the suitability of its criteria
  • Consistency between supplier certificates and in-house test results
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]광동제약(주) — Recall for assay out of specification in stability
MFDS💊 Small moleculeRecall

A domestic pharmaceutical company is conducting a voluntary recall of a cream product due to an out-of-specification result in an item (assay) of the stability test.

Published 2026-10-30 · Product 큐아크네플러스크림

Original text
안정성 시험 일부 항목(함량) 기준일탈로 인한 영업자 회수
Key facts · Basis: official source record kept by the collector
  • Product: a cream product
  • Reason: voluntary recall by the marketing company due to out-of-specification result in a stability test item (assay)
  • Mandatory: N
  • Recall order date: 20261030
Insight · Editorial insight

An assay deviation found in post-release stability testing led to a voluntary recall, a sign that maintaining assay through shelf life is key to marketed product quality. Assay loss in creams can generally relate to storage conditions or active ingredient degradation, so check stability trend data.

Check points
  • Trend analysis of stability assay results over time
  • Procedure for assessing impact on distributed lots when a stability OOS occurs
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS](주)바른한방제약 — Recall for heavy metal nonconformity
MFDS▫️ OtherRecall

MFDS ordered a recall of a Pueraria root herbal product from a domestic herbal pharmaceutical company due to quality nonconformity (heavy metals).

Published 2026-10-29 · Product 바른갈근

Original text
품질 부적합(중금속)
Key facts · Basis: official source record kept by the collector
  • Reason: quality nonconformity (heavy metals)
  • Product: a Pueraria root herbal product
  • Mandatory: Y
  • Recall order date: 20261029
Insight · Editorial insight

Heavy metal nonconformity can generally relate to the growing and harvesting environment of the material, signaling that material-stage control is the issue. If other products use the same material, check heavy metal test results by supplier.

Check points
  • Whether heavy metal testing is performed on incoming material
  • Trend of heavy metal test results by material supplier
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS](주)한성비씨씨 — Recall for total volatile organic compounds
MFDS▫️ OtherRecall

MFDS ordered a recall of a portable oxygen product from a domestic company due to quality nonconformity (total volatile organic compounds).

Published 2026-10-29 · Product 오투포유휴대용산소

Original text
품질부적합(총휘발성유기화합물)
Key facts · Basis: official source record kept by the collector
  • Reason: quality nonconformity (total volatile organic compounds)
  • Product: a portable oxygen product
  • Mandatory: Y
  • Recall order date: 20261029
Insight · Editorial insight

Total volatile organic compounds being the reason for an inhaled oxygen product signals that impurities from the container and filling system, not only the filling gas, are subject to control. Such nonconformities can generally relate to container and filling system control, so check these factors.

Check points
  • Inner surface treatment and washing state of filling containers
  • Whether total volatile organic compounds are tested before release
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]주식회사 지리에어 — Portable oxygen TVOC nonconformity recall
MFDS▫️ OtherRecall

MFDS ordered a recall of a portable oxygen product from a domestic company due to quality nonconformity (total volatile organic compounds).

Published 2026-10-29 · Product 오투미휴대용산소

Original text
품질부적합(총휘발성유기화합물)
Key facts · Basis: official source record kept by the collector
  • Reason: quality nonconformity (total volatile organic compounds)
  • Product: a portable oxygen product
  • Mandatory: Y
  • Recall order date: 20261029
Insight · Editorial insight

A mandatory recall for total volatile organic compounds signals that the organic impurity limit is a key release item for inhaled oxygen products. A portable oxygen manufacturer should check the basis for controlling volatile organics in the source gas and filling process.

Check points
  • Volatile organic items on the source gas supplier's test certificate
  • Control of possible contamination entry points in the filling process
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]주식회사래퓨 — Purity nonconformity: TVOC and formaldehyde
MFDS▫️ OtherRecall

MFDS ordered a recall (Mandatory: Y) of a portable oxygen product from a domestic company due to quality nonconformity in purity (total volatile organic compounds and formaldehyde).

Published 2026-10-29 · Product 에어리아휴대용산소

Original text
품질부적합(순도(총휘발성유기화합물 및 포름알데히드))
Key facts · Basis: official source record kept by the collector
  • Product: a portable oxygen product
  • Reason: quality nonconformity (purity: total volatile organic compounds and formaldehyde)
  • Mandatory: Y
  • Recall order date: 20261029
Insight · Editorial insight

Total volatile organic compounds and formaldehyde being flagged under the purity item signals that control of impurity gases, beyond the main component content, can decide quality judgments. Such impurities can generally originate from filling containers or contact materials, so check these pathways.

Check points
  • Whether total volatile organic compounds and formaldehyde are included in purity test items
  • Migration assessment of volatile substances from filling containers and contact materials
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]제이케이제약(주) 후레쉬드림아이알지피액(20%염산폴리헥사메칠렌비구아니드) 외 1품목 — Recall for total aerobic microbial count
Evidence AMFDSSignal High · T3▫️ OtherRecall

MFDS ordered a recall of two products from a domestic pharmaceutical company due to total aerobic microbial count. It is a combined recall of two products for the same reason.

Published2026-10-27
Document no.recall-014fb4381520
Companies제이케이제약(주)
Product후레쉬드림아이알지피액(20%염산폴리헥사메칠렌비구아니드) 외 1품목
All 2 products
  • 후레쉬드림아이알지피액(20%염산폴리헥사메칠렌비구아니드)
  • 드롭애니액(폴리헥사메틸렌비구아니드염산염 액 20%)
Original text · representative case
총호기성미생물수
Key facts · Basis: official source record kept by the collector
  • Reason: total aerobic microbial count
  • Mandatory: Y
  • Recall order date: 20261027
  • Merged: combined recall of 2 products for the same reason
Insight · Editorial insight

Two polyhexamethylene biguanide-based liquid products from the same company being recalled together for total aerobic microbial count suggests looking at a common process or equipment problem rather than individual lots. Liquid microbial limit failures can generally relate to purified water and filling environment control, so check these items.

Check points
  • Microbial control records for liquid manufacturing water
  • Microbial limit test trends across products sharing the same equipment
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall / sales suspension · MFDS]주식회사 케이앤제이씨 드롭드림아이2액(폴리헥사메틸렌비구아니드염산염 액 20%)(수출명: OASYSACTIVE… — Recall of 3 products for aerobic microbial count
Evidence AMFDSSignal High · T3▫️ OtherRecall

MFDS ordered a recall of three products from a domestic company due to total aerobic microbial count. It is a combined recall of three products for the same reason.

Published2026-10-27
Document no.recall-6011a2264ad4
Companies주식회사 케이앤제이씨
Product드롭드림아이2액(폴리헥사메틸렌비구아니드염산염 액 20%)(수출명: OASYSACTIVE) 외 2품목
All 3 products
  • 드롭드림아이2액(폴리헥사메틸렌비구아니드염산염 액 20%)(수출명: OASYSACTIVE)
  • 크린워시액(염화나트륨)
  • 유렌즈드롭액(폴리헥사메틸렌비구아니드염산염 액 20%)
Original text · representative case
총호기성미생물수
Key facts · Basis: official source record kept by the collector
  • Reason: total aerobic microbial count
  • Mandatory: Y
  • Recall order date: 20261027
  • Merged: combined recall of 3 products for the same reason
Insight · Editorial insight

Three products, including ones with different ingredients, being recalled on the same day for the same microbial reason suggests looking at common manufacturing environment factors rather than formulation. Such patterns can generally relate to shared equipment cleaning and water control, so check microbial control records on shared lines.

Check points
  • Microbial confirmation records after cleaning of shared manufacturing equipment
  • Microbial monitoring results for water shared across products
Findings detail · a record the regulator published in KoreanRead it in the Korean edition
[Recall (Health Canada) · Health Canada]Equate — Recall for possible metal fragments
Health Canada💊 Small moleculeRecall

Health Canada announced a Type II recall under Product quality for Equate Ultra Strength Antacid Assorted Fruits (1000 mg chewable tablets) because it may contain metal fragments as foreign matter.

Published 2026-10-30 · Document no. hc-82891 · Guardian Drug Company Inc. · Product Equate Ultra Strength Antacid Assorted Fruits · Type II

Original text and translation
Product quality
Key facts · Basis: official source record kept by the collector
  • Category: Natural health products
  • Reason: Product quality (possible metal fragment foreign matter)
Insight · Editorial insight

Possible metal fragments in a chewable tablet being the recall reason signals that dosage forms taken directly require stricter metal foreign matter control. Metal foreign matter can generally relate to damaged parts of tableting and milling equipment, so check equipment inspection intervals.

Check points
  • Metal detector sensitivity setting and periodic verification records
  • Inspection intervals for equipment parts such as tablet punches and screens
Recall detail · From the source · Health Canada
Active ingredient · 1000 mgDosage form · Tablet, chewable
What you should do
Original · Health Canada

Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.

[Recall (UK) · MHRA]Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40… — Precautionary batch recall
MHRARecall

Advanz Pharma Limited is recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure, and MHRA announced it as Class 2.

Published 2026-10-29 · Class 2 · Advanz Pharma Limited

Original text and translation
Advanz Pharma Limited are recalling specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure.
Key facts · Basis: official source record kept by the collector
  • Product: Mynzepli 40 mg/mL solution for injection in pre-filled syringe
  • Nature of recall: precautionary measure
Insight · Editorial insight

Specified batches of a pre-filled syringe product being recalled as a precaution shows that recall decisions can be made before a defect is confirmed. The specific reason needs review of the original text, so check the criteria for precautionary recall decisions for similar dosage forms.

Check points
  • Criteria and decision records for precautionary recall decisions
  • Distribution record traceability to identify affected batches
Recall detail · From the source · MHRA
Full alert (Drug Alert)
Original · MHRA

DMRC reference number DMRC - 41252013 Marketing Authorisation Holder Advanz Pharma Limited Medicine Details Mynzepli 40 mg/mL solution for injection in pre-filled syringe PL: 56734/0022 Active Ingredient: aflibercept SNOMED code: 45567511000001107 GTIN: 05021691005605 Affected Lot Batch Numbers Batch No. Expiry Date Pack Size First Distributed 2325742 Jun-2027 1 02/01/2026 2325726 May-2027 1 10/10/2025 Background Advanz Pharma Limited are recalling the specified batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe as a precautionary measure because a small variation in the size of the finger grip could affect how the medicine is administered and potentially pose a risk to patient safety. The finger grip/flange provides a platform/surface for better grip of the syringe. It allows the user to securely hold the pre-filled syringe while applying pressure to the plunger rod during product administration. Advice for Healthcare Professionals: Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. Advanz Pharma have confirmed that other unaffected batches of Mynzepli 40 mg/mL solution for injection in pre-filled syringe are currently available for distribution. Advice for Patients: This is a Pharmacy and Wholesaler level recall, therefore no further action is required by patients. This product is only administered by a qualified healthcare professional experienced in administering intravitreal injections. Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme . Additional information: For all enquiries and information on this product, please email [email protected] , or telephone +44 (0) 208 588 9131. Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 [email protected] Download document Class 2 Medicines Recall: Advanz Pharma Limited, Mynzepli 40 mg/mL solution for injection in pre-filled syringe, EL(26)A/44

[Recall (UK) · MHRA]Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydro… — Recall for packaging mix-up (wrong strength)
MHRA💊 Small moleculeRecall

Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength, and MHRA announced it as Class 2.

Published 2026-10-29 · Class 2 · Accord-UK Ltd

Original text and translation
Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength.
Key facts · Basis: official source record kept by the collector
  • Product: Lercanidipine Hydrochloride 10mg Film-Coated Tablets
  • Reason: packaging mix-up involving the incorrect strength
Insight · Editorial insight

A product of a different strength was mixed in at packaging, showing that mix-up risk is real on lines packing multiple strengths of the same ingredient. Packaging mix-ups can generally relate to line clearance and material identification control, so check these controls.

Check points
  • Line clearance records at changeover between strengths
  • System for verifying packaging material and tablet strength identity
Recall detail · From the source · MHRA
Full alert (Drug Alert)
Original · MHRA

DMRC reference number DMRC - 41285957 Marketing Authorisation Holder Accord-UK Ltd Medicine Details Lercanidipine Hydrochloride 10mg Film-Coated Tablets PL: 00142/1154 Active Ingredient: lercanidipine hydrochloride SNOMED code: 16607111000001105 GTIN: 05055565768242 Affected Lot Batch Numbers Batch No. Expiry Date Pack Size First Distributed M2510877 11/2028 28 24/06/2026 Background Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength. One complaint has been received to date, in which a sealed carton of Lercanidipine Hydrochloride 10mg Tablets 28 (Batch No. M2510877) was found to contain one blister strip of the correct tablets, and one blister strip of Lercanidipine Hydrochloride 20mg Tablets (Batch No. M2510831). This recall is being conducted at the pharmacy and wholesaler level as Accord-UK Limited has shown that the likelihood of the mix up, and the subsequent risk to patients, is low. If a patient prescribed lercanidipine 10 mg were to inadvertently receive 20 mg daily for approximately two weeks, the anticipated risk would be an exaggerated pharmacological effect; particularly reduction in blood pressure with associated symptoms such as dizziness, headache, flushing, palpitations or symptomatic hypotension. However, 20 mg remains within the authorised therapeutic dose range for routine use of this product. The tablets have distinct colours and the occurrence of the defect is currently anticipated to be very low. Advice for Healthcare Professionals: Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. This recall is at the pharmacy and wholesaler level and not directed to patient level as 20 mg remains within the authorised therapeutic dose range for routine use of this product. The tablets have distinct colours and the occurrence of the defect is currently anticipated to be very low. However, should a patient present a pack with the incorrect medicine, pharmacy teams should exercise their professional judgement to supply the correct medication. Advice for Patients: Accord has received a single report of a carton of Accord-UK Ltd Lercanidipine Hydrochloride 10 mg Tablets containing a blister strip of Lercanidipine Hydrochloride 20 mg Tablets and are being recalled as a precautionary measure. 20 mg remains within the authorised therapeutic dose range for routine use of this product. The tablets have distinct colours and the occurrence of the defect is currently anticipated to be very low. If you were prescribed Lercanidipine Hydrochloride 10 mg Tablets, and received an Accord pack with batch number M2510877, please carefully check the blister strips inside (the batch number and expiry date information can be found on outer carton, see the images in Annex 1). If the carton contains blister strips that are labelled as Lercanidipine Hydrochloride 10 mg Tablets, you do not need to take further action and may continue to take the tablets. If the carton contains a blister strip that is labelled as Lercanidipine Hydrochloride 20 mg Tablets, do not take the medicine, contact your pharmacy. If you believe you have taken the Lercanidipine 20 mg Tablets and are currently experiencing any side effects such as dizziness, headache, flushing or palpitations then please seek immediate medical advice. Please take the leaflet that came with your medicine and any remaining tablets with you to your pharmacy or GP practice. If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals involved in your treatment. Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme. Additional information: For all medical information enquiries and information on this product, please email Accord-UK Medical Information Department [email protected] , or telephone 01271 385257. For stock control enquiries please email Accord-UK Customer Services Team [email protected] , or telephone 0800 373573. Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 [email protected] Download document Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45 Annex 1 Lercanidipine Hydrochloride 10mg Tablets – Carton Lercanidipine Hydrochloride 10mg Tablets – showing Batch details Lercanidipine Hydrochloride 10mg Tablets – Correct blister of 14 tablets BN M2510877 Lercanidipine Hydrochloride 20mg Tablets – Incorrect blister of 14 tablets BN M2510831 Differences in appearance between Lercanidipine Hydrochloride 10mg Tablets and Lercanidipine Hydrochloride 20mg Tablets.

[Recall (UK) · MHRA]Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liqu… — Recall for less than labelled amount
MHRA💊 Small moleculeRecall

Xeal Pharma informed MHRA that all strengths of its Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel, and MHRA announced a Class 2 recall.

Published 2026-10-26 · Class 2 · Xeal Pharma

Original text and translation
Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel.
Key facts · Basis: official source record kept by the collector
  • Product: Clopidogrel Oral Suspension and Oral Solution (all strengths)
  • Reason: contain less clopidogrel than labelled amount
Insight · Editorial insight

All strengths, not specific batches, being recalled for less than the labelled amount shows that assay assurance in oral liquids can be a risk across the whole product line. Assay loss in liquids can generally relate to active ingredient degradation or homogeneity, so check the formulation and stability basis.

Check points
  • Assay stability trend of the oral liquid products
  • Suspension homogeneity and dose content uniformity evaluation
Recall detail · From the source · MHRA
Full alert (Drug Alert)
Original · MHRA

DMRC reference number DMRC - 41238898 Marketing Authorisation Holder Xeal Pharma Medicine Details Clopidogrel Oral Solution, Clopidogrel Oral Suspension Unlicensed medicine (MS 46688) Active Ingredient: clopidogrel hydrogen sulfate SNOMED code: N/A GTIN: N/A Affected Lot Batch Numbers For a list of defected batches, see Annex 1 Background Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel. Due to a formulation error, the impacted batches contain 76% of the required amount of clopidogrel. All batches produced prior to this notification are affected. Please note this is a Class 2 Patient, Pharmacy and Wholesaler level recall. Advice for Healthcare Professionals: Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process. Based on the risk assessment by Xeal Pharma, patient harm is not anticipated in patients receiving the affected product for long-term preventative treatment. However, patients would not receive the full, prescribed dose. Pharmacists should identify and immediately contact all patients who have been dispensed these batches and ask them to confirm if they have remaining stock within their possession. If batch traceability information is not available, all patients dispensed this product from 20 July 2026 should be contacted. Patients should be informed that the product contained a lower dose than prescribed and patients and carers should be reminded that suddenly stopping this medicine may cause serious thrombotic events. If the pharmacist identifies any patients with an impacted product, they should contact the patient’s GP or prescriber and discuss ongoing treatment for the patient. As patients may require monitoring, other clinicians and healthcare professionals may need to be involved. Prescribers, clinicians, and other healthcare professionals involved in the prescribing/monitoring of patients who are using Clopidogrel Oral Solution or Suspension should contact their patients and/or carers directly to ensure that their treatment is reviewed. Healthcare professionals should be aware that there are no licensed clopidogrel oral suspension/solutions available. Patients with impacted batches may require a dose correction, alternative licensed formulations or a different treatment option. Xeal Pharma have confirmed that all future stock will be manufactured with the correct strength and calculations applied. Advice for Patients: Never stop taking medicines such as clopidogrel without medical advice. Suddenly stopping clopidogrel may cause serious thrombotic events. Your GP, specialist, pharmacist, or other healthcare professional will contact you to, where required, make sure you get a new prescription for an alternative product. Once you have a replacement, you should return the impacted product to your pharmacy as part of the recall. You can contact your healthcare professional directly if you are worried, but you should keep taking your medicine as advised until you get an alternative. No reports of patient harm have been received regarding this issue and the recall is being undertaken out of an abundance of caution. Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme . Additional information: For all enquiries and information on this product, please email [email protected] , or telephone 0121 3090067. Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information. Yours faithfully Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574 [email protected] Download document Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43

[Recall · FDA]Teva Pharmaceuticals USA, Inc — Recall for foreign tablets or capsules
FDA💊 Small moleculeRecall

Teva Pharmaceuticals USA, Inc is conducting a Class II recall of bottled Metoclopramide Tablets, USP, 5 mg because other tablets or capsules were mixed in.

Published 2026-10-21 · Document no. D-0038-2027 · Product Metoclopramide Tablets, USP, 5 mg, [100 or 500] Tablets per bottle, Rx Only, Man… · Class II

Original text and translation
Presence of Foreign Tablets/Capsules
Key facts · Basis: official source record kept by the collector
  • Product: Metoclopramide Tablets, USP, 5 mg (bottles of 100 or 500 tablets)
  • Reason: Presence of Foreign Tablets/Capsules
Insight · Editorial insight

Other tablets or capsules being mixed into bottled tablets signals that mix-up prevention on multi-product bottle packaging lines is directly tied to recall risk. Mixing of foreign tablets can generally relate to handling of leftover product at changeover, so check line clearance procedures.

Check points
  • Confirmation of residual tablet removal at product changeover on bottle lines
  • Means of detecting foreign tablets in the filling process
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-09-29FDA classification · 2026-10-13FDA published · 2026-10-21
Affected lots and expiry
Original · OpenFDA

Lot, expiry: [100 Tablets] Lots 8634085, 8635085, 8636085, exp 07/2027; [500 Tablets] Lot 8633085, exp 07/2027

Recall size and scope

Quantity — 240,448 cartons

Distribution — US Nationwide.

Company location — Parsippany, NJ, United States

Product identification

Brand name — METOCLOPRAMIDE

Generic name — METOCLOPRAMIDE

Active ingredient — METOCLOPRAMIDE HYDROCHLORIDE

Route of administration — ORAL

Application number — ANDA070184

[Recall · FDA]Zydus Pharmaceuticals (USA) Inc — Impurities/degradation specification failure
FDA💊 Small moleculeRecall

Zydus Pharmaceuticals (USA) Inc is recalling Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial as Class II for failed impurities/degradation specifications.

Published 2026-10-21 · Document no. D-0039-2027 · Product Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial, 1 Vial, Rx Only,… · Class II

Original text and translation
Failed Impurities/Degradation Specifications.
Key facts · Basis: official source record kept by the collector
  • Product: Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial
  • Reason: Failed Impurities/Degradation Specifications
Insight · Editorial insight

An injectable recalled for impurity and degradation specification failure shows that degradant growth during distribution can surface as a market quality issue. Degradant growth can generally relate to storage conditions or formulation stability, so check degradant trends in the stability data.

Check points
  • Degradant growth trend in stability testing and margin to specification
  • History of deviations from distribution and storage conditions
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-01FDA classification · 2026-10-13FDA published · 2026-10-21
Affected lots and expiry
Original · OpenFDA

Lot #: LB00047A, LB00048A, Exp. Date 03/2028

Recall size and scope

Quantity — 70776 vials

Distribution — Nationwide within the United States

Company location — Pennington, NJ, United States

Product identification

Brand name — HYDROCORTISONE SODIUM SUCCINATE

Generic name — HYDROCORTISONE SODIUM SUCCINATE

Route of administration — INTRAMUSCULAR, INTRAVENOUS

Application number — ANDA217191

[Recall · FDA]Houston Rx LLC Tirzepatide/Niacinamide 2mL vial (40 MG per V… — Combined recall for lack of sterility assurance
Evidence AFDASignal Med · T2Recall

Houston Rx LLC is recalling two injectable vial products as Class II for the same reason, lack of assurance of sterility.

Published2026-10-21
Document no.D-0040-2027
CompaniesHouston Rx LLC
ProductTirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032. 외 1품목
ClassClass II
All 2 products
  • Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
  • Sermorelin, 1 mg/mL, 10 ml vial, Sterile injectable solution, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Original text and translation · representative case
Lack of assurance of sterility.
Key facts · Basis: official source record kept by the collector
  • Company: Houston Rx LLC
  • Reason: Lack of assurance of sterility
  • Class: Class II
  • Merged: combined recall of 2 products for the same reason
Insight · Editorial insight

Several injectable products being recalled together for the same reason, lack of sterility assurance, suggests the facility's aseptic process system itself may have been judged the problem rather than individual product defects. Such a lack can generally relate to aseptic process validation or environmental control, so check the assurance basis for the common process.

Check points
  • Status of process simulation (media fill) for the aseptic compounding process
  • Common risk assessment across injectable products made in the same facility
Recall detail · From the source · OpenFDA · Based on the representative product

This card groups 2 products into one entry. All values below refer to one representative product (including lots, quantity, and status).

Status · OngoingVoluntary: Firm initiatedFirst notified · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Status
Recall initiated · 2026-09-25FDA classification · 2026-10-13FDA published · 2026-10-21
Affected lots and expiry
Original · OpenFDA

Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.

Recall size and scope

Quantity — 64 vials

Distribution — Nationwide in the USA.

Company location — Houston, TX, United States

[Recall · FDA]American Health Packaging — Foreign tablets in packaged units recall
FDA💊 Small moleculeRecall

American Health Packaging is recalling Metoclopramide Tablets, USP, 5 mg, 100 Tablets (10 x 10) as Class II because other tablets or capsules were mixed in.

Published 2026-10-21 · Document no. D-0042-2027 · Product Metoclopramide Tablets, USP, 5 mg, 100 Tablets (10 x 10), Rx Only, Distributed b… · Class II

Original text and translation
Presence of Foreign Tablets/Capsules
Key facts · Basis: official source record kept by the collector
  • Product: Metoclopramide Tablets, USP, 5 mg, 100 Tablets (10 x 10)
  • Reason: Presence of Foreign Tablets/Capsules
Insight · Editorial insight

Foreign tablets or capsules were found in a unit dose packaged product, signaling that distributors and repackagers are also subject to mix-up risk control. Mix-ups in unit packaging can generally relate to item verification at the packaging input stage, so check controls at that step.

Check points
  • Product and lot reconciliation before unit dose packaging input
  • Foreign tablet inspection on the unit dose packaging line
Recall detail · From the source · OpenFDA
Status · OngoingVoluntary: Firm initiatedFirst notified · Letter
Status
Recall initiated · 2026-10-06FDA classification · 2026-10-14FDA published · 2026-10-21
Affected lots and expiry
Original · OpenFDA

Lot 1028135, 1029555; Exp. Date 07/31/2027

Recall size and scope

Quantity — 5,363 cartons

Distribution — US Nationwide

Company location — Columbus, OH, United States

Product identification

Brand name — METOCLOPRAMIDE

Generic name — METOCLOPRAMIDE

Active ingredient — METOCLOPRAMIDE HYDROCHLORIDE

Route of administration — ORAL

Application number — ANDA072801

[Recall (Health Canada) · Health Canada]PHARMASCIENCE INC. — Recall for possible foreign particles
Health Canada💊 Small moleculeRecall

Health Canada announced a Type II recall under Contamination for the affected lot of PMS-FAMPRIDINE 10 mg Tablet from PHARMASCIENCE INC., which may contain foreign particles.

Published 2026-09-28 · Document no. hc-82684 · Product PMS-FAMPRIDINE · Type II

Original text and translation
Contamination
Key facts · Basis: official source record kept by the collector
  • Product: PMS-FAMPRIDINE 10 mg Tablet
  • Reason: Contamination (possible foreign particles)
  • Issue date: 2026-09-28
Insight · Editorial insight

A tablet product recalled for possible foreign particles shows that foreign matter control in solid dose processes is tied directly to recall risk. Foreign particles can generally relate to equipment wear or the raw material, so check the in-process foreign matter detection system.

Check points
  • Operating status of foreign matter detection and sorting devices in the tableting process
  • Root cause tracing and affected lot scope determination when foreign matter occurs
Recall detail · From the source · Health Canada
Active ingredient · 10 mgDosage form · Tablet
What you should do
Original · Health Canada

Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concerns.Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.

Trade press briefing 3 items

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.

AI Disclosure

How this content is produced, and caveats

1. Information generated by AI

Card titles, summaries, Korean translations, implications, check items, and detailed analysis are content generated automatically by generative AI from published primary official material.

2. Information provided as in the source

Figures, codes, dates, agency and company names in the fact table, quotations from the original text, source and official-document links, and findings tables (FDA Form 483 observations, MFDS routine inspection findings, and so on) are extracted mechanically from the source and are not reworded or rewritten.

3. Verification, limitations, and user notes

  • To improve accuracy, GRM provides evidence grades (A, B, C) and signal tiers (1–3). Evidence A means the information can be checked directly against a primary official document.
  • Summaries, translations, implications, check items, and detailed analysis generated by generative AI may contain mistranslations, omissions, misread context, or information that is not up to date.
  • This service is reference material intended to provide regulatory and quality information; it does not provide legal, regulatory, quality, or compliance advice or official interpretation.
  • Before using this material for decisions, quality system operation, regulatory response, or audit preparation, users must check the official source and the relevant agency's latest material themselves.

This digest is AI-generated from primary sources; interpretations are not official or legal advice — verify against the original before acting.